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Abstract
African swine fever virus (ASFV) is a large double-stranded DNA virus which 
causes an acute haemorrhagic disease in domestic swine. The natural host reservoir is 
the bushpig {Potomochorus porcus), warthog (Phacochoerus aethiopicus) and soft 
ticks of the Omithodoros species. ASFV is apathogenic in these hosts. One of the 
defining characteristics of ASFV induced haemorrhagic fever is massive lymphocyte 
apoptosis. This induction of apoptosis is most likely due to a combination of factors 
released from infected macrophage cells. Tumour necrosis factor alpha (TNFce) has 
been shown to induce apoptosis in lymphocytes but it is not solely responsible 
(Gomez del Moral et al., 1999). Galectin-3 is a multi-ftanctional protein expressed in 
macrophages. Previously transcription of galectin-3 has been shown to be up- 
regulated during ASFV infection. Porcine galectin-3 has been characterised as part of 
this project and the effect ASFV infection has on expression and localization of this 
protein has been investigated. The results show that ASFV infection induces 
secretion of galectin-3. It is possible that galectin-3 secreted from ASFV infected 
macrophage cells contributes to lymphocyte apoptosis.
ASFV produces a large repertoire of proteins, a number of which have been shown to 
modulate host immune responses. Another aim of this project has been to investigate 
global host gene expression in response to early events in ASFV infection using a 
porcine micro array. In order to distinguish between the specific effects of virus entry 
and early viral gene transcription, host gene expression in cells infected with UV- 
inactivated virus was compared to gene expression in cells infected with untreated 
virus and mock-infected cells. The genes that were differentially-regulated included 
those from a number of signalling pathways. These included genes involved in the 
mitogen activated protein kinase (MAPK) pathway. This pathway is important in 
control of cell proliferation, survival, inflammation and cytokine synthesis. The 
manipulation of this pathway by ASFV is likely to facilitate virus replication and 
evasion of host defences.
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Introduction
1.1 African swine fever virus
1.1.1. Epidemiology and transmission
African swine fever (ASF) was first discovered in Kenya in 1921 by Montgomery 
R.E. (Montgomery, 1921) who discovered the disease in domestic pigs and attributed 
it to a viral infection which was named African swine fever virus (ASFV). The virus 
can cause a devastating, acute, haemorrhagic fever in domestic pigs. Infection with 
the most virulent strains results in up to 100% mortality. Since its first description 
ASF has been reported in most African countries south of the Sahara. The disease 
first spread from Africa in 1957 when outbreaks occurred in Portugal (Manso, 1958). 
Although this outbreak was eradicated the virus was reintroduced into Portugal in 
1960 and remained endemic in Spain and Portugal from that time until the 1990s. 
Sporadic outbreaks have occurred in other parts of Europe, the Caribbean and South 
America. The virus has now been eradicated from these countries but has become 
well established in sub-saharan Africa and remains endemic in Sardinia since its 
introduction in 1982. In 2007 ASF was introduced into Georgia in the Caucasus and 
has spread to neighbouring countries in that region including Armenia. Since the 
virus spread to Europe and the rest of the world, new variants have emerged. These 
variants can be moderate or low in virulence causing reduced mortality or chronic 
infections. Infection with less virulent types of ASFV may lead to persistence of the 
virus in pigs which recover from disease (Wardley et al., 1983). These persistently 
infected pigs may transmit the virus to healthy ones or healthy pigs may become 
infected by eating infected meat. There is currently no vaccine available and control 
of the virus relies on rapid diagnosis, implementation of quarantine measures and 
mass slaughter. This is expensive and difficult to achieve in many African countries 
which lack the infrastructure to implement these measures.
The disease can be transmitted by direct contact between pigs and by bites from 
infected ticks of the Omithodorus sp (Wilkinson, 1989). In Africa the virus persists 
in the field in warthogs (Phacochoerus aethiopicus) and bush pigs (Potamchoenis
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porcus). Warthogs become infected early in life after being bitten by infected ticks.
In these hosts no clinical symptoms are apparent even when infected with strains 
which are highly virulent for domestic pigs. When young warthogs are first infected 
low levels of virus can be found in lymph nodes, spleen and circulating in the blood 
for several weeks. This is thought to be sufficient to infect uninfected ticks which 
feed on these warthogs (Thomson et al., 1980). The virus replicates in ticks and can 
be transmitted transtadially (Endris and Hess, 1992), trans-sexually from male to 
female and transovarially (Rennie et al., 2001), at least in O.mobata. Other species of 
ticks have been identified as vectors of the disease. In Spain and Portugal O.erraticus 
is the main vector but O.coriaceus and O.turicata can maintain virus and transmit it 
to domestic pigs (Groocock et al., 1980; Hess et al., 1987). The virus may spread 
from wildlife to domestic pigs if pigs are bitten by ticks that have been feeding on 
bush-pigs and warthogs in wildlife reserves (Plowrigh.W et al., 1969). They may 
also be infected by eating infected warthog tissue and whole ticks (Oura, 1998b).
1.1.2. Pathogenesis
In domestic pigs ASFV infections can be categorised into four disease states; 
peracute, acute, subacute and chronic (Boinas et al., 2004; Hess, 1981; Wardley et al., 
1983). Peracute infections occur when animals die with no apparent clinical signs. 
However, there may be internal haemorrhagic lesions observed during post-mortem.
In acute infections the initial signs of the disease are a rise in temperature, loss of 
appetite and respiratory problems. This is followed by severe haemorrhaging of the 
lymph nodes, the heart and kidneys. Lesions may also occur on the liver and the 
spleen becomes enlarged. Death can occur within 4 to 15 days. Subacute infections 
vary in their clinical presentation and mortality with abortion often the only 
consequence (McDaniel, 1978). During chronic viral infections the virus may persist 
for several months causing a range of conditions from pyrexia, pneumonia, arthritis, 
joint swelling and hypergammaglobulinaemia. Post mortem may also reveal the 
presence of haemorrhagic lesions (Leitao et al., 2001; Pan et al., 1970; Wardley et al., 
1983). ASFV has been isolated from lympth nodes of animals up to 48 days post­
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infection (Oura, 1998a) and viral DNA has been detected in peripheral blood mono- 
nucleocytes more than 500 days post infection by PCR (Carrillo et al., 1994).
Infection of macrophages has been well characterised and is considered the primary 
site of replication. The virus has also been detected in fibroblasts, endothelial cells 
and reticular cells (Carrasco et al., 1997; GomezVillamandos et al., 1997).
Replication in vitro in endothelial cells has been shown (Vallee, 2001) but replication 
in vivo is limited and has only been observed at late stages of acute infections 
(Carrasco et al., 1992; Fernandez et al., 1992a; Fernandez et al., 1992b; Fernandez et 
al., 1992c; Gomez-Villamandos et al., 1995). The ability of ASFV to infect cells of 
the monocytic linearage is considered to play a central role in disease pathology. 
During acute infections massive lymphocyte apoptosis occurs. This is thought to be 
caused indirectly by the presence of infected macrophage cells. Lymphocytes are not 
infected (Carrasco et al., 1996a; Fernandez et al., 1992a; Fernandez et al., 1992b; 
Fernandez et al., 1992c; Perez et al., 1994) but apoptotic lymphocytes are observed 
surrounding infected macrophage cells (Oura, 1998a; Ramiro-lbanez et al., 1996).
The mechanism of lymphocyte apoptosis has not been defined but the number of 
cells undergoing apoptosis is much higher than would be expected considering the 
number of cells infected. This suggests other factors are involved as there is release 
of proinfiammatory cytokines such as TNF-aand 1L-Ij8 from infected macrophage 
cells resulting in activation of signalling cascades in bystander cells. This is likely to 
play a role in inducing apoptosis in lymphocytes as well as endothelial cells (Vallee, 
2001). Cells of the mononuclear phagocyte system produce large quantities of TNF-a 
in response to ASFV infection and it can be detected in seum as well as at the site of 
replication with the onset of clinical signs (del Moral et al., 1999). High levels of 
TNF-ce in pulmonary intravascular macrophages which show significant activation 
following infection with ASFV (Carrasco et al., 2002). Infections with the Malawi 83 
isolate showed massive lymphoid destruction but not replication in these cells 
(Carrasco et al., 1996b). Increased levels of TNF-a and lL-1/3 in serum coincide with 
an increase in lymphocyte apoptosis. Various studies have also shown an increase in 
the number of macrophage cells expressing TNF-o; 1L-Ij8 and lL-6 (Salguero et al., 
2008; Salguero et al., 2002; Salguero et al., 2005).
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Investigations comparing pathogenesis in pigs caused by infection with the highly 
virulent Malawi and moderately virulent Malta isolates, showed greater levels of 
infection with Malawi and increased viral replication. This has been associated with 
more severe pathological damage caused by high levels of apoptosis in lymphoid 
tissue. This may lead to increased vascular permeability and fibrin deposits. During 
infection with the Malta isolate, virus is cleared from the blood, liver, spleen and 
kidneys but can persist in lymphoid tissue. The amount of apoptosis in lymphoid 
tissue is much less following infection with the Malta isolate compared to the 
Malawi isolate. Infection of pigs with another highly virulent Spanish isolate E70 
was also shown to differ, compared to infection with the Malawi, in the numbers of T 
and B cells which enter apoptosis. Following infection with Malawi isolate a greater 
number of T cells seem to undergo apoptosis before B cells. In contrast infection 
with the E70 isolate has been reported to cause more apoptosis in B cells than T cells 
(Ramiro-lbanez, 1997). The lack of control of apoptosis in pigs infected with highly 
virulent strains seems to contribute to lethal pathogenesis (Oura, 1998a).
1.1.3. Virus structure
ASFV was first classified as a member of the Iridoviridae due to its icosahedral 
structure and cytoplasmic location. However, it has now been put into a family called 
ihs Asfraviridae of which it is the only member. A diagram of the virus particle is 
shown in figure 1.1.
The virion consists of a DNA containing nucleoid surrounded by a layer of core 
protein (Carrascosa et al., 1984). This is surrounded by a loose membrane which 
recent evidence suggests is a single membrane, possibly derived from the 
endoplasmic reticulum (ER) (Hawes et al., 2008). This membrane is then covered in 
an icosahedral capsid 170 to 190 nm in sze (Breese and Deboer, 1966; Carrascosa et 
al., 1984). The complete extracellular virions have an outer membrane which is 
gained by budding through the cell plasma membrane (Breese and Deboer, 1966; 
Carrascosa et al., 1984). The virion contains over 50 polypeptides (Carrascosa et al..
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1985; Esteves et al., 1986) which includes structural proteins as well as enzymes 
necessary for early mRNA transcription and processing. The structural protein p72 
makes up about 32% of the total virus particle while 25% is made up of 4 proteins 
derived from the pp220 polypeptde (Andres et al., 1997).
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Figure 1.1 Electron micrograph of an ASFV partical -  Particle shows the loose 
outer membrane surrounding the capsid and inner membrane. This then surrounds 
the inner core particle and DNA nueleoid. Image courtesy of Dr Sharon Brookes and 
Dr Linda Dixon.
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1.1.4. Genome organisation
Although structurally ASFV resembles members of the Iridoviridae, the genome and 
replication strategies are more comparable to the poxviridae (Caeiro, 1990; Vinuela, 
1985). ASFV has a linear double stranded genome with inverted terminal repeats and 
covalently linked hair-pin loops at each end (Gonzalez et al., 1986; Sogo et al., 1984). 
DNA is typically between 170 and 190 kbp in length depending on the isolate 
(Chapman et al., 2008). The complete coding sequences, apart from those within the 
inverted terminal repeats, of 10 ASFV genomes have been determined. 151 to 167 
ORPs have been identified and are read from both strands (Chapman et al., 2008; 
Yanez et al., 1995). A schematic of the ASFV genome has been included in figure
1.2 and highlights different proteins produced by the virus and the direction in which 
they are transcribed from the ORF. The tissue culture-adapted strain of ASFV,
Ba71V, and the attenuated CURT 88/3 isolates, have large deletions compared to 
field isolates. The Kenyan isolate discovered in 1950 is 194 kbp and is the largest 
isolate sequenced so far.
The genome has a central region which is highly conserved in length with variable 
regions at each end which encode a number of multigene families (MGFs). The 
function of these MGFs is not fully understood but they are thought to play a role in 
host range and virulence (Zsak, 2001). It is also possible that they play a role in 
modulating the host interferon (IFN) response (Alfonso et al., 2004; Neilan, 2002; 
Zsak, 2001). Variations in genome length are due primarily to insertions and 
deletions in the MGFs (Blasco et al., 1989b; Dixon and Wilkinson, 1988). Small 
variations also occur within coding and intergenic regions (Aguero et al., 1990;
Blasco et al., 1989a; Dixon et al., 1990; Yozawa et al., 1994).
Comparison of predicted protein sequences with other known proteins has enabled 
many of the open reading frames (ORFs) to be assigned ftinctions. A number of 
ORFs encode proteins involved in DNA replication, repair, recombination, mRNA 
transcription and processing. 3 ORFs have sequence similarity with sub-units of 
RNA polymerases. One ORF shares similarity with a 147kDa sub-unit of vaccinia
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virus RNA polymerase. There is also another ORF that has similarity with the 
mRNA capping enzyme encoded by vaccinia virus. Other ORFs encode proteins of 
the helicase super-family, enzymes involved in nucleotide metabolism including 
deoxyuridine triphosphatases and enzymes involved in post-translational 
modification of proteins including a serine threonine protein kinase, and a ubiquitin 
conjugating enzyme (Chapman et al., 2008).
The majority of ORFs have not been assigned functions. It is possible that some are 
involved in survival and replication within the tick vector. The amino acid identity 
compared with other proteins is generally quite low. This suggests that the 
relationship between ASFV and other viruses including the Poxviridae is distant 
(Dixon, 1993).
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Figure 1.2 A map of the African Swine Fever virus genome -  The genome map of the Ba71v tissue 
culture adapted isolate. Multigene families are shown in mid-blue and dark blue, structural proteins in 
red, modifying enzymes in pink, proteins involved in host-interactions and immune evasion are shown 
in black, proteins involved in replication and nucleotide metabolism are shown in light blue and genes 
encoding other proteins are shown in orange. The orientations of the arrows denote the direction in 
which the open reading frame is read. Diagram provided by Dr. Gavin Bowick, adapted from Yanez 
et al, 1995.
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1.1.5. ASFV Replication
A summary of the replication cycle of ASFV is shown in figure 1.3.
1.1.5.1 Virus binding and entry
A number of proteins have been shown to be involved in ASFV binding and entry 
into cells including, p i2, p30, p54 and p72. The p i2 protein has been identified as a 
virus attachement protein and is located to outer membranes (Carrascosa et al., 1993). 
The purified p i2 protein can inhibit ASFV binding and infectivity (Angulo et al., 
1993). The p54 and p30 proteins are also involved in attachement. Antibodies against 
these proteins prevents virus attachement and purified p54 and p30 proteins can 
inhibit ASFV binding (Alcami et al., 1992; Gomez-Puertas et al., 1998).
Macrophages are the primary site of ASFV infection. The virus is a large ligand 
interacting with quite a large area on the cell surface. Therefore, a number of surface 
molecules can co-fi-actionate with virus particles (Smith, 2004). Entry of ASFV is via 
receptor-mediated endocytosis. This is an active process which does not require 
cytoskeletal functions (Valdeira, 1998). A candidate receptor has been identified as 
CD 163 (Sanchez-Torres, 2003). Following internalization a pH change induces 
fusion of the viral envelope with the endosome and release of the core partical into 
the cytoplasm (Valdeira, 1998).
1.1.5.2 Virus transcription and replication
Transcription begins in the cytoplasm following virus entry to the host cell and 
partial uncoating of the virus particle. The virion contains proteins required for early 
gene transcription and mRNA processing including; virus encoded RNA polymerase, 
poly A polymerase and capping enzymes as well as factors required for early gene 
transcription. Virus gene transcription is independent of a host RNA polymerase. 
There are 4 sub-sets of genes, which are expressed at different times during the 
replication cycle; immediate-early, early, intermediate and late genes. Immediate-
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early and early genes are transcribed immediately following entry using enzymes and 
factors packaged in the virus particle. Early genes may be transcribed throughout 
infection but immediate-early genes are silenced when viral DNA replication begins 
(Almazan et al., 1992). Intermediate gene expression requires viral DNA synthesis 
and occures 4 to 6 hours post infection following the maximum expression of early 
genes. Intermediate gene expression decreases rapidly when late gene transcription 
increases. Late gene transcription occurs after the initiation of DNA synthesis 
(Rodriguez et al., 1996b). This type of cascade in gene expression is similar to that 
found for vaccinia virus where factors from one class of genes are required for 
synthesis of genes from the following temporal class (Moss and Earl, 2001).
Poxvirus early transcription factors are packaged into virus particals for use 
following virus entry. Intermediate factors are synthesised early in infection and late 
factors at the intermediate stage.
Newly synthesised viral DNA is present in the nucleus and cytoplasm of infected 
cells at early stages but is present in the cytoplasm only at later stages. There is 
evidence of an early nuclear step in replication but the reason for this is unclear 
(Rojo, 1999). The nuclear step may indicate the involvement of host nuclear factors 
in early viral DNA synthesis (Garciabeato et al., 1992). Replication of full length 
ASFV genomes is via head to head concatemers present in viral factories which form 
in the cytoplasm close to the nucleus and adjacent to the microtubule organising 
centre. The factories form 6 to 8 hours post infection (hpi) and increase in size 
significantly between 12 and 18 hpi (Brookes et al., 1996). The factories resemble 
aggresomes since a vimentin cage is formed around them and mitochondria 
accumulate (Heath, 2001). The p54 protein is able to interact with the LC8 light 
chain of minus-end directed micro tubule dyenin motor complex. This may be 
involved in transport to the microtubule organising centre and maintain viral 
factories (Alonso et al., 2001).
1.1.5.3 Virus Assembly and budding
Virus assembly is initiated by insertion of structural proteins into membranes of the 
ER (Andres et al., 1998; Heath et al., 2003). The p54 protein can be detected on these
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membranes and may play a role is assembly by recruitment of ER membranes to 
factories (Brookes et al, 1998; Rodriguez et al, 1996a; Rodriguez et al, 2004). Core 
particles are assembled from p37, p i50, p34 and pl4 proteins which are derived by 
processing of polyprotein precursor pp220 (Andres et al, 1997) and the p32 and pi 5 
products of polyprotein pp62 (Andres et al, 2002a). The polyprotein p220 is 
essential for viral and core assembly and envelopment (Andres et al, 2002b). It is 
worth noting that the normal secretory pathway may be disrupted in ASFV infection 
since the trans golgi network could not be detected. This may be important in 
preventing MHC expression and transport of cytokines to the cell surface 
(McCrossan, 2001).
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1. 3 The ASFV replication cycle- A summary of the replication cycle of ASFV. 
Virus enters cells by endocytosis and viral cores are released from endosomes into 
the cytoplasm. The virus replicates and assembles in viral factories fonned near the 
microtubule organising centre. As viral particles assemble they gain an inner 
membrane onto which the icosahedral capsid is assembled. They then bud through 
the plasma membrane where they obtain the loose outer membrane.
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1.2 Host pathogen interactions
1.2.1 The host innate immune sytem
The host defence system is two pronged and includes the innate and adaptive 
immune responses. The primary or innate immune response is non-specific and is 
activated immediately when the host recognises a foreign invader. The adaptive 
response is a more gradual but a more specific defence mechanism. There are many 
similarities between cellular responses to bacterial infections and viral infections 
(Pitha, 2004). The mammalian defence system includes a number of different cell 
types whose primary role is detecting and eliminating unwanted material or 
dangerous pathogens. Macrophages are an important part of this defence army. 
Macrophages are derived fi*om the mononuclear phagocytes and are found in almost 
every tissue in the body. These cells are important effector cells in innate immunity. 
They are able to recognise, ingest and destroy foreign bodies. Macrophages also 
produce a range of secretory products involved in migration and activation of other 
immune cells. They have a large number of membrane receptors for pathogen 
recognition and secrete various signalling molecules, including cytokines and 
chemokines, which are important in immune modulation. These cells are also the 
primary site of ASFV infection and replication.
During viral infection various receptors, including toll-like receptors (TLRs) which 
recognise pathogen-associated molecular patterns or PAMPs may be activated. At 
least 13 mammalian TLRs have been identified to date and their discovery has 
significantly changed our understanding of the innate immune system. All TLRs 
have a Toll/IL-1 receptor (TIR) domain which interacts with an adaptor molecule 
such as MyD88. The adaptor molecule dictates to some extent the signalling 
pathways activated. Initial engagement of TLRs in macrophages activates the innate 
immune system leading to an inflammatory and anti-microbial response. The type I 
interferon (IFN) response is part of this innate immune system and is important to the 
host cell for control and clearance of viruses. Activation of type I IFNs, IFN-ce and 
IFN-/3, activate a number of genes which induce an antiviral state in the cell and 
neighbouring cells. This causes activation of type II IFNs such as IFN-y which is
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involved in adaptive immunity. Many viruses have evolved mechanisms to 
manipulate the IFN response (Randall and Goodboum, 2008; Weber and Haller, 
2007).
TLRs are located at the surface of a cell and on endosomes. TLR 2 and 4 are at the 
surface and 3, 7, 8 and 9 are on endosomes recognising whole virions, replication 
intermediates and viral proteins (Onomoto et al., 2006). TLR3 can be activated by 
dsRNA, TLR4 by LPS and also some viral envelope proteins such as mouse 
mammary tumour virus (MMTV) env protein. TLR7 (mouse) or TLR8 (human) are 
activated by ssRNA (most work has been carried out on TLR7 and not TLR8 so I 
will only refer to TLR7 from now on). TLR9 is activated by unmethylated DNA (von 
Landenberg and Bauer, 2007).
In addition to TLRs two RNA helicases have been identified as intracellular pattern 
recognition receptors which can recognise viruses or viral products in the cytoplasm 
and activate type 1 IFNs. The DExD/H box-conatining RNA helicase, retinoic acid 
inducible gene I (RIG-I) and the melanoma differentiation-associated gene 5 
(MDA5). RIG-I and MDA5 have a C-terminal helicase domain and two copies of a 
caspase recruitment domain (CARD) at the N-terminal (Yoneyama et al., 2004). It is 
possible that RIG-I and MDA5 recognise different groups of viruses (Kato et al., 
2006). A third helicase, LGP2, induced by type 1 IFNs shares homology to RIG-I but 
lacks the CARD region. This protein appears to function as a regulator of RIG-I and 
MDA5 (Saito et al, 2007; Yoneyama et al, 2005). A new sensor in pathogen 
recognition which detects cytosolic DNA has been proposed by Takaoka et al 
(Takaoka et al, 2007) and named DAI (DNA-dependant activator of IFN-regulatory 
factors). DAI has an N-terminal DNA binding region and a C-terminal TBK1/IRF3 
binding region. It is able to induce type 1 IFNs via activation of interferon regulatory 
factor 3 (IRF3) and interferon regulatory factor 7 (IRF7). This may be more 
significant for detection of DNA viruses such as ASFV. Figure 1.4 shows the 
pathways activated by RIG-I and MDA5. The helicase domain of these proteins can 
bind dsRNA which results in a conformational change allowing the CARD domains 
to self associate and interact with the adaptor protein, IFNjS promoter stimulator 1 
(IPS-1). IPS-1 has a hydrophobic transmembrane region in the C-terminus which
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links it to mitochondria. IPS-1 then activates TBKl and IKKe, in a similar way to 
TLRs, to phosphorylate IFR3 and IRF7. RIG-I and MDA5 can also activate nuclear 
factor kappa B (NF-kB) in a similar way to TLRs (Thompson and Locamini, 2007).
Activation of transcription from the IFN/3 promoter depends on at least 4 regulatory 
elements called positive regulatory domains (PRDs) I, II, III and IV. These elements 
direct the assembly of transcription factors; IRF3 and IRF7 (PRDI and III), NF-kB 
(PRD II) and the API (c-Jun/ATF-2) complex (PRD IV). Assembly of these factors 
and the high mobility group protein HMG-I(y) form the ‘enhancesome’ which then 
recruits histone acetyltransferases (HATS), the general-control-of-amino-acid 
synthesis 5 (GCN5) and CREB binding protein (CBP). This acylates lysine residues 
of the histones in the nucleosome which cover the transcription start site of the INFjS 
gene. Acétylation of histones recruits a nucleosome modification complex and 
displacement of the nucleosome enabling transcription to proceed. The assembly of 
API, NF-kB and IRF3 all activate the IFNjS promoter (Iwamura, 2001; Perry, 2005). 
The IFNce promoter region only contains PRD I and PRD Il-like elements (Honda et 
al., 2006). Figure 1.4 shows a summary of the signalling pathways which can be 
activated by viral infection.
Binding of ligands to TLRs causes their homo-dimérisation and a conformational 
change enabling them to interact with adaptor proteins. Generally TLR signalling is 
split into MyD88-dependent and MyD88-independent signalling. TLR3 signals via 
the MyD88-independent pathway and TLR7 and 9 via the MyD88-dependent 
pathway. TLR4 is unique in that it can signal via both pathways.
TLR3 uses the adaptor protein TRIF which interacts with TNF receptor associated 
factor 3 (TRAF3) and the receptor interacting protein 1 (RIP-1) to activate TRAF- 
family-member-associated NF-kB activation (TANK)-binding kinase (TBKl) and 
the non-canionical inhibitor of NF-kB kinase IKKi or IKKe (as shown in figure 1.4). 
This leads to phosphorylation of IRF3 and dimerisatioin which reveals a nuclear 
localization signal (Panne et al., 2007). The IRF3 dimer is translocated to the nucleus 
and associates with the CBP binding protein on the IFN/3 promoter (Mamane, 1999; 
McWhirter, 2003; Servant, 2002). IRF7 is also phosphorylated by TBKl and IKKe.
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IRF7 forms a homodimer which translocates to the nucleus and activates a number of 
IFN-stimulated genes (ISGs) in the primary and delayed IFN responses. TLR3 
signalling through TRIF can also induce IRF5 which in turn induces various 
cytokines such as IL-6, IL-12 and TNFa (Takaoka et al., 2005). TLR3 induces 
activation of NF-kB by TRIF which acts as a scaffold to recruit RIP-1 and TRAF6. 
These co-operate with the IKK complex and transforming growth factor (TGF)- /3- 
activated kinase 1 (TAKl). IKKjS of the IKK complex is phosphorylated by TAKl 
which in turn leads to phosphorylation and proteosome degredation oflkB leaving 
NF-kB free to move to the nucleus activating transcription of IFNjS and other pro- 
inflammatory cytokines (Ghosh, 2002; Karin, 2000). Continuous low level 
expression of NF-kB genes is controlled by regulation of IkB turnover. Nuclear 
retention of IkB can prevent activation ofNF-xB transcription (Rodriguez, 1999).
TLR4 is unique in that it can act independently of Myd88, similar to signalling via 
TLR3, but can also signal in a Myd88-dependent way like TLR7 and 9. TLR4, 7 and 
9 can activate NF-kB using MyD88 to recruit TRAF3 and interleukin-1 receptor- 
associated kinases (IRAKs) 1 and 4. IRAK4 phosphorylates IRAKI which then 
undergoes autophosphorylation to become fully active and then binds TRAF6. 
Polyubiquitination of TRAF6 induces oligomerisation (Chen et al., 2005) and 
association with TAKl and the TAKl-binding proteins (TAB) 1, 2 and 3. TAKl 
phosphorylates IKK/3 which in turn phosphorylates IkB and NF-kB moves to the 
nucleus to bind the IFN/3 promoter as in TLR3 signalling. IRF7 induction by TLR4,
7 and 9 requires TRAF6 and RIP-1 recruitment to the MyD88 adaptor complex 
where IRAKI can phosphorylate IRF7. This group of proteins (complex not 
illustrated in figure 1.4) can then translocate to the nucleus and bind the IFN/S 
promoter in a similar way as the IRF3 dimer.
TLR7 can also activate IRF3 and IRF7 via MyD88 and TRAF6 activation of Ikka It 
is gemerally believed IRF3 activates IFN/3 and that IRF7 is required to activate IFNce 
but IRF7 can also activate IFN/3 (Honda et al., 2005).TBK1 and IKKe phosphorylate 
IRF3 and IRF7 but IRF7 can also be activated via the TLR7/9 pathway. This 
pathway also activates NF-kB, as shown in figure 1.4, but it is thought
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phosphorylation of IKKceby NIK and subsequent phosphorylation of IRF7 is also 
possible (Wang and Liu, 2007).
On activation of TLR3 and 4, IRF3 is phosphorylated (Servant, 2002) by TBKl 
(McWhirter, 2003) and IKKe. IRF3 forms a dimmer and translocates to the nucleus 
where it binds CBP/p300 on the IFN/3 and IFNO! promoter (Mamane, 1999). IRF7 is 
also phosphorylated by TBKl and IKKe. IRF3 and IRF7 can also form a heterodimer 
which translocates to the nucleus and activates a number of IFN-stimulated genes 
(ISGs) in delayed IFN responses.
The c-Jun and ATF-2 proteins are activated by phosphorylation through stress- 
activated protein kinases (SAPK). They form a heterodimer making up the AP-1 
complex. This is translocated to the nucleus and activates the IFN/3 promoter as well 
as those from other pro-inflammatory cytokines such as IL-6 and TNF-üü NF-kB is 
activated by phosphorylation of IkB by the IKK complex (Ghosh, 2002). IkB is then 
targeted for ubiqutination and proteosome degradation releasing NF-kB. The NF-kB 
dimer moves to the nucleus activating transcription ofIFN/3 and other pro- 
inflammatory cytokine genes (Karin, 2000).
IFN/3 and IFNce are secreted from the cell and act in a paracrine/autocrine fashion to 
activate other delayed type 1 IFN genes in adjacent cells and the primary infected 
cell itself. IFN/3 binds to the IFNoR receptor which causes dimérisation of the 
receptor. This leads to phosphorylation of tyrosine kinase 2 (Tyk2) through Janus (or 
just) another kinase 2 (JAK2). This in turn phosphorylates JAKl and STAT2 leaving 
a free binding site on STATl. The activated ST AT 1 and 2 form a heterodimer 
which creates a nuclear localization signal (Banninger and Reich, 2004). The 
ST AT 1/2 dimer translocates to the nucleus where it associates with IRF9 forming the 
ISGF3 complex. This binds to the IFN-stimulated response element (ISRE) in gene 
promoters and activates a range of IFN stimulated genes (ISGs) including 2’-5’- 
oligoadenylate synthetase (2’-5’-OAS), RNase L, double stranded RNA dependent 
protein kinase (PKR) and matrix metalo- (MX) proteins like GTPases (Bonjardim, 
2005; Perry, 2005). These are important anti-viral responses interrupting protein
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synthesis and viral replication as well as activating programmed cell death to prevent 
spread of infection.
TLRs and IFN also play an important role in activating the adaptive immune 
response (Bonjardim, 2005). IFNjS is important in maturation of dendritic cells (DCs) 
and production of type 2 IFN. TLRs on antigen presenting cells, primarily DCs but 
also macrophage, produce IL-12. This is important in T cell differentiation and 
natural killer (NK) cell cytotoxicity (Hawlisch, 2006; Trinchieri, 2003).
 ^^  s ^
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1.2.2 Apoptosis
In order to regulate cell growth, and prevent cancers, immunodeficiency and auto- 
reacitvity, cells have developed a mechanism for programmed cell death or apoptosis.
As well as activating TLRs, pathogens can activate a number of death receptors. These 
death receptors can also activate downstream effector pathways including NF-kB, p53, 
various cysteine-aspartic actid proteases (caspases) and a number of other proteins 
involved in apoptosis.
Apoptosis is a tightly regulated process involving a large number of proteins and 
interlinking pathways. There are two main pathways through which apoptosis can occur 
in mammalian cells. These are via the mitochondrial pathway or via death receptors. The 
mitochondrial pathway can be activated by external and internal stimuli. Death receptors 
are activated by external stimuli. The death receptors can be activated by cytokines such 
as TNF-a, Fas-L and TNF-related apoptosis inducing ligands (TRAIL) (see fig: 
1.5)(Wang and El-Deiry, 2003). Activation of the death receptor then activates the 
adaptor molecules such as F ADD and TRAF. This activates caspase 8 which can then 
directly activate caspase 3 or cause cytochrome-c release from mitochondria.
Cytochrome c is released from mitochondria in response to pro-apoptotic stimuli and 
elevated calcium levels. Release of cytochrome c can then activate caspase 9 which in 
turn can activate caspase 3 and 7. Tight regulation of a family of Bcl-2 related proteins is 
required for control of release of cytochrome-c from mitochondria. There are three 
groups of Bcl-2 like proteins. The first includes Bcl-2 itself which is anti-apoptotic. 
Group two includes Bax and Bak which are pro-apoptotic and the third group contains a 
diverse group of proteins with two Bcl-2 homology domains which are the only common 
feature in this group. This pro- or anti-apoptotic activity of these related proteins, seems 
to be evolutionarily conserved between very simple and more complex organisms 
(Hanada, 1995; Wemer, 2002).
As well as activating caspase 8, the death receptors can also activate the IKK complex, 
which in turn activates NF-kB. As discussed in the previous section, NF-KB controls
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many different factors involved in immune regulation and cell survival. Viruses have 
developed a complex array of proteins which can interfere with various stages of NF-kB 
activation, transcription and translation. Caspases can be activated directly or inhibited 
by production of inhibitor of apoptosis proteins (lAPs). A number of Bcl-2 protein 
family members regulate cytochrome-c release from mitochondria and their transcription 
is activated by NF-kB. Release of cytochrome-c then activates caspase 9 through 
association with the Apaf-1 and procaspase-9 complex (Baetu, 2002).
The p53 protein is also activated by NF-kB. This protein is normally stabilised by 
phosphorylation in the nucleus or rendered inactive in the cytoplasm by the Mdm2 
protein. Activation and regulation ofp53 is controlled by a number of different 
mechanisms. Active p53 induces apoptosis. The various p53 control mechanisms can be 
exploited by viruses, including ASFV, to control cell death and proliferation.
34
Bcl-2
O \
Caspase 8
Bid
I
TNRF, Fas, 
TRAIL-Rl. 
TRAIL-R2
Death i—i
Receptor I I
JbBTRAP
Cytochrome c
Caspase 9 
activation
Caspase 3 |
-Apaf-1 and 
procaspase-9
IKK complex 
activation
TRAF
Caspase
activation
Mitochondria
Regulation of 
TRAF1&2, C-IAPI&2, 
Fas L, TNF-aand 
TRAIL ligands
p53
Apoptosis ^ NF-kB
Figure 1-5 Activation of apoptosis pathways - The mitochondrial pathway requires 
activation of caspase 8 or Bcl-2 like proteins. This is activated by either internal or 
external stimuli. Once caspase 8 is activated it can either induce apotosis directly 
through caspase 3 or by activating release of cytochrome-c from mitochondria in a 
similar way to the pro-apoptotic Bcl-2 proteins. The other pathway uses death receptors 
and requires activation by external stimuli. Activation of death receptors can activate 
caspase 8 or the Ikk complex. Activation of the Ikk complex leads to NF-kB activation 
which in turn is able to activate components involved in apoptosis.
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Another important immune modulator is the transcription factor nuclear factor of 
activated T-cells (NFAT). Although first described in T cells this transcription factor has 
been identified in a variety of cell types including both immune and non-immune cells 
such as muscle. NFAT proteins play a crucial role in the transcription of cytokine and 
other immune response genes (Crabtree and Olson, 2002; Rao et ah, 1997). Activation 
of NFAT through a receptor varies depending on cell type and stimuli. In response to 
activation of the receptor or low Ca^  ^in cells the IPS receptor is activated. This in turn 
opens the Ca^  ^release-activated Ca^ '*' channel (CRAC). The increase in Ca^  ^activates 
the calcium calmodulin dependent serine phosphatase, calcineurin (CaN). This de- 
phosphorylates cytoplasmic NFAT family members, which reveals a nuclear localization 
signal (NLS). NFAT translocates to the nucleus and binds co-operatively with AP-1 
transcription factors which consist of c-Jun and c-Fos to induce expression of various 
immune response genes (Crabtree, 1999).
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Figure 1-6 Activation of NFAT genes - Binding of a receptor activates the IP3 complex 
and causes an influx of calcium or a calcium spike through the Ca^  ^release activated 
channels (CRAC). The increase in Ca^  ^activates the calcium calmodulin dependent 
serine phosphatase, calcineurin (CaN). This deposphorylates NFAT, which is then 
translocated to the nucleus and activates a range of immunomodulatory genes such as 
AP-1, c-MAF and G AT A4.
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1.2.3 ASFV interactions with host defence mechanisms
Viruses have evolved many mechanisms to counteract host defence strategies. These 
mechanisms include interference with many signalling pathways, blocking or mimicing 
cytokines, inhibition or promotion of apoptosis and interference with antigen 
presentation with MHC class I and II molecules (Ploegh, 1998). Virus infection activates 
the innate immune system. Ultimately a virus requires the host cell to remain intact 
while it undergoes replication. Some viruses even depend on host cell machinery in 
order to replicate. In order to spread and infect new hosts the virus needs to break free 
from the host cell. The regulation of apoptosis is clearly crucial for enabling viruses to 
complete their Hfe cycle. Large viruses like ASFV encode a large number of proteins 
which can exploit cells to facilitate productive viral infections. Although much work has 
been done to investigate the function of some ASFV proteins there are many proteins 
whose frmctions are undefined. Proteins identified so far are involved in inhibition of 
apoptosis, cell adhesion proteins and proteins which interfere with host macrophage 
signalling pathways to regulate transcriptional activation of immune response genes 
(Dixon, 2004).
1.2.3.1 Modulation of host gene transcription
Many viruses encode proteins that interfere with NF-kB activation to promote viral 
spread by inducing apoptosis, blocking apoptosis or to evade other host defences 
(Hiscott, 2003). The ASFV A238L protein is an Ik-B like protein which interacts with 
NF-kB p65 subunit. Recent data has implicated A238L in inhibition of p300/CBP 
transcriptional co-activation . Two forms of A238L are observed. One form migrates at 
28 KDa and a 32 KDa form is thought to be post translationally modified. It is this 32 
KDa protein that is co-precipitated with the p65 sub-unit of NF-kB. Activation of the 
NF-kB pathway by a number of stimuli including virus infection induces 
phosphorylation dependent ubiquitination and degredation of the Ik-B inhibitor of NF-
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kB. The A238L protein is not subject to signal induced degradation and acts as a 
homologue of I-kB to prevent the signal induced degradation of I-kB that normally 
occurs during virus infection (Tait, 2000). The A238L protein may also play a key role 
in reduction and control of pro-inflammatoiy cytokine transcription (Dixon, 2004;
Powell, 1996).
A238L can also bind the catalytic sub-unit of calcineurin (CaN) (Miskin, 1998; Miskin 
et al, 2000a; Miskin et al, 2000b). CaN regulates various cellular pathways including 
activation of the NFAT family of transcription factors. The binding of A238L to CaN 
has been localised to a 14 amino acid region between 200 and 213. The binding site on 
CaN is situated in the catalytic domain. The NFAT and A238L CaN docking domains 
are similar and allow binding but do not block phosphatase activity of CaN. Competition 
assays suggest A238L binds more strongly to CaN than NFAT does. Data also suggests 
that CaN binding stabilises the A238L protein. An 82 amino acid domain from the C- 
terminus of A238L can bind and strongly inhibit CaN phosphatase (Abrams et al, 2008). 
There may be a direct link between the affinity of binding of the docking motif of 
A238L to CaN and its ability to inhibit CaN phosphatase activity. Mutation of critical 
residues PxIxIT within the docking motif prevents binding of A238L to CaN and A238L 
inhibition of CaN phosphatase (Miskin, 2000).
There is growing evidence of a number of viruses that inhibit prostaglandin production. 
Prostaglandins are important in inflammation and modulation of immune responses. In 
particular prostaglandin E2 (PGE2) which is secreted by macrophage. Synthesis of these 
molecules requires the cyclo-oxygenase (COX) enzymes. COX-2 requires activation by 
various stimuli such as cytokines. The promoter site on COX-2 has binding sites for 
transcription factors such as NFAT and NF-kB. ASFV infection can induce COX-2 
activation but this is inhibited by the A238L protein. This appears to be carried out via 
inhibiting transactivation of NFAT transcription factor (Granja, 2004a). Studies have 
also demonstrated that A238L is able to inhibit expression of TNF-ce and iNOS through 
transcriptional co-activator p300/CBP (Granja et al, 2006a; Granja et al, 2006b).
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1.2.3.2 ASFV inhibition of apoptosis
The onset of apoptosis is only seen late in ASFV infection at around 16 to 18 hpi 
suggesting that the virus has mechanisms to inhibit apoptosis. There are three proteins 
shown to inhibit apoptosis; A224L, A179L and EP153R. A224L has similarity with the 
inhibitor of apoptosis (lAP). It has been shown to interact with the catalytic region of 
caspase 3 and thus play a role in inhibiting apoptosis and promoting cell survival 
(Chacon et al., 1995; Nogal et al., 2001). The A224L protein is also able to activate NF- 
kB (Rodriguez, 2002). The A179L protein is a viral Bcl-2 homologue which has been 
shown to inhbit apotosis via porcine BID protein which acts downstream of caspase 8 
(Galindo et al, 2008a). The EP153R protein may inhibit apotosis by inhibiting the 
transactivating potential ofp53 (Hurtado et al, 2004).
ASFV has a number of mechanisms which promote apoptosis. The proteins involved in 
this have not been identified as yet. Infection with ASFV can induce apoptosis by 
activating caspase 3 and 9. This causes an increase in the amount of cytochrome-c 
released from mitochondria and thus induces apoptosis. This activation is due to an early 
step in ASFV infection. Viral DNA replication and protein synthesis is not required 
(Carrascosa, 2002). Apoptosis can also be induced by the activation ofp53. This may be 
held active in the cytoplasm by the retention of Mdm2 protein in viral factories (Granja, 
2004b).
1.2.3.3 Regulation of IFN response
The major variable regions of the ASFV genome seem to be restricted to the terminal 
regions of the genome, the left 35kb and the right 15kb. These contain at least 5 multi 
gene families (MGFs). Infection of cells with these deletion mutants of members of 
MGF360 and MGF 530 showed an increase in type 1 IFN production suggesting these 
regions are involved in regulation of IFN (Alfonso et al, 2004).
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The EP402R gene encodes a protein similar to the T cell adhesion molecule CD2 and is 
called CD2v. It contains an extracellular domain that resembles host CD2, a signal 
peptide, a predicted trans-membrane domain and a cytoplasmic tail (Borca et al, 1994; 
Rodriguez et al., 1993). Expression of CD2v protein causes erythrocyte haemadsorption 
around cells infected with most ASFV strains and binding of extracellular virus particles 
to red blood cells. This haemadsorbtion is thought to facilitate dissemination of the virus 
around the host. CD2v is not essential for replication in primary macrophage cells and 
does not reduce mortality. However, pigs infected with CD2v deletion mutants exhibit 
an initial reduction in viremia and delayed spread to lymph nodes (Borca et al., 1998). In 
the host cell CD2 is involved with a number of inter and intracellular signalling events. 
CD2v binds to and co-localises with SH3P7 (SH3 domain is found in many proteins e.g. 
enzymes and those involved with cytoskeleton) at virus factories (Kay-Jackson and - 
Dixon, 2004).
Porcine macrophages have been shown to express swine leukocyte antigens (SLA). 
These are the pig equivalent of human MHC molecules. During infection with highly 
virulent isolates of ASFV, these have been shown to be down regulated (Gonzalez- 
Juarrero, 1992).
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1.3 DNA microarray technology
The first micro array experiments were carried out in 1997 by Trent et al, (Trent, 1997). 
DNA micro array technology enables the expression levels of thousands of genes to be 
measured simultaneously. The technology is based on hybridization. mRNA binds to 
specific DNA templates or oligos spotted onto a slide. Each spot contains sequence from 
a single gene. mRNA is fluorescently labelled and hybridised to the spots. mRNA from 
different sources can be labelled with green or red fluorophores. The hybridised 
micro array is then excited by a laser and scanned at wavelengths suitable to detect green 
and red. The amount of fluorescence emitted corresponds to the amount of nucleic acid 
bound to each spot (See figure 1.7). This is measured by computer which can then show 
which genes are up-regulated. These results can be compared with other samples to look 
at specific gene regulation patterns under different conditions and in different systems, 
for example during infection, under different growth conditions, or in different cell types 
etc. By understanding what genes are turned on by what stimuli in different systems we 
can dissect the intricate pathways involved in host-pathogen interactions and therefore 
gain a better understanding of whole organism.
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RNA extraction and 
amplification
Alveolar 1 / 
Macrophage RNA labelling
Computer
Analysis
Hybridization
Slide spotted with oligo 
array
Figure 1.7 A diagram summarising the steps involved in a microarray experiment -
RNA is extracted from alveolar macrophages. The RNA is amplified and labelled. This 
is then hybridised to a slide spotted with oligos from different genes. The image from 
the slide is then captured by laser scanning and analysed using appropriate software.
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1.3.1 ASFV microarray experiments
A number of micro array experiments have been carried out within the ASFV group at 
the Institute for Animal Health. These experiments compared gene expression levels in 
ASFV infection compared to uninfected cells. A porcine cDNA microarray containing 
2880 genes has been used to compare host gene activation at different time points. Two 
time points after infection were chosen and compared to each other and to mock infected 
cells. The time points chosen were 4 hours and 16 hours post infection (hpi). At 4 hpi 
early viral protein synthesis has begun. Transcription levels of host mRNAs analysed 
previously by real time PCR, show activation of a number of genes peaked at this time. 
At 16 hpi late gene expression and production of new virions is in progress. The mock 
infection results showed little difference between 4 and 16 hours post infection so these 
samples were pooled and used together in comparisons.
The results showed a large number of genes were significantly altered in their expression 
levels. These were clustered according to their expression patterns (temporally-regulated 
clusters) and according to their function (Functional clusters of differentially regulated 
genes). The table below (Table: 1.1) shows the fold increase in expression of a number 
of different genes analysed in this experiment. Expression of galectin-3 was one gene 
shown to be up-regulated in alveolar macrophages during ASFV infection in microarray 
experiments carried out by Zhang et al (Zhang et al., 2006).
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Table 1.1 A selection of differentially regulated genes from cDNA microaray 
experiment. A previous microarray experiment carried out, compared host gene 
expression in Malawi virus infected cell at 4 and 16hpi. These were compared to mock 
infected cells as a reference. A list of some of the differentially-regulated genes are 
included in this table (Zhang et al., 2006).
Protein Expressed Protein Function Fold changes in expression of 
infected cells compared to mock 
4hpi 16hpi
MlPljS CC Chemokine 3-3.5 1.0
MJPlo, CC Chemokine 4.5 1.5
RANTES CC Chemokine 1.5 1.1
AMCFl CXC Chemokine 1.5 1.0
IL-lj8 Cytokine 2.0 1.0
TNF-a Cytokine 2.0 1.0
IFN-i8 Cytokine 1.5 1.0
Syndycan2 Cell surface/secreted 4.5 1.5
Galectin-3 Cell surface/secreted 4.0 1.0
Mannose Receptor Cell surface/secreted 4.0 1.0
CREB Intracellular Signalling 
Molecule
3.0 1.0
JAK2 Intracellular Signalling 
Molecule
3.0 0.5
STAT2 Intracellular Signalling 
Molecule
1.7 1.1
NF-kB p50 subunit, 
IkB
Intracellular Signalling 
Molecule
1.4 1.0
Sorting NexinlO Protein Trafficking 4.1 1.0
Leptin Receptor 
Gene Related 
Products
Protein Trafficking 1.4 1.0
Heat shock protein 
40 and 70
Stress Response 1.0 1.0
Cathepsin S Cystine Protease 5.0 1.0
Prostaglandin G/H 
Synthetase 2
General translation 
factor
1.0 1.0
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1.4 Galectins
Galectins are a group of carbohydrate binding proteins which have binding affinity for 
/3-galactosides. 14 galectins have been identified so far which all have conserved 
sequence elements in their carbohydrate recognition domains (CRD) (Barondes SH and 
Hirabayashi J, 1994). Interestingly there have also been a number of galectins identified 
in amphibians, birds, fish, worms, fiingi and sponges (Trends in glycos and 
glycobiology, 9 1997, 1-184). The 14 different animal lectins have been divided into 3 
structural groups. The first or prototype group contains galectins 1, 2, 5, 7, 10, 11, 13 
and 14. These have a single CRD. Galectin-3 is in a group on its own called the chimera 
type galectin and consists of an N-terminal region of about 100 to 150 amino acids in 
length and a CRD (Wang et al., 2004). All the other galectins are part of the tandem 
repeat group and consist of two CRDs joined together by a flexible linker. The CRDs are 
typically 135 amino acids in length for all the galectins identified. The interaction of this 
CRD and monosaccharide ligand galactose is quite weak. The lactose disaccharide has a 
much higher affinity in the galectins that have been tested (Leflier and Barondes, 1986). 
Galectins are expressed in many different cell types or at various stages in development. 
Nearly every cell in the body expresses at least 1 galectin at any time (Cooper and 
Barondes, 1999). Their functions vary widely, with many being multifunctional proteins 
whose function depends to a large extent on its localization within a cell. Galectin-1 and 
3 seem to have a tightly linked relationship. They are both involved with inhibiting and 
promoting apoptosis when expressed in the cytoplasm or in the extracellular 
environment (Hernandez and Baum, 2002). In the nucleus both are involved in pre- 
mRNA splicing (Liu et al., 2002; Wang et al., 2004). Galectins are thought to be 
synthesised in the cytoplasm on ribosomes but secretion fi*om cells follows a non- 
classical pathway (Hughes, 1999).
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1.4.1 Galectin-3
Galectin-3 proteins range from 29 to 35 kDa in molecular weight depending on the 
species and as mentioned above this is the only chimera type galectin identified so far. 
Galectin-3 is encoded by the gene LGALS3BP. The protein also has a number of other 
names such as Ig-E binding protein, Mac-2, CBP35, L-34 and L-29 but is more 
commonly reffered to as galectin-3 these days. Figure 1.8 shows a schematic of the 
protein structure with the N-terminus and the CRD indicated. The N-terminal domain 
contains 8 repetitive regions. Each region consists of a sequence of 9 amino acid 
residues; Pro-Gly-Ala-Tyr-Pro-Gly + 3 other variable amino acids (Jia, 1988).
Galectin-3 is expressed in a number of different cell types; macrophages, fibroblasts, 
activated T-cells, epithelial cells and various types of tumour cells (Krzeslak, 2004). The 
protein is localised predominately in the cytoplasm but is also found in the nucleus, at 
the surface of cells and also in the extra cellular environment. The protein has a number 
of functions partly related to its different locations within a cell (Wang et al., 2004). In 
3T3 mouse fibroblasts galectin-3 is found in the nucleus and the cytoplasm depending 
on the state of the cell. In resting cells galectin-3 is found predominantly in the 
cytoplasm, often in a phosphorylated form. In proliferating fibroblasts intense nuclear 
staining of the native non-phosphorylated form was demonstrated. The intra-nuclear 
distribution of galectin-3 has also examined in 3T3 cells by immunofluorescence and 
immunoelectron microscopy. The protein is distributed throughout the nucleosome and 
nucleoli with no particular areas having significantly more intense staining. When these 
cells were treated with RNAse, galectin-3 was translocated from the nucleus. Treatment 
with DNAse had no effect, suggesting that there is an association with ribonucleoprotein 
complexes (RNPs) and maybe an involvement in pre-mRNA splicing and mRNA 
transport (Hubert, 1995).
Galectin-3 has also been shown to have an anti-apoptotic effect on cells. Jurkat cells are 
resistant to apoptosis induced by various stimuli when galectin-3 is expressed
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ectopically. Other cell lines transfected with galectin-3 have higher rates of prohferation. 
Interestingly the N-terminal region of galectin-3 has a region which is highly conserved 
in the BHl domain of Bcl-2 family of apoptosis repressor proteins. Galectin-3 has 
similarities to Bcl-2. At the C-terminus they both have a sequence of 4 amino acids, 
NWGR. At the N-terminal they are both rich in proline, glycine and alanine. Galectin-3 
can bind Bcl-2, forming a heterodimer in the way that Bcl-2 usually forms homo dimers. 
Exactly how the anti-apoptotic effect of galectin-3 is mediated is not known. The protein 
does not have a hydrophobic domain at the C-terminus and hence is probably not 
inserted into intracellular membranes in particular the mitochondrial membrane. 
However, this hydrophobic tail is dispensable in other apoptotic proteins. Galectin-3 also 
forms a homodimer which binds to the Bax pro-apoptotic protein. However, this 
interaction with Bax alone is not sufficient to block apoptosis (Hanada, 1995). The 
conserved sequence, Asn-Trp-Gly-Arg is also known as the death domain. Both 
galectin-3 and Bcl-2 undergo post-translational modification by serine phosphorylation. 
Phosphorylation at the N-terminal serine 6 on galectin-3 is required for its anti-apoptotic 
effect. The major acidic residues either side of the serine suggest phosphorylation is 
carried out by casein kinase 1. This phosphorylation, although required for anti- 
apoptotic function, seriously impairs the binding of galectin-3 to its ligands. This means 
that phosphorylation of galectin-3 could act as an on-off switch for sugar binding 
(Yoshii, 2002). The fact that galectin-3 can prevent apoptosis activated by a range of 
stimuli, suggest that it functions at an important commitment step in apoptosis.
Other data suggest that phosphorylation of galectin-3 is required for its export from the 
nucleus and that this enhanced export due to phosphorylation is required for anti- 
apoptotic fimction. After translocation to the cytoplasm galectin-3 activates the mitogen 
activated protein kinase (MARK) pathways via ERK and JNK. These pathways can lead 
to a block in cytochrome-c release from mitochondria and thus inhibit caspase activation 
and apoptosis. Experiments have shown that galectin-3 activated the ERK pathway but 
that galectin-3 mutants unable to undergo phosphorylation at serine 6 did not (Takenaka, 
2004).
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Galectin-3 has also been linked to cytochrome-c more directly. Immunofluorescence 
studies show galectin-3 translocates to the mitochondria on stimulation with inducers of 
apoptosis. It also co-localises with cytochrome-c at the mitochondria. Over expression of 
galectin-3 prevented cells from losing their mitochondrial membrane potential and thus 
prevented release of cytochrome-c. Intracellular translocation of galectin-3 requires 
synexin to transport it to the mitochondria but excretion from the cell requires another 
method (Yu et al., 2002b).
Galectin-3 is also secreted from cells. However, the mechanism of secretion is unknown. 
It lacks signal peptides used in the classical secretory pathways. Secretion does not 
involve the ER or Golgi. The N-terminal region has been shown to be required for 
export from the cell (Mehul and Hughes, 1997). Galectin-3 binds to glycosylated 
extracellular matrix proteins such as lamin, fibronectin, tenascin and Mac-2 binding 
protein. It can also bind some cell surface integrins (Krzeslak, 2004). These interactions 
with various ligands could be important in host pathogen interactions. The extracellular 
protein can crosslink via /3-galactoside to cell surface glycoconjugates and may modulate 
cell signalling. By doing this it could alter cell signalling, adhesion and cell survival 
(Rabinovich, 2002a; Rabinovich, 2002b).
Levels of galectin-3 expression have been shown to be up-regulated and down-regulated 
in various cancers in which the parental cells do not normally express the protein. 
Experiments with galectin-3 knock out mice show a decrease in numbers of monocytes, 
lymphocytes and macrophages. The cells grow slower and with a spindly morphology. 
The knock-out mice were more sensitive to apoptotic stimuli (Hsu, 2000). While 
gelectin-3 clearly plays a multifunctional role in a range of cell types more recent work 
has focused on its function in different types of cancer. There has been less work done to 
investigate any role galectin-3 may play during infection with viruses.
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N -term inal CRD
=400-150 aa =435 aa
Figure 1. 8 The organisation of the galectin-3 polypeptide. The N-terminal is 100-150 
amino acids long with a region of 8 tandem repeats. The C-terminal has the carbohydrate 
recognition domain (CRD) and is about 135 amino acids long.
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1.5 Project aims and objectives
The ultimate aim of this project is to gain a greater understanding of how virus infection 
affects cell fonction. Ultimately this will lead to development of new vaccines or better 
treatments. The specific aims of this project were to look at global gene expression in 
host macrophage cells infected with ASFV and compare this with gene expression in 
uninfected cells. The complex nature of virus infection, replication and host-pathogen 
interactions mean there is much to be investigated. In particular looking at early stages 
during ASFV infection may be helpful to define immediate host cell reactions and what 
measures could be used to counteract viral invasion. Activation of both the innate and 
adaptive immune system is important for development of a good vaccine. There are 
many cellular signalling pathways which interact and regulate the immune system. It is 
important to understand how these pathways are regulated during infection. Earlier work 
has already highlighted a number of genes or proteins which require forther 
investigation. The up-regualtion of galectin-3 shown in previous micro arrays is one 
candidate as it may play a critical role in immune modulation or regulation of apoptosis 
during ASFV infection.
This project has been divided into two parts. The first section focuses on galectin-3; with 
characterisation of the porcine protein, production of several anitbodes against the pig 
protein and forther investigations into the expression and locahzation of galectin-3 
during ASFV infection. In the second part of this project the effect of ASFV on host 
gene expression has been studied with the focus on early infection and the signalling 
pathways modulated.
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The main aims of the project can be summarised:
1 - Investigate the expression and location of galectin-3 during ASFV infection
2 - Investigate which early stages in ASFV infection are involved in activating host 
macrophage transcriptional responses
3 - Highlight the signalling pathways activated by these early events of ASFV
infection
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Materials and Methods
2.1 Materials
2.1.1 Reagent suppliers
Chemicals were supplied by Sigma-Aldrich Company (Dorset, England) unless 
otherwise stated. Enzymes and buffers were purchased from Promega Ltd (Southampton, 
England) and kits for nuclear extraction were purchased from Qiagen Ltd (West Sussex, 
England). Radioisotopes were from Amersham Biosciences, (GE Healthcare, Berkshire, 
England). Foetal calf serum was purchased from PAA laboratories (Pasching, Austria). 
Fico 11-Hypaque separation media from Amersham Biosciences.
2.1.2 Cell culture media
HEPES-buffered Dulbecco’s modified Eagle’s medium (DMEM): - N-2- 
hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES) buffered Dulbecco’s 
modified Eagles medium supplemented with 10% foetal calf serum (FCS), 20mM L- 
glutamine, 100 units/ml penicillin, 100 units/ml streptomycin and 2.5pg/ml 
Amphotericin B.
RPMI - medium supplemented with 10% foetal calf serum (FCS), 20mM L-glutamine, 
100 units/ml penicillin, 100 units/ml streptomycin, and 2.5pg/ml Amphotericin B.
2x Eagles medium -  used for PBL isolation and not supplemented with any antibiotics 
or serum.
IMDM (GIBCO) -  medium supplemented with 10% FCS, 20mM L-glutamine, 100 
units/ml penicillin, 100 units/ml streptomycin and 2.5pg/ml Amphotericin B.
Earle’s media -  supplemented with 15% porcine serum, 20mM L-glutamine, 100 
units/ml penicillin, 100 units/ml streptomycin, and 2.5pg/ml Amphotericin B.
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HANKS -  HBSS 10 x from GIBCO in 50ml water with enough sodium bicarbonate 
(7.5%) so the colour just changes.
Versene Trypsin - 136mM NaCl, 5.3mM KCl, 5.5mM NaHCOg, 0.02% weight/volume 
(w/v) trypsin, 0.01% (w/v) ethylenediaminetetraacetic acid (EDTA), 0.1% (w/v) phenol 
red.
2.1.3 Bacterial culture media 
Lauria-Bertani media (LB): - 1% (w/v) tryptone, 0.5% (w/v) yeast extract, 0.5% (w/v) 
NaCl in distilled water.
Agar plates: 1.5% (w/v) Bacto agar (Oxoid Nol) in LB medium 
Amplicillin resistance: lOOpg/ml ampicillin 
Kanomycin resistance: 50pg/ml kanomycin
2.1.4 Cell lines
Vero: African green monkey kidney cells, were obtained from the European Collection 
of Animal Cell Cultures (lAH tissue culture services). Cells were grown at 37°C in 
DMEM, supplemented with 10% FCS, 20mM L-glutamine, 100 units/ml penicillin, 100 
units/ml streptomycin and 2.5pg/ml Amphotericin B.
Hela Cells: Cervical cancer cells, were grown at 37°C in DMEM, supplemented with 
10% FCS, 20mM L-glutamine, 100 units/ml penicillin, 100 units/ml streptomycin and 
2.5pg/ml Amphotericin B.
3T3 cells: Transformed mouse fibroblast cells, were grown at 37°C in DMEM, 
supplemented with 10% FCS, 20mM L-glutamine, 100 units/ml penicillin, 100 units/ml 
streptomycin and 2.5pg/ml Amphotericin B.
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PK15 cells: Transformed porcine kidney cells, grown in alpha MEM (GIBCO) 
supplemented with 10% FCS, 20mM L-glutamine, 100 units/ml penicillin, 100 units/ml 
streptomycin and 2.5pg/ml Amphotericin B.
MAX cells: Porcine kidney cells, grown in IMDM (Invitrogen GIBCO, Paisley, UK) 
with 10% FCS, 20mM L-glutamine, 100 units/ml penicillin, 100 units/ml streptomycin 
and 2.5 pg/ml Amphotericin B
Primary, porcine, alveolar macrophage (PMs): Macrophage cells were harvested 
from normal outbred pigs by lung lavage with PBS. Cells were pelleted by 
centrifugation at 1200 rpm at room temperature for 10 minutes. Cells were then 
resuspended in RPMI supplemented with 10% FCS, 20mM L-glutamine, 100 units/ml 
penicillin, 100 units/ml streptomycin and 2.5pg/ml Amphotericin B and maintained at 
37°C.
Primary, porcine, bone marrow cells (PBMs): Bone marrow cells were harvested 
from piglet femur bones courtesy of the central services unit at lAH. Adherent 
monocytes and macrophages were cultured for further use. Cells were maintained in 
Earl’s media supplemented with 15% porcine serum, 100 units/ml penicillin, 100 
units/ml streptomycin and 2.5pg/ml Amphotericin B.
Primary porcine blood lymphocytes (PBLs): Whole blood was taken from pigs. 50 ml 
of heparinised blood was centfrfuged for 10 minutes at 2100 rpm at 4°C. The huffy coat 
(white ring of cells between red cells and serum) was removed and re-suspended in 2ml 
HANKS solution. 8ml of Ficoll-Hypaque (Amersham biosciences) was then layered 
under the cells and they were centrifiiged at 1,600 rpm for 20 minutes. The layer of 
lymphocytes at the interface of the gradient was harvested and re-suspended in HANKS. 
Cells were centrifiiged at 1,400 rpm for 5 minutes. To remove all red blood cells the 
cells pellet was re-suspended in 10ml water and then 10ml 2x Eagles media quickly 
added. Cells were centrifiiged at 1,400 rpm for 5 minutes. This was repeated until all the 
red cells have been removed. Finally PBLs were re-suspended in IMDM media (GIBCO)
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supplemented with 10% FCS, 20mM L-glutamine, 100 units/ml penicillin, 100 units/ml 
streptomycin and 2.5pg/ml Amphotericin B.
2.1.5 Viruses
Initial stocks of virus were obtained from Dr. Charles Abrams (Institute for Animal 
Health, Pirbright, England). The attenuated, tissue culture adapted BA71V (Enjuanes et 
al., 1976) and the virulent ASFV Malawi isolate Lil 20/1 and OURT 88/3 isolate (Dixon, 
1988; Dixon and Wilkinson, 1988; Haresnape, 1984) have been described previously.
2.1.6 Antibodies
Antibodies and Anti-sera to viral proteins
The mouse monoclonal antibody specific for the ASFV early protein p30 (cl8) was a 
gift from Dan Rock (Plum Island Animal Disease Centre, New York, USA) and has 
been described previously (Afonso et al., 1992). The M192 pig anti-ASFV serum was 
obtained from a large white pig inoculated with several different ASFV isolates. Rabbit 
antibody for p34 was generated from recombinant His-tagged protein using the pTrcHis 
expression vector from Invitrogen (Heath, 2001).
Antibodies to cellular proteins and common epitopes 
A mouse anti-human galectin-3 antibody (ab2785) was purchased from Abeam pic. An 
anti-V5 antibody was purchased from Serotec. All antibody concentrations for use in 
Western blot and immunfluorescence are shown in table 2.1.
Conjugated antibodies 
Goat anti-rabbit and goat-anti mouse IgG (H+L) Alexa Flour^^ 488 (green) and Alexa 
Flour™ 594 (red) conjugates were purchased from Molecular Probes (Netherlands). The 
DNA stain, 4’-6’- Diamidino-2-phenylindole (DAPl) was also from Molecular probes.
A goat anti-mouse HRP conjugated antibody was purchased from Promega (UK).
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Table 2.1 Antibody concentrations -table 2.1 shows the antibodies used for 
immunofluorescence (IF) and western blot (WB) with the corresponding concentrations.
Antibody Concentration
Human Anti Galectin-3 (Abeam) 1:7500 WB, 1:100 IF
Anti VP30 1:200 IF and WB
Anti p34 1:1001F and WB
Anti Mouse HRP 1:3000 WB
Goat anti mouse Alexa Fluor 488 or 594 1:500 IF
Anti Rabbit FITC 488 or 594 1:500 IF
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2.1.7 Buffers and Solutions
PBS (Ix) (pH 7.4)
NaCl
KCl
MgCi2.6H20
KH2PO4
N a 2 H P 0 4
CaCi2.2H20
138 mM 
2.70 mM 
0.49 mM 
1.47 mM 
9.67 mM 
6.80 mM
PBST
IX PBS + 0.1 % Tween TW20
Protein Sample Preparation Buffer (SPB) (2x)
1 MTris/HClpH 6.8 
SDS
p-mecaptoethanol
Glycerin
Bromophenol Blue
125 mM  
4 % (w/v)
1.8 % (w/v)
20 % (v/v) 
0.006 % (w/v)
RIPA
Tris-Cl pH 8.0
EDTA
Triton X-100
Sodium deoxycholate
SDS
NaCl
lOmM 
ImM 
1% (v/v) 
0.1% (w/v) 
0.1% (w/v) 
140mM
PMSF (phenylmethylsulphonyl fluoride) ImM
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SDS-PAGE resolving gel (10%)
Acrylamide 25 % (v/v)
(40% stock solution N,N’-methylene bisacrylamide 37.5:1) 
Tris-CLpH 8.8 0.4 M
SDS 0.1 % (w/v)
Ammonium persulphate 0.1 % (w/v)
TEMED 1.5 /d/ml
(N,N,N’ ,N’ -tetramethylethylenediamine)
SDS-PAGE stacking gel (4%)
Acrylamide 10 % (v/v)
(40% stock solution N,N’-methylene bisacrylamide 37.5:1) 
Tris-HCl pH 6.8 125 mM
SDS 0.1 % (w/v)
Ammonium persulphate 0.2 % (w/v)
TEMED 1.5 /d/ml
(N,N,N’,N’-tetramethylethylenediamine)
Protein gel resolving buffer
Glycine 1.92 M
Tris 250 mM
SDS 1 % (v/v)
Transfer Buffer
Tris 25 mM
Glycine 190 mM
Methanol 20 % (v/v)
Blocking solution
Dried low-fat skimmed milk 5 % in PBS 
+ 0.1% (v/v) Tween TW20
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ECL reagent
Tris-HCLpH 8.5 0.1 M
H2O2 3 mM
Reagent A (p-coumaric acid; 90 mM in DMSO) 22 pi 
Reagent B (Luminol; 250 mM in DMSO) 50 pi
Made up to 10ml in dd H2O
IF blocking buffer - 0.5% BSA/PBS
Bovine serum albumin 0.5% (w/v)
Tween-20 1% (v/v)
In Mg/Ca^  ^free PBS
Plasmid DNA purification (alkaline lysis method) 
Solution 1
Tris pH8.0 50 mM
EDTA 10 mM
RNase A 100 pg/ml
Solution 2
NaOH 200 mM
SDS 1 % (w/v)
Solution 3
Potassium acetate pH5.5 3M
TE
Tris.Cl pH 8.0 
EDTA
10 mM 
1 mM
Microarray buffers:
20xSSC
NaCl 3 M
Sodium citrate buffer (pH7.0) 0.3 M
(3 M NaCl and 0.3 M sodium citrate made up to pH 7.0 with 10 M NaOH)
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Pre-hybridization buffer
3x SSC containing 0.1 % SDS
Wash 1: 2x SSC containing 0.2 % SDS 
Wash 2: 2x SSC 
Wash 3: 0.2x SSC
Annexin V staining buffer (lOx)
HEPES (pH7.4) 0.1 M
NaCl 1.4 M
CaCl2 25 mM
2.2 Methods
2.2.1 Amplification of virus stock
A T175 flask containing alveolar macrophages was washed with PBS and infected with 
10ml of ASFV Malawi (Lil 20/1) isolate with a multipUcity of infection (MOI) of 1 to 5. 
Infections were left at 37°C rocking for 2hrs. Virus was removed and cells washed with 
PBS. 30ml RPMI maintenance media was then added to the cells. Infected cells were 
left at 37°C for 3 days. Any cells left on the flask were scraped into the media and 
sonicated for 2x30 seconds at level 4 using a cup horn sonicator. Virus preparation was 
then centrifuged for lOmin at 3000 rpm to remove cell debris.
2.2.2 Purification and concentration of virus stock
4ml of OptiPrep™ (Axis-Shield) was put into a Beckman SW28 tube and overlaid with 
34ml of virus stock. The tubes were centrifuged at 80 OOOg for 75min at 4°C. Two 
protein bands were formed about 2mm apart. The tube was wiped with 70% ethanol. A
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needle was inserted just below the lowest band and 4 ml of virus preparation removed. 
4ml of PBS was added and the diluted virus was then put onto a VIVASPIN 20 
concentrator with a MWCO of lOOOkDa. This was centrifuged in a swing rotor at 4000 
rpm at 4°C for about 1 hour or until the volume had reduced at least by half. PBS was 
added to bring the volume up to 20ml. This was centrifiiged again and repeated until no 
pink colour media was left in the virus preparation. This volume was brought down in 
the final spin to about 5ml. The purified virus stock was then titrated.
2.2.3 Virus titration
Ba71V isolate in Vero cells by immunoflourescence: Vero cells were plated onto a 96 
well plate to be confluent the following day. Media was removed fi*om the confluent 
cells and cells washed with PBS. Serial dilutions of 1:10 of the virus stock were made up 
to 10''^. 50pl of media was put in each well of the first column in the 96 well plate. The 
second column had 50pl of virus stock added to each well and then serial dilutions of 
this were added to the following wells. Virus was left on the cells over night. Cells were 
washed with PBS and the primary antibody against the viral protein vp30 added at a 
concentration of 1:100 (see table 2.0 of antibody concentrations). The antibody was left 
for Ihr. The cells were washed 3 times with PBS and the secondary, goat anti-mouse fitc 
488 antibody added at a concentration of 1:500. The secondary antibody was left on for 
Ihr. Cells were washed 3 times with PBS and then viewed using a Nikon Eclipse TE300 
fluorescence microscope. All wells containing an infected cell were labelled positive and 
the virus titration estimated using the Reed and Muench method (Reed and Muench, 
1938).
Malawi isolate (Lil 20/1) in macrophage cells by haemadsorbtion; Macrophages 
were plated onto a 96 well plate by adding lOOul of a 7 logio cell suspension ml'  ^of 
alveolar macrophages. The following day cells were washed in PBS and serially diluted 
virus stocks added to the corresponding well as described above. Virus was left on the 
cells overnight. Virus media was removed and replaced with RPMI containing 10% FCS 
and 0.5% washed homologous pig red blood cells. The plate was re-sealed and the cells
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were observed by light microscopy using a Nikon model TMS, every day for 6 days. 
Virus titres were calculated using the Reed and Muench method (1983) as above and the 
titre expressed as a logio 50% haemadsorbtion units (HAD50) ml'\
2.2.4 Virus infection
Cells were washed in PBS and then infected with 5-10 TCID 50/ml for Ihour at 37°C. 
After infection, cells were washed with PBS and jfresh media added. Cells were then left 
at 37®C for the indicated time periods.
2.2.5 Radio-labelling cells
A 6 well plate of cells was starved with methionine, cysteine (met/cys) reduced (1/10) 
media for 2hrs. Cells were then labelled with lOOpCi ml'  ^ of [^ S^] methionine and 
cysteine (Redivue PROMIX [^ S^] cell labelling mix, Amersham) in met/cys reduced 
media for 1 hr before infection or treatment with inhibitors.
2.2.6 Time course of infection with ASFV
Cells were plated into 6 well plates to be 80% confluent. The following day cells were 
infected with ASFV Malawi Lil 20/1 or BA71V isolate at an MOI 5-10. Virus was left 
to infect cells for 1 hour before replacing with culture media and leaving for set time 
periods. Supernatants were harvested and cells lysed in 1ml RIPA of protein running 
buffer for protein assay or RNA extraction.
2.2.7 The separation of proteins using SDS polyacrylamide gels (SDS-PAGE)
Cells were plated into a 6 well plate so as to be approximately 80% confluent the 
following day. Cells were washed with PBS and then lysed by the addition of 1 ml 
sample preparation buffer (SPB) or RIPA. Cells were scraped fi*ee fi*om the solid support
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and transferred to 1.5 ml eppendorf tubes. The cells were vortexed briefly and then 
centrifuged at 12,OOOg for 10 minutes to pellet insoluble cell debris. The supernatants 
were transferred to clean tubes and heated at 90°C for 5 minutes to denature the protein 
sample. Cell supernatants were also harvested fi'om the 6 well plate and diluted in 5x 
SPB. These were also heated at 90®C for 5 min. 25 pi of cell lysates and supernatant 
were resolved on 10 % polyacrylamide mini gels with a 4 % polyacrylamide stacking 
gels at 150 V for about 2 hrs in resolving buffer.
2.2.8 Western blotting
Proteins resolved using SDS-PAGE were transferred onto Hybond-C extra nitro­
cellulose membrane (Amersham Biosciences) using a transfer cassette submerged in 
transfer buffer for 1 hr at 200 mA. The system was cooled using a pre-fi*ozen cooling 
block. After protein transfer, the membrane was incubated in blocking buffer containing 
5% w/v milk powder over night at 4°C. The membrane was then incubated with the 
primary antibody at the concentrations indicated in table 2.1 and diluted in blocking 
buffer. After 1 hour the membrane was washed 3 times in PBST for 10 minutes. The 
secondary horse radish peroxidase (HRP) conjugated antibody was diluted in blocking 
buffer and incubated with the membrane for 1 hr. The membrane was then washed 3 
times in PBST for 10 minutes. All incubation steps took place at room temperature with 
gentle agitation. To detect antibody bound proteins, the membrane was incubated in 
fi'eshly prepared ECL reagent for 1 minute. The membrane was placed in a cassette and 
exposed to Kodak MXl film for variable time periods. The film was developed using an 
X-ograph Imaging System Compact X-4 machine.
2.2.9 Indirect immunofluorescence microscopy
Cell monolayers were grown on 13 mm glass covershps in a 24 well plate. Following 
cell transfection and or infection cells were fixed for 20 minutes in PBS containing 4% 
paraformaldehyde. The cover slips were washed once in PBS, incubated in 1% Triton x- 
100 PBS for 30 minutes to permeabhse the cytoplasmic and nuclear cell membranes.
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The cells were blocked by incubation with 0.5% BSA/PBS for 30 minutes to inhibit non­
specific antibody binding and then incubated for a further hour with primary antibody 
diluted in 0.5%BSA/PBS. Excess antibody was removed by washing the cells 3 times in 
PBST for 5minutes. The secondary antibody was diluted in 0.5% BSA/PBS and applied 
to the cells for 1 hour. Covershps were then washed 3 times in PBS for 5 minutes. Cover 
slips were then stained with DAPI for lOmin then washed 3 times with PBST and once 
with water. Cover slips were mounted onto glass slides, cell-side down, using 
vectorshield (Vector labs, UK) containing DAPI (Molecular probes). Covershps were 
secured by painting round the edge with nail varnish. The cells viewed at 60x/1.4 NA 
with a Nikon E800 microscope. Images were captured with a Hamamatsu C-4746A 
DCC camera. Software used to analyse the images was by Openlab 2.1.3 software 
(Improvision, UK).
2.2.10 Tissue staining
Small Icm^ sections were cut from kidney, lung and spleen from pigs which had been 
infected with Benin 97/1 isolate of ASFV for 5 days. Sections were cut using a scalpel. 
Tissue was fixed in 4% PFA for 60 to 90 minutes and then stored in Ca/Mg free PBS in 
the fridge until sectioning and staining. Tissue was harvested from spleen, lungs, kidney, 
mesenteric lymph nodes, sub-mandibula lymph nodes and lymph nodes. 70pm sections 
of fixed spleen were cut on a vinrating microtome (Leica).
A chamber was fixed to microtome and filled with cold PBS and left to cool for 15 
minutes. A petri dish was filled with cold water and tissue placed in the dish and cut into 
smaUer pieces about 5mm .^ A small amount of super glue was applied to the mounting 
stage and the tissue sample mounted. The base of the sample was blotted with filter 
paper. Half of a feather blade was placed in the blade holder ensuring it was straight and 
that it was secure. The blade was positioned so it was totally immersed in PBS and just 
touching the tissue. Each 70 pm section was placed onto sterilin and covered in PBS 
containing 0.1% Triton xlOO for 60 to 75 minutes. Tissue sections were blocked 
overnight in PBS/BSA (0.5%) in a moist chamber. Sections were incubated with the
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primary antibody, in PBS/BSA (0.5%) for 90 to 120 minutes and then washed 10 times 
for approximately 2 minutes in Ca/Mg free PBS. Sections were then incubated with the 
secondary antibody for 90 to 120 minutes at 37°C. Sections were washed 10 times for 
approximately 2 minutes in Ca/Mg free PBS and incubated with DAPI (1:5000) stain for 
30 minutes. Sections were washed in ultra pure water 5 times for 1 mintue and then 
mounted onto slides with vector shield and sealed with a cover slip and nail varnish.
2.2.11 Extraction of RNA from macrophages 
Using QIAGEN RNA extraction kit
RNA extraction was carried out according to the manufacturers protocol. Cells from 1 
well of a 6 well plate containing confluent cells were lysed in 350 pi RLT buffer 
containing ^-mercapto ethanol. Homogenisation was carried out bypassing the cells 
through an 18 guage needle 5 times. Lysed, homogenised cell preparations were put onto 
a prepared column which RNA binds to. The columns were washed twice with wash 
buffer and RNA was eluted in 2x 40 pi of RNAse free water.
Using TRIREAGENTTM
Total RNA was extracted using TRI REAGENT'^^, following manufacture guidelines. 
All reagents used for this procedure were certified RNAse free. Alveolar macrophages 
grown in a T 175cm flask were washed once with PBS and then lysed by the addition of 
2 ml of TRI REAGENT'T .^ The cell lysate was transferred to 2x 1.5 ml eppendorf tubes 
and then incubated at room temperature for 5 minutes (to allow complete dissociation of 
nucleoprotein complexes). Following the addition of 400 pi of chloroform, the samples 
were vortexed for 15 seconds, allowed to settle for 10 minutes at room temperature and 
then centrifuged at 12,000 g for 15 minutes at 4°C to separate the mixture into an 
organic phase (containing protein) an interphase (containing DNA) and an aqueous 
phase (containing RNA). The aqueous phase was transferred to a fresh tube, mixed with 
1 ml of isopropanol and incubated at room temperature for 10 minutes. Precipitated
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RNA was pelleted at 12,000 g for 10 minutes at 4°C, washed once in 75 % ethanol and 
then re-suspended in 0.1 % DEPC treated ddH20.
2.2.12 Reverse transcription
Reverse transcription reactions were carried out using the Superscript III kit from 
Invitrogen. 0.5 pg of total RNA was used in the reaction. A combination of ohgo dT 
primers and an 18s rRNA specific primer were used in the same RT reaction.
2.2.13 Restriction enzyme digestion
Restriction enzyme digestions were carried out in a volume of 20 pi per 1 pg of DNA 
using 0.5 pi of each restriction enzyme (5 -1 0  units) and 2pl of the corresponding 
buffer (Promega, USA). Reactions were incubated at 37°C for at least 1 hour.
2.2.14 Primer design
Two primers were designed to clone the porcine galectin-3 cDNA from mRNA from 
alveolar macrophage into the pcDNA 3.1 vector. The 5’ primer was designed using the 
porcine sequence used in the previous micro array experiments (Zhang et al, 2006). The 
3’ primer was designed using the human sequence (accession number: M64303). Two 
primers were also designed to clone the porine galectin-3 sequence into TriEx 1.1 with 
and without a PK tag and primers were also designed to detect the transcript by real time 
PCR. The cloned porcine sequence was used for the design of these primers to produce a 
fragment of 150 base pairs (See table 2.1 for primer sequences). As a control for the real 
time PCR 188 RNA primers were also designed against the porcine sequence. Various 
other real time PCR primers were designed using either the human or porcine sequences 
available from genbank. These primers were designed towards the 3’ end using the 
Primer 3 package (http://primer3.sourceforge.net/).
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Table 2.2 Table of primer sequences -  the table includes a list of all primers used for 
amplification and cloning of galectin-3 and QRTPCR. The restriction enzyme 
sequences have been highlighted in red in the primer sequences.
Primer name Forward primer sequence Reverse primer sequence
Gelectin-3 Bam 
HI for
CGGGATCCATGGCAGACGGATTTTC
Gelectin-3 Eco CGGAATTCTTATATCATGGTATATGAAGCA
R1 rev CTGG
Gal-3 Nco 1 for CCCATGGCAGACGGATTTTC
Gal-3 Xho 1 rev CCTCGAGGTTATATCATGGTATATGAAGC
Gal-3 QPCR TGTGCCATATGACCTGCCTTTG GCGTGGGTTAAAGTGGAAAGC
18s QPCRrt CATTCGAACGTCTGCCCTATC
18s QPCR TCGCGGAAGGATTTAAAGTG AAACGGCTACCACATCCAAG
V5 forward CATGGTAAGCCTATCCCTAACCCTCTC CATGCGCGTAGAATCGAGACCGAGGAGAG
CTCGGTCTCGATTCTACGCG GGTTAGGGATAGGCTTACC
ME2 CAGAGGTCATGTTAGATCAATTGTG CAATCAGGTCATCATACTGTTGTGT
JUND TTTGGAAGAGAGAAGAACAGAGTGT AGGATTACAAACAGGAATGTGGACT
TGFB2 CACATATACCAGTGGTGATCAGAA GTTTTGCCAATGTAGTAGAGAATGG
MAPK6 AGGAAGAAGGAGACTCTAATTTTGG AGGAATAGAGAGGAGGTGATTTGAG
IL-17 CAGCAAGTCTAACTCTGTTCCAT CTCCTCCCAGAACTTCTTGTATTTT
SLA-3 AAAAAGGAGGGAGGCTACACTCAG ATAGGAACACAGACCCTTTCAGAG
CXCLIO AGATCAGTGACAGACCTGTTAATC TAGTATAGTGCCTGGGCAGAGTTAC
cAMP GCTTAGGGCTCTTAGACGAATATCT CTGGTCAGTTGTTGGTAAACTTTCT
AKTl CTACTTCCTCCTCAAGAATGATGG GTACTCAAACTCGTTCATGGTCAC
AKT2 CCCTTAAACAACTTCTCCGTAGC AAGGAGTTTGAGATAGTCGAAGTCA
MAPK14 AAATGTCAGAAGCTTACAGATGACC ATATGGTCTGTACCAGGAAACAATG
MAPK8 TACCTTCTCTATCAGATGCTGTGTG GTAAGTCCTTACTGTTGGTTGCAGT
TBKl ATTGAAGAGGAGACAACAACAAGAC TCTCTCATACATATCAGGATGCAAA
IRF9 CAAGAGTTCTGAATTTAAGGAGGTTC TCAGTTGTGTCTGTAACTTCCTGTG
MAPKl CACACAAGAGGATTGAAGTAGAACA CATAAAAGCCACAACTACCAGAAAC
IRF3 TCTATGAGTTTGTGACCTCAGGAGT GTAGAAGACGGTCACCTGGAACT
IRFl AGAGGAAAGAGAGAAAGTCCAAGTC GAGCTTCATGATGTCCTCAGTTAAT
IRF7 TCTTCGGAGACTGGCTTCTG ATATACACCTTATGAGGGTCAGTGG
SOCS3 CCCCCTAGAAGAGCCTATTACATCT GAGTTTTTCAAGCATCTCCTAACAG
HSP70 AGCTAACAAGATGACTCTCACCAGT TTCCTGACACTTGTCTTGTACTTTG
TNFRSFIB CCCCTGAAAGAATACTATGACACAA AGTGCAGGCTTGAGTTTCTACCT
MAPK12 CCCTGGATGATTTTACAGACTTTTA CATCCAATTCAAGATGACCTCAG
68
2.2.15 PCR amplification
Unless stated otherwise, PCR reactions were carried out using the TripleMaster®PCR 
reagents (Eppendorf, Cambidge, England). Reaction mixtures of 50 pi contained High- 
Fidelity Buffer with Mg2 (xl), 10 pMol of each primer, dNTPs (200 uM), triple master 
DNA polymerase (1 unit), and 50-100 ng of DNA. Thermal cycling was carried out 
using an Eppendorf Mastercycler. The PCR program consisted of 95°C for 2 minutes, 30 
cycles of 95°C for 1 minute, 55°C for 1 minute and 72°C for 1 minute followed by a 
final elongation step of 72°C for 10 minutes. Samples were held at 4°C prior to use.
2.2.16 QPCR
Real time quantitative PCR (QPCR) was carried out using SYBR green reaction mix 
from STRATAGENE (La Jolla, California, USA). 25ul reactions were set up in a 96 
well plate using a ribosomal 18s RNA primer set to normalize each reaction. Reactions 
were carried out in triplicate and a standard curve produced each time for both the 
normalizer and test gene in order to calculate accurate primer efficiencies for each 
reaction. Optimum primer concentrations were determined prior to carrying out the real 
time reaction. The STRAT AGENE MX3005P™ machine was used and the 
corresponding MX3005P™ QPCR software used to calculate relative expression levels 
for each gene under the different conditions.
2.2.17 Separation of DNA on agarose gel
DNA samples were mixed with DNA loading buffer, containing bromophenol blue 
(Biogene) at a ratio of 5:1 and loaded onto a 1% agarose/TAE gel containing ethidium 
bromide (3 pg/ml). DNA fragments were separated at 100 V for 1 hour in TAE buffer 
and detected by a GeneDoc gel viewer (BioRad, Hertforshire, England).
69
2.2.18 Extraction of DNA from agarose
DNA fragments were purified from agarose gels using a GFX PCR DNA and Gel Band 
Purification Kit (Amersham Bio sciences) according to manufacturer’s guidelines. All 
centrifiigation steps were at 12,000 g for 1 minute. DNA fragments were excised from a 
1% agrose gel and incubated at 60°C in 10 pi of capture buffer for every 10 mg of 
agarose gel in order to dissolve the gel and denature any proteins present in the sample. 
The solution was then loaded onto a GFX column and centrifuged. DNA was retained 
within the column on a glass fibre matrix due to the high salt concentration of the 
capture buffer. The matrix bound DNA was washed once to remove contaminants and 
then eluted from the GFX column in 50 pi of ddH20.
2.2.19 Ligation
50 ng of vector was incubated with a 16 ng of insert in a 10 pi reaction volume of 1 xT4 
ligase buffer (Promega) containing T4 ligase (3 Weiss units). The reaction mix was 
incubated overnight at 16°C.
2.2.20 Transformation of bacterial cells
Competent XL 1-Blue cells (stored at -70°C) were defrosted on ice and aliquoted into 50 
pi volumes and stored on ice. 2 pi of hgation product was added to individual aliquots. 
The cells were incubated on ice for 20 minutes and then heat shocked at 42°C for 45 
seconds. Cells were immediately placed back on ice for at least 2 minutes. The aliquots 
were made up to a final volume of 500 pi using antibiotic free LB broth and incubated at 
37°C with constant shaking for 30 minutes. To isolate transformed colonies LB agar 
plates, supplemented with ampicillin 100 pg/ml, were inoculated with 200 pi of 
transformed XL 1-blue culture and incubated overnight at 37°C. Single colonies were 
selected for further analysis.
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2.2.21 Small scale isolation of DNA from bacterial cells
Plasmid DNA was purified using a GenElute^M Plasmid Miniprep Kit (Sigma). The 
procedure was carried out following manufacturers guidelines. All centrifiigeation steps 
were carried out at 12,000 g for 1 minute unless stated otherwise. Single colonies were 
inoculated into 10 ml of LB broth supplemented with ampicillin (100 pg/ml) and 
incubated overnight at 37°C with constant agitation. Cells were harvested from 1.5 ml of 
culture by centrifugation at 13000 rpm for 2 minutes. Following re-suspension of the 
cells in 200 pi of resuspension solution containing RNase (100 pg/ml), the cells were 
lysed by the addition o f200 pi of lysis solution. Genomic DNA and cell debris were 
precipitated by the addition of 350 pi of neutrahsation solution and removed by 
centrifiigation. The supernatant was transferred to a GenElute Miniprep binding column 
for plasmid purification. Following centrifiigation, the plasmid DNA (which was 
retained within the column on a silica membrane, due to the high salt concentration of 
the plasmid prep) was washed once with 750 pi of wash solution and the flow-through 
discarded. The column was then centrifuged again to remove excess ethanol and the 
plasmid DNA eluted in 50 pi of ddH20. The plasmid DNA was stored at -20°C until use.
2.2.22 Large scale isolation of DNA from bacterial cells
Plasmid DNA was isolated using alkaline-SDS lysis followed by purification using a 
CsCl-ethidium bromide density gradient. 200 ml of LB broth supplemented with 
ampicillin (1 mg/ml) was inoculated with a single bacterial colony and incubated over 
night at 37°C with constant shaking. Cells were pelleted by centrifugation at 6,000 g for 
10 minutes and resuspended in 10 ml of Solution 1 (see materials section 2.1) containing 
1 mg/ml lysozyme (Sigma) and left at room temperature for 5 mintues. Cells were then 
lysed in 20 ml of freshly prepared cold solution 2 and incubated on ice for 10 minutes. 
The solution was neutralised by the addition of 15 mis of solution 3 and incubated for a 
further 20 minutes on ice. Cell debris and chromosomal DNA was pelleted by 
centrifugation at 7,000 g for 30 minutes at 4°C. The supernatants, containing the plasmid 
DNA, were transferred to a new tube and the plasmid DNA was precipitated by the
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addition of isopropanol at a ratio of 1:1 for 20 minutes incubation on ice. DNA was 
collected by centrifiigation at 8,000 g for 10 minutes. The pellet was washed once in 
70 % ethanol, resuspended in 8 ml of TE buffer and mixed with 8 g of CsCl and 200 pi 
of ethidium bromide solution at 10 mg/ml. The solution was transferred to a Quick- 
Seal™ 16 X 76 mm Beckman (High Wycombe, England) centrifuge tube and 
centrifiiged at 55 K overnight in a Beckman Type 70.1 Ti rotor, using a Beckman 
Ultracentrifiige, to create a CsCl density gradient. The band of closed circular DNA was 
removed using a syringe and the ethidium bromide extracted by repeatedly mixing the 
sample in an equal volume of water saturated n-butanol. This was continued until the 
organic phase became clear. The aqueous phase was removed, made up to 10 ml in TE 
buffer and diluted at a ratio of 1:3 in ethanol to precipitate the DNA. The DNA was 
pelleted using centrifiigation at 3,000 g for 15 mins, washed once in 70 % ethanol and 
then re-suspended in 250 pi of ddH20. Plasmid DNA was stored at -20°C until use.
2.2.23 Quantification of DNA and RNA
Concentrations of DNA and RNA solutions were estimated using a nanodrop ND-1000 
Spectrophotometer (Agilent, West Lothian, UK) or the Agilent 2100 bioanalyser.
2.2.24 Sequencing
Sequencing of plasmids was performed using the CEQ DTCS Quick Start Kit (Beckman 
Coulter) following manufacturer’s guidelines. 350 pg of plasmid DNA and 3.2 pmol of 
primers per reaction were used. The DTCS quick start master mix was used at a 1 in 2 
dilution, diluting with lOx dilution buffer provided with the kit. All sequencing was 
conducted on a Beckman Coulter CEQ 8000 Genetic Analysis System.
2.2.25 Sequencing clean-up
Sequencing reaction mixtures were purified to remove unincorporated nucleotides using 
reagents and protocols supplied by Beckman Coultier. A stop solution was made up
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containing 2 volumes 100 mM EDTA, 2 volumes 3 M NaOAc (pH5.2) and 1 volume 
glycogen. 5 pi of stop reaction was used to stop each sequencing reaction. 60 pi 95% 
ethanol was added, mixed thoroughly and centrifuged at 13 000 x g for 15 minutes at 
4°C. Supernatants were removed, 200 pi of 70% ethanol was added, mixed gently and 
centrifuged at 13 000 x g for 10 minutes at 4°C. The ethanol wash was repeated. DNA 
pellets were left to dry at 37°C for about 15 minutes. Pellets were re-suspended in 40 pi 
sample loading solution. Samples were loaded onto the sequencing plate with a drop of 
mineral oil to cover the reaction mixture.
2.2.26 Transfection using Lipofectamine™ 2000 and Lipofectamin Transfection 
Reagent
Approximately 1x10^ cells were seeded into each well of a 24-well plate and incubated 
at 37 °C in 5 % CO2 until 80-95% confluent. For each transfection, 0.8 pg of DNA was 
diluted in 100 pi OptiMEM (Life Technologies) and 2 pi Lipofectamine 2000 
(Invitrogen) was diluted in 100 pi OptiMEM in a sterile bijou. The two solutions were 
then incubated at room temperature (RT) for 5 minutes. The solutions were combined 
and incubated at RT for 20 minutes. Cells were then washed once with OptiMEM and 
200 pi of each Lipofectin/DNA complex transfection mix added to each well. Cells were 
then incubated for 4-5 hours with the transfection mix before being replaced with 
OptiMEM and left overnight at 37 °C with 5% CO2.
2.2.27 Transfection using Nucleofectin^ (Amaxa biosystems)
Macrophage cells were prepared from lungs or whole pig blood and 5-7 x 10^  cells used 
per transfection reaction. Cells were centrifiiged at 200 xg for 10 minutes at room 
temperature and supernatants removed. Cells were re-suspended in lOOpl room 
temperature Nucleofectin solution. 2pg of plasmid DNA was added to the cells and the 
mixture put into a cuvette. The cuvette was placed in the Nucleofector and the Y-OlO 
program selected. The transfected cells were then placed in a 24 well plate containing
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warm macrophage SFM media (GIBCO, 12065-074) and a glass cover slip. Cells were 
left overnight and then either fixed in 4% PFA or infected with ASFV.
2.2.28 Microarray experiments
2.2.28.1 RNA amplification
RNA was amplified using the Amino Allyl MessageAmp II aRNA amplification kit 
(Ambion, 1753). 1 pg of total RNA was added to the reverse transcription reaction. 
cDNA production, second strand synthesis, cDNA purification, synthesis of biotin- 
labelled aRNA and final aRNA purification was carried out according to manufacturer’s 
instructions. The in vitro transcription step was incubated for 14 hours at 37°C. All other 
incubation steps were carried out on a PCR block with a heated fid. A ratio of 1:1 of 
UTP to aaUTP was used. Amplified RNA was measured for quality and quantity using 
the agilent bioanalyser and nanodrop.
2.2.28.2 aRNA labelling
The aRNA was labelled using the Amersham CyDye (Cy3/Cy5) kit (RPN5661). 8 pg 
aRNA was labelled with Cy3 and Cy5 according to manufacturer’s instructions. The 
labelled RNA was cleaned up using either the labelled RNA clean up procedure fi*om the 
amplification kit above or using the QIAGEN RNeasy MiniElute cleanup kit (74204). 
The RNA concentration and dye incorporation was measured using the nanodrop. The 
level of incorporation was slightly lower for Cy5, typically around 50. The dye 
incorporation for Cy3 was typically around 60. In order to get sufficiently intense signal 
for the micro array, the labelling density should be between 30 and 60 (1 dye per 30 to 60 
unlabelled nucleotides).
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2.2.28.3 Slide preparation
The SCOTT (Jena, Germany) Nexterion HiSens E slides and protocol were used for 
hybridization as described by the manufacturer’s protocol. Slides were prepared by a 
series of wash and blocking steps. The first wash was for 5 minutes in 0.1% Triton XlOO. 
Then 2 washes in 1 mM HCl for 2 mintues followed by a 1 minute wash in 100 mM KCl 
and rinse for 1 minute in ddHzO. Slides were blocked for 15 minutes in Nexterion 
blocking solution at 50°C, washed in ddHiO for 1 minute and then dried by 
centrifiigation at 200 g for 5 minutes. Shdes were used immediately in hybridizataion.
2.2.28.4 Hybridization
Hybridizations were carried out using the Tecan HS400Pro hybridization station. 2 pg 
of each labelled aRNA was used in the hybridization reaction and made up to 130 pi 
with the Nexterion hybridization buffer making sure there was a 90 % v/v of buffer. The 
hybridization programme was optimised for this experiment and consisted of; a 30 
second prime step with pre-hybridization buffer, injection and denaturiastion of sample 
for 3 minutes at 95 °C, followed by hybridization for 12 hours with gentle agitation at 60 
°C. After hybridization shdes were washed and dried within the chamber. Three wash 
solutions were used; wash 1 was carried out at 25°C, wash 2 and 3 were carried out at 
23°C. All washes were for 1 minute with a constant flow and 45 seconds with a static 
wash. Shdes were then dried on the machine. All washes and buffers were filtered and 
degassed by sonication for 30 minutes before use in the hybridization chamber.
2.2.28.5 Scanning
Slides were scanned using the GenePix 4000B scanner fi'om Molecular Devices 
(Sunnyvale, CA, USA) and the GenePix Pro6.0 software was used to capture spot
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intensities from the slides. The data was then analysed using; Bluefrise (BlueGnome Ltd, 
Cambridge, England), the TM4 suite (formerly the Institute for genomice research, TIGR 
and now part of the J. Craig Venter institute) and ‘R’. Both the TM4 suite and ‘R’ are 
freely available on the internet. ‘R’ is an environment which was designed for statistical 
computing and graphics and is a GNU project launched to develop unix-like operating 
systems which are freely available software, similar to the S language, developed at Bell 
Laboratories (formally AT&T, now Lucent Technologies) by John Chambers and 
colleagues.
2.2.29 Apotosis Assay
Peripharal blood leukocytes (PBLs) were harvested from whole blood as described 
earlier. Cells were then incubated with supernatants harvested from ASFY Malawi 
infected cells or, supernatants from mock-infected cells, for approximately 16 hours. 
PBLs were also incubated with culture media on its own, containing TNFa at 6  ng/ml 
(del Moral et al., 1999) or containing staurosporine at 1 pM or 0.1 pM final 
concentrations. These were also left for 16 hours. Analysis of apoptosis in the 
lymphocytes was carried out either by nucleosome ELISA or FACS staining for annexin 
V and propidium iodide (PI).
2.2.29.1 Nucleosome ELISA
A kit was purchased from Pierce biothechnologies (Northumberland, England) and the 
ELISA carried out as described in the manufacturer’s instructions.
2.2.29.2 FACS analysis
Cells were harvested after incubation with supernatants, media or media containing 
apoptosis inducers TNFoJor Staurosporine. TNFawas used at final concentration of 6  
pg/ml and staurosporine was used at 0.1 and 1 pg/ml. Cells were centrifuged and then 
counted. Approximately 1x10^ cells were put into a well of a 96 well plate and washed 
with 100 pi annexin V staining buffer. Plates were spun at ISOOrpm for 2 minutes and
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the supernatants decanted off. 25 pi of fluorophore-conjugated annexin V antibody at 
0.5 pg/ml diluted in the staining buffer was added and cells left for 10 minutes. Cells 
were then washed in the staining buffer. Cells were stained with PI at 100 pg/ml at the 
same time as the annexin V staining was carried out. Cells were then washed twice with 
the annexin V staining buffer and fixed in 4% PFA for 20 minutes. Fluorescence data 
was collected using a Becton Dickinson FACSCalibur with CellQuest software. Results 
were analysed using FCS Express version 3 (De Novo Software).
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Results
3. Characterisation of porcine galectin-3 and antibody production
Galectin-3 was one of the transcripts shown to be upregulated following ASFV 
infections (Zhang et al., 2006). Over the past decade interest in galectins in general has 
increased dramatically. The galectin-3 cDNA has been sequenced in a number of 
different mammals. However, there was no information available on the porcine gene or 
protein. In this chapter porcine galectin-3 has been characterised and compared with data 
published on galectin-3 from other species. The cDNA encoding the complete porcine 
galectin-3 was amplified by RT-PCR and cloned. The nucleotide sequence was 
determined and compared to that of other mammals and the predicted amino acid 
sequence was compared to the human sequence. Key features have been identified 
which are present in the porcine sequence and sequences from other mammalian species. 
An anti human galectin-3 antibody was purchased (Abeam, ab2785) in order to 
characterise porcine galectin-3 and investigate the effect ASFV infection has on 
expression and localization of the protein. The work in this chapter shows that the 
human antibody recognises porcine galectin-3 poorly. Four antibodies were, therefore, 
produced using synthetic peptides designed using the porcine protein sequence. The 
production and characterisation of these antibodies is detailed in this chapter.
3.1 Cloning and sequence analysis of porcine galectin-3
The human galectin-3 sequence was obtained in 1991 (Cherayil et al., 1990; Raz et al., 
1991). Rabbit galectin-3 has also been sequenced (Gaudin et al., 1995) and primers to 
amplify the rabbit galectin-3 cDNA were designed using the human sequence. The 
human sequence was also used here to design a 3’ primer for amplification of the 
complete porcine galectin-3 cDNA. A 5’ primer was designed using the pig sequence 
from the cDNA array used in previous micro array experiments (Zhang et al, 2006).
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RNA was extracted from porcine alveolar macrophage cells and these primers were used 
to amplify the porcine galectin-3 cDNA by RT-PCR. A product of 890 bp in length was 
produced, which is similar in size to the published human, mouse and rabbit galectin-3 
cDNA. Figure 3.1 shows the PGR products run on a 1.5 % agarose gel. Lane 1 shows the 
pcDNA 3.1 vector digested with Bam HI and Eco Rl. Lane 2 shows galectin-3 
amplified by RT-PCR. Lane 3 is a negative control for the PGR reaction where no RNA 
was added to the RT-PGR reaction. The primer sequences also contained restriction sites 
in order to clone galectin-3 into pcDNA 3.1 vector (Invitrogen). The porcine galectin-3 
was cloned into pcDNA 3.1 vector as there is a large choice of restriction sites available 
for cloning into this vector. There is also a T7 promoter sequence with primers available 
for easy sequencing. The primer sequences are included in Chapter 2 in table 2.1. The 5’ 
primer contained a Bam HI site and the 3’ primer an Eco Rl site. The cloning strategy is 
shown in figure 3.2. In order to confirm successful cloning of galectin-3 and compare 
the porcine cDNA to that of other mamalian species, the insert was sequenced on both 
strands using the primers available with the plasmid. The porcine sequence was then 
compared to pubhshed human, mouse, rat, rabbit, hamster, dog and bull sequences from 
GenBank (Fig:3.3).
Most of the sequence variation occurs in the N-terminal region where there are a number 
of tandem repeats rich in proline and glycine. The sequence alignment in figure 3.3 
shows the N terminal region has been divided into 8 variable regions, I to VIII, marked 
by different font colours. These regions have been described by other groups for 
different mammals (Hughes, 1999) and each region contains a specific pattern of tandem 
repeat units. The basic repeated unit consists of Pro-Gly-Ala-Tyr-Pro-Gly + 3 random 
amino acids. The mouse and rat sequence has seven regions I to VII which have been 
marked on figure 3.3. The mouse, rat and hamster have a region VI which is not present 
in the other mammalian sequences in figure 3.3. The dog sequence has the most, 14, 
tandem repeat units with region III being repeated 6 times. The variation in the number 
of repeated units accounts for the difference in size of the PGR products and the protein 
sizes from different animals.
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The N-terminal region is preceded by the small N-terminal domain of 12 amino acids 
common to all species. All sequences have a conserved /3-galactoside binding site near 
the 5’ end of the CRD. In this region there is also a short sequence of amino acids, 
NWGR, which is conserved in the death domain of Bel-2 like proteins and may be 
important in control of apoptosis. This sequence is present in both the human and 
porcine amino acid sequences shown in figure 3.5.
A phylogenetic tree was mapped using the nucleotide sequences displayed in figure 3.4. 
The tree was produced using tree view (http://taxonomv.zoologv.gla.ac.uk/rod/treeview.htinl) and 
shows the sequence relationship between galectin-3 from different mammalian species. 
The porcine galectin-3 is most similar to the rabbit sequence. The mouse, rat and 
hamster sequence are all very similar to each other as might be expected. The two 
human sequences are grouped on one branch and the dog and bull sequence on another 
branch. The predicted amino acid sequence for the human and porcine galectin-3 has 
been compared in figure 3.4. The end of the N-terminal region and start of the CRD is 
marked by a thick red line. The j8-galactoside binding site is also marked by a green line. 
The amino acid differences have been highlighted with arrows or underlined with a 
black line where there is a run of differences. It is clear to see that the main difference is 
in the number of tandem repeat units which varies between the human and porcine 
sequence.
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Figure 3.1 Agarose gel of galectin-3 PCR -  The pcDNA 3.1 (Invitrogen) vector was 
digested with Bam HI and Eco Rl and shown in lane 1. Galectin-3 was amplified by 
RT-PCR from alveolar macrophage and is shown in lane 2. Lane 3 is a negative control 
for the PCR reaction where no cDNA was added to the PCR reaction.
Macrophaj
RNA extraction 
and RT-PCR
Eco RlBam H 1 Porcine galectin-3
890 nucleotides
Bam H 1 E coR l
pcDNA3.1
CMV M  
promoter
Figure 3.2 Strategy for cloning porcine aglectin-3. RNA was extracted from porcine 
alveolar macrophages and the complete galectn-3 cDNA amplified by RT-PCR using 
primers containing the restriction sites Bam HI and Eco Rl. The amplified product was 
then cloned into pcDNAB.l (Invtrogen),
N-terminal domain
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B u l l  XM _58834 0 
Dog X M 8 4 8 5 8 2
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse  01 0 7  05 
R a t  N M _031832 
H a m s te r  X 7887 9
ATGGCAGA.CGGTTTTTCGCTTAATGATGCCTTRTCTGGGTCTGGAAAACCAAACCCCCAA 60 
ATGGCAGACAGTTTTTCACTTAATGATGCTTTATCTGGGTCTGGAAACCCAAACCCTCAA 60 
ATGGCAGACAATTTTTCGCTCCATGATGCGTTATCTGGGTCTGGAAACCCAAACCCTCAA 60 
ATGGCAGACAATTTTTCGCTCCATGATGCGTTATCTGGGTCTGGAAACCCAAACCCTCAA 60 
ATGGCGGATGGTTTTTCGCTCAACGATGCCCTATCTGGGTCTGGACACCCCCCAAACCAA 60 
ATGGCAGACGGATTTTCGCTTAACGATGCTTTATCCGGGTCTGGAAAACCAAACCCTCAA 60 
ATGGCAGACAGCTTTTCGCTTAACGATGCCTTAGCTGGCTCTGGAAACCCAAACCCTCAA 60 
ATGGCAGACGGCTTCTCACTTAATGATGCCTTAGCTGGCTCTGGAAACCCAAACCCTCGA 60 
ATGGCAGACGGTTTTTCGCTTAATGATGCCTTAGCTGGCTCTGGAAACCCAAACCCTCAA 60
Region I Region II
B u l l  XM _58834 0 GGTTGGCCTGGTTCATGGGGAAACCAGCCTGCTGGGGCAGGAGGCTACCCAGGAGCGGCC 120
Dog X M 8 4 8 5 8 2  GGATGGCCTGGTCCATGGGGAAACCAGCCTGCTGGAGCAGGGGGCTACCCAGGGGCCTCC 120
Human M64 3 0 3  GGATGGCCTGGCGCATGGGGGAACCAGCCTGCTGGGGCAGGGGGCTACCCAGGGGCTTCC 120
Human M 57710 GGATGGCCTGGCGCATGGGGGAACCAGCCTGCTGGGGCAGGGGGCTACCCAGGGGCTTCC 120
R a b b i t  0 6 4 7 0  GGATGGCCTGGCCCATGGGGGAACCAGCCTGCTGGGCCAGGGGGCTACCCAGGGGCGGCC 120
P ig  GGATGGCCTGGTGCATGGGGAAACCAGCCTGCTGGGCCAGGAGGCTATCCAGGGGCTTCC 120
M ouse  0 1 0 7 0 5  GGATATCCGGGTGCATGGGGGAACCAGCCTG----- GGGCAGGGGGCTACCCAGGGGCTGCT 117
R a t  N M _031832 GGATGGCCTGGTGCATGGGGGAACCAGCCTG----- GGGCAGGAGGCTACCCAGGGGCCTCC 117
H a m s te r  X 7887 9 GGATGGCCTGGTGCATGGGGGAACCAACCTG GGGCAGGGGGCTACCCAGGGGCTTCC 117
B u l l  X M 5 8 8 3 4  0 
Dog X M 8 4 8 5 8 2
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse 0 1 0 7  05 
R a t  N M 0 3 1 8 3 2
H a m s te r  X7 887 9
B u l l  XM _58834 0 
Dog X M 8 4 8 5 8 2
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse  0 1 0 7  05 
R a t  N M 0 3 1 8 3 2
H a m s te r  X 7887 9
Region III
TAT CCTGGGGCCTACCCTGGACAGGCCCCTCCT GGCCCCTACCCT GGACAAGGACCT CCT 18 0  
TATCCTGGTGCCTACCCTGGCCAGGCACÇTCCCGGCGGCTACCCTGGCCAGGCACCTCCC 180
TAT CCTGGGGCCTACCCCGGGCAGGCACCCCCAGG----------------------------------------------------- 155
TAT CCTGGGGCCTACCCCGGGCAGGCACCCCCAGG----------------------------------------------------  155
TATCCTGGGGCCTACCCTGGACATG CACCTGG----------------------------------------------------- 152
TAT CCTGGCACCTACCCT GGGCAGGGGCCT CCT GG----------------------------------------------------- 155
TATCCTGGGGCCTACCCAGGACAAGCTCCTCCAGG----------------------------------------------------- 152
TAT CCT GGGGCCTACCCAGGACAGGCT CCT CCAGG----------------------------------------------------- 152
TAT CCT GGG GCCTACCCCGGACAGGCT CCT CCAGG----------------------------------------------------- 152
* * * * * * * *  * * * * * * *  *  *  *  *  *  * * * * *
GG-GGC C 18 6
GGCGGCTACCCTGGCCAGGCACCACCCGGCGGCTACCCTGGCCAGGCACCTCCCGGTGGC 24 0
 GGG------------------------------------------------------------------------------------------------------------------T 15 9
 GGC------------------------------------------------------------------------------------------------------------------T 15 9
  T 15 6
 TGC------------------------------------------------------------------------------------------------------------------C 1 59
 GGC------------------------------------------------------------------------------------------------------------------C 156
 GGG------------------------------------------------------------------------------------------------------------------T 15 6
 GGC------------------------------------------------------------------------------------------------------------------T 15 6
B u l l  XM 5 8 8 3 4  0 TACCCTGGACAGGGACCTCCTGGGGCCTACCCTGGACAGGGACCTCCTGGGGCCTACCCT 24 6 
Dog X M 8 4 8 5 8 2  TACCCTGGCCAGGCACCTCCCGGCGGCTACCCTGGCCAGGCGCCTCCTGGCACCTACCCT 30 0
Human M 64303 TAT CCT GGACAGGGACCT CCAGGCGCCTACCATGG AGCACCTGGAGCTTATCCC 2 1 3
Human M 57710 TATCCTGGACAGGGACCTCCAGGCGCCTACCATGG AGCACCTGGAGCTTATCCC 213
R a b b i t  0 6 4 7 0  TATCCCGGGCAAGCGCCTCCTGGCCCCTACCCTGG----------------------------------------------------- 191
P i  g  TACCCTGGACAGGGACCT CCT GGC GCCTACCCT GGACAG GCACCT CCAGGGGCCTACCCT 2 1 9
M ouse  010 7  05 TAC CCAGGACAGGCT CCT CCAGGGGCCTACCCAGGACAG GCT CCT CCTAGT GCCTACCCC 2 1 6
R a t  NM 0 3 1 8 3 2  TAT CCT GGACAGGCT CCT CCTAGT GCCTAT CCGGGCCCAACT GGC CCTAGT GCTTAT CCT 21 6
H a m s te r  X 7 8 8 7 9  TAT CCT GGGCAGGCT CCT CC---------------------------------------------------------- TGGT GCCTACCCT 1 89
Region IV
B u l l  XM 5 8 8 3 4  0 GGCCCAACAGCACCTG----CTTATCCTGGGCCAACTGCACCGAGTGCCTACCCCGGAC—  3 0 1
Dog X M _848582 GGCCCCACAGCACCTG----CTTATCCTGGCCCAACAGCACCAGGAACCCAACCCGGGCAA 357
Human M 64303 GG------------ AGCACCTG------C--ACCTGGAGTCTAC----------CCAGGGCCACCCAGCGGCC—  2 5 6
Human M 57710 GG------------ AGCACCT G------C--ACCTGGAGTCTAC----------CCAGGGCCACCCAGCGGCC—  2 5 6
R a b b i t  0 6 4 7 0  -------------------------------------------------------------- CCCAGGAGCACATGGAGCCTACCCTGGGCAG 222
P ig -------------------------------GGCCCAACAGCACCTG----GTTATCCTGGCCCAGCCGCACCAGGAGCCTACCCTGGGCAA 27 6
M ouse  0 1 0 7 0 5  GGCCCAACTGCCCCTGGAGCTTATCCTGGCCCAACTGCCCCTGGAGCTTATCCTGGCTCA 2 7 6
R a t  N M 0 3 1 8 3 2  GGCCCAACTGCCCCTGGAGCTTATCCTGGCCCAACTGCCCCCGGAGCCT-TCCCAGGGCA 27 5
H a m s te r  X 7887 9 GGCCCAACTGCCCCTGGAGCTTACCCTGG-- -ACCTGCCCCAGGAGCTT-ACCCAGGGCA 245
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Region V and Region VI
B u l l  X M _58834 0 
Dog XM_84 858 2  
Human M 64303 
Human M 57710 
R a b b i t  064  7 0 
P ig
M ouse  0 1 0 7 0 5  
R a t  N M 0 3 1 8 3 2
H a m s te r  X 7887 9
GGAC?.GCCAAGTGI
CCG----------- AGTGGGC' ; G G 'll-------------- -"T A C C C G C C 'l
CCA----------- GGTGGTCCIGGGO--------------'^''TACCCGTCTC.
CCA----------- GGTGGGCCl GGCG------------- CCTACCCGCCTCCTGCACACCCAAGTGCÎC',
ACTGCCCO'rG-i.'-.GO'-'TTCCa^GGGCAACCTGGGGCACCTGGGGCCTACCCCAGTGCTCC
A ' ----------- CT G IG G G/ :CT GGA GCCT7 C ^ ': C ACT GCT CCT GGGGCCTACCCCAGT GCT CC
AC------------------------------------------------------- CTGGAGCATCTGGGGCCTACCCCAGTGCTCC
33 9
405
294
294
2 7 0
324
33 6
330
2 7 9
B u l l  X M 5 8 8 3 4  0 
Dog X M 8 4 8 5 8 2
Human M 64303 
H uman M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse  0 1 0 7 0 5  
R a t  N M 0 3 1 8 3 2
H a m s te r  X 7887 9
Region VII
GGAGCCTACCCTG-CTGCCGGTCCCTACGGCATCCCTTCCGGACCACTGAATGTGCCTTAT 39 9  
GGA'GCCTACCCll^CGGCTGGTCCCTTTGGCATCCCTGCTGGACCACTGACTGTGCCTTAT 4 65 
GGAGCCTACCCT.GCCACTGGCCCCTATGGCGCCCCTGCTGGGCCACTGATTGTGCCTTAT 354
GG}"'.GCCTACCCTGCCACTGGCCCCTATGGCGCCCCTGCTGGGCCACTGATTGTGCCTTAT 354 
GGAGCTTACCCTGGCGCCAGCCCTTACAGCGCCTCTGCTGGACCACTGCCTGTGCCTTAT 33 0
GGAGCCTACCCTGCCACTGGCCCCTATGGTGCCCCTTCTGGACCACTGAATGTGCCATAT 384 
GGAGGCTATCCT GCT GCT GGCCCT TAT GGT GTCCCCGCT GGACCACTGACGGT GCCCTAT 3 96 
GGGGCCTATCCTGCTACTGGCCGCTTTGGTGCCCCGACTGGACCACTGACAGTGCCCTAC 39 0  
CllAGCCTATCCTGCTGCTGGCCCCTATGGCGCCCCTACCGGAGCATTGACAGTGCCCTAT 3 39
B u l l  X M _58834 0 
Dog X M _848582 
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M o u se  010 7  05 
R a t  N M _031832 
H a m s te r  X7 887 9
GACCTGCCTTTTCCTGGAGGAATCAGGCCTCGCATGCTGATAACAATCCTGGGTACAGTA 459  
GACCTACCTTTGCCTGGAGGAGTCAAGCCTCGCATGCTGATAACAATTCTGGGCACAGTA 525  
AACCTGCCTTTGCCTGGGGGAGTGGTGCCTCGCATGCTGATAACAATTCTGGGCACGGTG 414 
AACCTGCCTTTGCCTGGGGGAGTGGTGCCTCGCATGCTGATAACAATTCTGGGCACGGTG 414 
GACCTGCCTCTGCCTGGAGGAGTCATGCCCCGCATGCTGATAACGATTGTGGGCACGGTG 390  
GACCTGCCTTTGCCTGGAGGAGTCATGCCTCGCATGCTGATAACAATTCTGGGCACAGTA 444  
GACCTGCCCTTGCCTGGAGGAGTCATGCCCCGCATGCTGATCACAATCATGGGCACAGTG 456  
GATATGCCCTTGCCTGGAGGAGTCATGCCTCGCATGCTGATCACAATCATAGGCACAGTG 450 
AAGCTGCCCTTGGCTGGAGGAGTCATGCCTCGAATGCTGATCACAATCATGGGCACAGTG 3 9 9
B u l l  X M _58834 0 
Dog X M 8 4 8 5 8 2
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse  01 0 7  05 
R a t  N M _031832 
H a m s te r  X7 887 9
AAGCCCAATGCGAACAGACTTGCTTTAGATTTCAAGAGAGGGAATGATGTCGCCTTCCAC 5 1 9  
AGGCCCAGTGCAAACAGACTTGCTCTAGATTTCAAGAGAGGGAATGATGTTGCCTTCCAC 585  
AAGCCCAAT GCAAACAGAATTGCT TTAGATTT CCAAAGAGGGAAT GAT GTT GCCTTCCAC 47 4 
AAGCCCAATGCAAACAGAATTGCTTTAGATTTCCAAAGAGGGAATGATGTTGCCTTCCAC 47 4 
AAGCCCAATGCAAACAGACTCGCTTTGGATTTCAAGAGAGGGAATGACGTTGCCTTCCAC 450  
AAG CCCAAT GCAAACAGACTT GCT TTAGATTT CAAGAAG GGGAAT GAT GTT GCTTT CCAC 504 
AAACCCAACGCAAACAGGATTGTT CTAGATTTCAGGAGAGGGAATGATGTTGCCTTCCAC 5 1 6  
AAGCCCAACGCAAACAGTATCACTCTGAATTTCAAGAAAGGGAACGACATCGCCTTCCAC 51 0  
AAG CCCAAT GCAAACAGGATTATTCTAAATTT CTTGAGAGGGAACGACATAGCCTTCCAC 459
CRD
B u l l  X M _58834 0 
Dog X M 8 4 8 5 8 2
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse  0 1 0 7  05 
R at N M 0 3 1 8 3 2  
H a m s te r  X 7887 9
B u l l  XM _58834 0 
Dog X M 8 4 8 5 8 2
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse  0 1 0 7 0 5  
R a t  N M _031832
H a m s te r  X 7887 9
TTTAACCCACGCTTCAATGAGGACAACAGGAGAGTCATTGTTTGCAATTCAAAGCTGAAT 57 9 
TTTAACCCACGCTTCAATGAAGACAACAAGAGAGTCATTGTTTGCAATACCAAGCTGGAT 645  
TTTAACCCACGCTTCAATGAGAACAACAGGAGAGTCATTGTTTGCAATACAAAGCTGGAT 534 
TTTAACCCACGCTTCAATGAGAACAACAGGAGAGTCATTGTTTGCAATACAAAGCTGGAT 534 
TTTAACCCCCGCTTCAATGAGAACAACAGGAGAGTCATTGTCTGCAACACAAAGGTGGAT 510  
TTTAACCCACGCTTCAACGAGGACAACAGGAGAGTCATTGTTTGCAATTCCAAGCTGGAT 5 64 
TTTAACCCCCGCTTCAATGAGAACAACAGGAGAGTCATTGTGTGTAACACGAAGCAGGAC 5 7 6  
TTTAACCCCCGCTTCAATGAGAACAACAGAAGAGTCATCGTGTGCAACACGAAGCAGGAC 57 0  
TTTAACCCTCGCTTCAATGAAAACAACAGGAGAGTCATTGTGTGCAACACCAAACAGGAT 51 9
AATAACTGGGGAAAGGAAGAAAGACAAATGGTTTTCCCATTTGAAAGTGGTAAACCTTTC 63 9 
AATATCTGGGGAAAGGAAGAAAGGCAGGCAGCTTTTCCATTCGAAAGTGGTAAACCATTC 70 5  
AATAACTGGGGAAGGGAAGAAAGACAGTCGGTTTTCCCATTTGAAAGTGGGAAACCATTC 594 
AATAACTGGGGAAGGGAAGAAAGACAGTCGGTTTTCCCATTTGAAAGTGGGAAACCATTC 594 
AACAACTGGGGAAGGGAAGAAAGGCAGACGACTTTCCCATTTGAAATTGGTAAACCATTC 570  
AATAACTGGGGAAGGGAAGAGAGACAGATGGTTTTTCCATTTGAATGTGGTAAACCATTC 624 
AATAACTGGGGAAAGGAAGAAAGACAGTCAGCCTTCCCCTTTGAGAGTGGCAAACCATTC 63 6 
AATAACTGGGGAAGGGAAGAAAGACAGTCAGCTTTCCCCTTTGAGAGCGGCAAACCATTC 630 
AATAACTGGGGAAGAGAAGAAAGGCAATCAGCTTTCCCATTCGAAAGTGGCAGACCGTTC 57 9
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B u l l  X M _588340 
Dog XM_84 8 582 
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M o u se  0 1 0 7 0 5  
R a t  N M _031832 
H a m s te r  X7 887 9
AAAATACAAGTGCTGGTTGAACCTGACCATTTCAAGGTTGCAGTCARTGATGCTCACTTG 699  
AAAATACAAGTGCTGGTTGAATCTGACCACTTCAAGGTTGCGGTCAATGATGCCCATTTG 7 65 
AAAATACAT GTACT GGTT GAACCT GAG CACTT CAAG GTT GCAGT GAATGAT GCT CAC TTG 654 
AAAATACAAGTACTGGTTGAACCTGACCACTTCAAGGTTGCAGTGAATGATGCTCACTTG 654 
AAAATACAAGTCCTGGTGGAGCCAGACCACTTCAAGGTTGCGGTCAATGATGCCCACTTG 630 
AAAATACAAGTCCTGGTTGAACCTGACCACTTCAAGGTTGCGGTCAATGATGCTCACTTG 684 
AAAATACAAGTCCTGGTTGAAGCTGACCACTTCAAGGTTGCGGTCAACGATGCTCACCTA 696 
AAAATACAGGTCCTGGTTGAAGCCGACCACTTCAAGGTTGCGGTCAATGATGTTCATCTG 690 
AAAATACAAGTCCTGGTTGAAGCTGACCATTTCAAGGTTGCAGTCAACGATGCTCACTTG 639
B u l l  XM_58 834 0 
Dog XM_848 582 
Human M643 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M ouse  0 1 0 7  05 
R a t  N M _031832 
H a m s te r  X7 887 9
TTGCAGTACAAT CATCGGGTGAAAAATTTCGGGGAAATCAGCACGCTGGGAATTTCT GGT 75  9 
TTGCAGTACAATCATCGGATGAAAAATCTCCCGGAAATCAGCAAACTGGGAATTTCTGGT 825 
TTGCAGTACAATCATCGGGTTAAAAAACTCAATGAAATCAGAAAACTGGGAATTTCTGGT 714 
TTGCAGTACAATCATCGGGTTAAAAAACTCAATGAAATCAGCAAACTGGGAATTTCTGGT 714 
TTGCAGTACAATCATCGCATGAGAAACCTCAAGGAAATCAACAAGCTGGGAATTTCTGGT 690 
TTGCAGTACAATCATCGGATGAGAAATCTCAGGGAAATCAGCAAACTGGGAATTTCTGGT 744 
CTGCAGTACAACCATCGGATGAAGAACCTCCGGGAAATCAGCCAACTGGGGATCAGTGGT 75 6 
TTGCAGTATAACCATCGGATGAAGAACCTCAGGGAAATCAGCCAACTGGGGATCATTGGT 75 0  
CT GCAGTACAAC CAT CGGAT GAAAAAC CT CAGG GAAATCAAC CAGATG GAAATTT CT GGT 699
B u l l  X M _588340 
Dog X M _848582
Human M 64303 
Human M 57710 
R a b b i t  0 6 4 7 0  
P ig
M o u se  0 1 0 7 0 5  
R a t  N M 0 3 1 8 3 2
H a m s te r  X 7887 9
-CTTAAATGGGCAGATACT
-CTTAAAGGAGAAGATTTA
-CTGAAAGGGGCAGAT-----
-CTGAAAGGGGCAGAT-----
GACATAACTCTGACCAGTGCTTCGCACACTATGATATAAT- 
GACATAGAT CT CACCAGT GCT T CATAT GCTAT GATATAAT - 
GACATAGACCTCACCAGTGCTTCATATACCATGATATAAT- 
GACATAGACCTCACCAGTGCT T CATATACCAT GATATAAT -
GACATACAACT CACCAGT GCTT CACAT GCTAT GATATAA--------------------------------------------
GACATAACTCTCACCAGTGCTTCATATACCATGATATAAGAATTCCGAAGGGCGAATTCC
GACATAACCCTCACCAGCGCTAACCACGCCATGATCTAAG— CCAGAAGGGG----------------
GACATAACCCTCACCAGCGCTTCCCACGCCATGATCTAAG— CCAGAAGGGGTGGGC-----
GATATAACCCTTACCAGTGCTGCACCCACCATGATCTAAC— CCGGAAGGGCAGCGCT—
817
883
7 6 9
7 6 9
7 2 9
804 
80 6
805  
7 5 5
B u l l  X M _588340 
Dog X M 8 4 8 5 8 2
H uman M643 03 
H uman M 57710 
R a b b i t  0 6 4 7 0  
P ig
M o u se  01 0 7  05 
R a t  N M 0 3 1 8 3 2
H a m s te r  X7 887 9
TTTTTAA-AGAAATGAATTTGAACGTAAACCTTACACATTTAAAAGGTTCATGTTGAGTG 87 6 
AAAAAAAGAGAATTGAATATTCATTTAAAC-TTACACATGTAAACTTCATGTTTCGACTG 942
 TAAAAAAAAAAAAAAAGAATCTAAACCTTACATGTGTAAAGGTTTCATGTTCACTG 825
 TAAAAAAAAAAAAAAAGAAT CTAAACCTTACATGT GTAAAGGTTT CATGT TCA CT G 825
AGCACACTGGCGGCCGTTACTAGTG-GATCCGAGCTCGGTACCAAGCTTGATGCATAGCT 863
--------------CGGCACCGAAACC-------------------------------------- GGCCCTGTGTGCCTTAGGAGTG 841
-------------- CGGCACCAGAACT-------------------------------------- G-CCCTGTGTG— TTATGAGCG 837
-------------- TGAAACTGAAGTTCAATGGTACTCATTTAAAGGCTCCGTGCTCATTCGGAGTG 808
B u l l  X M _588340 
Dog X M 8 4 8 5 8 2  
Human M 64303 
Human M 57710 
R a b b it  0 6 4 7 0  
P ig
M ouse  010 7  05 
R a t  N M _031832 
H a m s te r  X7 887 9
AAAAATTTTACCTTTA— TTGATCAAT GTCCTT CTT GTAAAT CACTGATTTAATAAATAT 934 
AAAAAT TTTACCTTTA— TTCATCACTATCCTTCTTGTAAATCATCCATTTAATAAACAT 1 0 0 0
TGAGAGAAAATTTTTACATTCATCAATATCCCCC------------------------------------------------------- 85 9
TGAGTGAAAATTTTTACATTCATCAATATCCCTCTTGTAAGTCATCTACTTAATAAATAT 885
TGAGTAT TCTATAGTGTCACCTAAATA---------------------------------------------------------------  8 90
GGAAACTTTGCATTTC— TCTCTCCTTATCCTTCTTGTAAGACATCCATTTAATAAAGT- 898  
GGAAACTTTGCATTTC--TCTCTCCTTATACTTCTTGTAAGACATCCATTTAATAAAGT- 894  
GAAAACT — ACAT GTA— TT CCAT CTTACCCTT CTT GTAAGGCAT GCACTTAATAAATAT 864
B u l l  XM 5 8 8 3 4  0 TCTAAGAGTTACTT-------------------------------------------------------------------------------------------------  948
Dog X M _848582 TCTA----------------------------------------------------------------------------------------------------------------------  1004
Human M643 03-----------------------------------------------------------------------------------------------------------------------------------------
Human M577 10 TACAGTGAAAG-------------------------------------------------------------------------------------------------------  896
R a b b i t  0 6 4 7 0 -------- --------------------------------------------------------------------------------------------------------------------------------
P ig ------------------------------------------------------------------------------------------------------------------------------------------------------------
M o u se  0 1 0 7  05 -CTCATGCTGAGAGATACCCATCGCTTTGGGGGTTTTTATGATACTGGATGTCAAATCTT 957
R a t  N M 0 3 1 8 3 2  -  CT CGT GCT GAGAGA-----------------------------------------------------------------------------------------------  908
H a m s te r  X7 8 87 9 GCCCGTGCTGACGGGTACCTGGTTGTTTTGCGGC------------------------------------------------------  8 98
Figure 3.3 Alignment of galectin-3 nucleotide sequence from different mammalian species. The
nucleotide sequence from bull (XM_588340), Dog (XM 848582), Human (M64303 and M57710), Rabbit 
(06470), Pig, Mouse (010705), Rat (NM 031832) and Hamster (X78879) were aligned using the clustaw 
tool from NCBI. The variable regions I to VIII, in the N- terminal, are marked by different colour fonts 
used in the sequence. The N-terminal and carbohydrate recognition domain (CRD) have been labelled. A 
thick green line under the sequence in the CRD marks where the |S-galactoside binding site is.
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- Bull 
Dog
Rabbit
M64303
M57710
0.1
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Mouse
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Figure 3.4 A phylogenetic tree of galectin-3 sequences from different mammals. A
phylogenetic tree was produced using tree view
(http://taxonomv.zoologv.gla.ac.uk/rod/treeview.html) and indicates the similarity of 
the nucleotide sequenees of galectin-3 from different mammalian species. The two 
sequences at the bottom of the tree (M64303 and M57710) are two different human 
sequences.
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3.2 Sub-cloning of porcine galectin-3 into TriEx 1.1 vector
In order to examine expression and localization of galectin-3 following ASFV infection 
of cells, the complete porcine galectin-3 cDNA sequence was cloned into TriEx 1.1 
expression vector (Novagen). Primers were designed to clone the cDNA from the 
pcDNA vector adding a Nco 1 restriction site at the 5’ and an Xho 1 site at the 3’ end. 
Figure 3.5 shows the cloning strategy. A sequence encoding the PK tag from V5 virus 
was also cloned at the 5’ end of the galectin-3 gene in frame with the start codon of the 
plasmid and the ATG of galectin-3. This was done by designing two primers containing 
the whole V5 tag sequence, annealing them to each other, digesting with Nco 1 and 
cloning the fragment into the Nco 1 site at the start of the porcine galectin-3 cDNA 
sequence. The plasmid was sequenced in order to check for correct orientation and 
insertion of the V5 tag. The insert was sequenced using primers in the plasmid, the 
galectin-3 forward and reverse primers and an internal galectin-3 primer designed using 
the porcine nucleotide sequence in figure 3.3. The sequence of the primers is shown in 
table 2.2 in the materials and methods chapter. Sequencing confirmed the orientation of 
the insert sequence and that it was in frame with the plasmid and V5 tag. The two 
plasmids were named TriEx/G3 and TriExA^5/G3 respectively.
A coupled transcription, translation (TnT) reaction was also carried out using these 
plasmids to check the galectin-3 protein is expressed and that it is the predicted size. The 
TriEx vector on its own was used as a negative control and TriEx with the ASFV A238L 
protein was used as a positive control. Fig 3.6 shows that the A238L (lane 2) and 
galectin-3 genes (lane 3) are both expressed and that the galectin-3 is the predicted size 
of about 32 kDa. The human protein is 31 kDa. Given that the porcine sequence has an 
extra tandem repeat at the start of region 4 the protein should be approximately 1 kDa 
larger.
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Nco 1/Xho 1
pcDNA3.1
PCR
galectin-3
Gal-3
Nco 1  Xho
TriEx 1.1
B
Primers of PK 
V5 sequence 
annealed
PK V5 tag
PK tag cloned 
into Nco 1 site
TriEx/G3
Plasmid TriEx/G3 Plasmid T riiExA^5/G3
Figure 3. 6 Strategy for cloning porcine galectin-3 into the TriEx 1.1 vector.
Galectin-3 was cloned into the TriEx 1.1 expression vector (Novagen) by amplification 
of the porcine galectin-3 cDNA from the pcDNA 3.1 clone using primers with the 
restriction sites Nco 1 and Xho 1 and called TriEx/G3 (picture A). The PK tag from V5 
virus was also cloned into the vector and called TriEx/V5/G3 (picture B).
46kD
30kD
1 2 3
3.7 A TnT reaction to show porcine galectin-3 was being expressed. A coupled 
transcription, translation (TnT) reaction was carried out to check galectin-3 was 
being expressed in the TriEx vector. Lane 1 shows the TriEx veetor without any 
cloned sequenee. Lane 2 shows the TriEx vector expressing the ASFV A238L 
protein and lane 3 shows TriEx/G3 is expressing galectin-3.
3.3 Expression of endogenous galectin-3 using a human anti-galectin-3 
antibody
3.3.1 Detection of endogenous galectin-3 by Western blot
A time course experiment was carried out to see if the levels of galectin-3 altered in cells 
following infection with ASFV. Vero cells were infected with BA71V isolate for a range 
of times. Cells were also mock-infected with serum free media for the same times. 
Supernatants were harvested for each time point and cells were lysed directly in sample 
loading buffer. Supernatants and cell lysates were run on a 10% SDS/PAGE gel. After 
transfer to nitrocellulose membrane, the membranes were stained for galectin-3 using a 
human anti-galectin antibody purchased from Abeam (ab2785). This antibody is raised 
against the first 58 amino acids of the N-terminal region of the human galectin-3 protein. 
As the human and porcine sequences are similar it was hoped the anti-human antibody 
would also be able to detect the pig protein. Bound antibodies were detected by staining 
with a goat anti-mouse hrp conjugated antibody and enhanced by chemiluminescence 
(ECL). The membrane was also stained for alpha-tubulin. This was performed as a 
control to ensure equal loading of samples in each lane. The western blot in figure 3.7 
shows the human antibody can detect galectin-3 in Vero cells. The results show there 
might be a slight increase in total galectin-3 in the infected and uninfected cells over 
time. There was no galectn-3 detected in the supernatants of infected or uninfected Vero 
cells.
A second time course experiment was carried out using porcne alveolar macrophage 
cells infected with ASFV Malawi isolate at an MOI of 5. Galectin-3 was detected using 
the antibody described above in Vero cells. The results in figure 3.8 show the anti­
human galectin-3 antibody detects the porcine protein very weakly. There are faint 
bands of the expected molecular weight in the supernatants harvested at 16 and 18 hpi 
from the infected cells.
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Vero cell time 
course
2
Infected (hpi)
4 8 16 18 2
Uninfected (hpi)
4 8 16 18
a  - tubulin -------  50 kDa
Galectin-3
^ -, ^0^ # 0 #
'# # #
-------  30 kDa
Figure 3.8 A western blot showing levels of galectin-3 during ASFV infection in 
Vero cells. Vero cells were infected or mock infected for a range of time points. 
Galecint-3 was stained for using a mouse anti-human galectin-3 antibody. Alpha tubulin 
was also stained for to ensure even loading of protein samples.
Alveolar macrophage
Infected (hpi)
8 12 16 18
Uninfected (hpi)
8 12 16 18
a  - tubulin 50 kDa
Human gal-3 (cell lysate) V 30 kDa
Human gal-3 (supernatant)
Infected (hpi)
8 10 12 15 16 18 8
Uninfected (hpi)
10 12 15 16 18
—  30 kDa
VP30 V  »  m w r n m 30 kDa
3. 9 Time course experiment of infection with ASFV Malawi in alveolar 
macrophage cells - Alveolar macrophage were infected with ASFV Malawi isolate or 
mock infected for a range of time points. Supernatants and cell lysates were harvested 
and galectin-3 detected by western blot. Cell lysates were also stained with anti VP30 to 
detect virus infection and with alpha tubulin as a loading control.
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3.3.2 Localization of endogenous galectin-3
Hela, Vero, NIH 3T3 and porcine macrophage cells were plated onto cover slips and left 
overnight. Cells were fixed with paraformaldehyde for 20 minutes before blocking with 
goat serum and permeabalising with Triton X-100. Cells were then stained with the anti­
human galectin-3 antibody and a fiuorochrome 488 or 568 secondary antibody used to 
visulaize galectin-3 in cells. The panels in figure 3.8 show the different localization 
patterns of galectin-3 in the different cells tested. The antibody for galectin-3, which was 
purchased fi*om Abeam, is a mouse monoclonal anti-human galectin-3 antibody. Work 
by other groups and the data sheet accompanying the antibody show slightly different 
localization patterns in different cell types. In most cells the protein is distributed 
throughout the cell with the majority forming a speckled pattern in the cytoplasm. This 
pattern is illustrated by the NIH 3T3 cells above in panels D-F. In the Vero cells and 
Hela cells the galectin-3 seems to be located predominantly in the nucleus (panels A-C 
and G-I). Staining with galeetin-3 seems to be working well in these cells. However, the 
porcine macrophage staining has not worked very well. There may be low cross 
reactivity between the porcine galectin-3 and the antibody directed against the human 
galectin-3.
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DNA staning Galectin-3 Combined
Vero Cells
NIH 3T3 Cells
Hela Cells
3. 10 Endogenous staining for galectin-3 - Vero cells (panels A, B, C), NIH 3T3 cells 
(panel D, E, F) and Hela cells (panel G, H, I) were fixed in paraformaldehyde (4%), 
permeabalised with triton X-100 and then blocked with goat serum before staining for 
galectin-3. The galectin-3 antibody used was a mouse anti-human antibody from Abeam. 
Goat anti-mouse Alexa Fluor 488 (green) and 568 (red) secondary antibodies were used 
to detect galectin-3. Nuclei have been stained with DAPI and are shown in blue.
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3.4 Peptide synthesis and antibody production
The previous results showed that the anti-human galectin-3 antibody recognised the 
galectin-3 from Vero cells but not from the porcine cells. In order to investigate what 
effect ASFV infection has on galectin-3 expression in porcine macrophages, four 
antibodies were produced against the porcine protein sequence.
3.4.1 Peptide synthesis
Two peptides were designed from the porcine galectin-3 sequence in order to raise 
antibodies which recognise the pig protein. The first peptide included amino acids 1 to 
25, the N-terminal region. The human antibody from Abeam was designed against the 
N-terminal 58 amino acids. The second peptide included amino acids 180 to 205. This is 
in the carbohydrate recognition domain and includes the /3-galactoside binding site. The 
peptide sequences are shown in fig 3. 11. The peptides were synthesised by Dr Larry 
Hunt at I AH Compton.
3.4.2 Antibody production and purification
The lyophilised peptides were dissolved and coupled to the keyhole limpet hemocyanin 
protein according to the antibody production, purification kit from Pierce (77649). 2 mg 
of each peptide was conjugated to 2 mg of the keyhole limpit hemocyanin protein. The 
peptide carrier conjugate was purified on a column supplied with the kit and each 
peptide was injected into two rabbits to produce four separate antibody preparations. The 
peptides were named as follows; LD2 Rl, LD2 R2 (peptide LD2 rabbit 1 and 2) and 
LD3 Rl and LD3 R2 (peptide LD3 rabbits 1 and 2). After two weeks the rabbits were 
given a booster of the same amount of peptide prepared as before. Three weeks after 
boosting, a test bleed was taken from the rabbits. Sera was tested by ELISA to check the 
peptides used for injection could be recognised by antibodies. The ELISA results in
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figure 3.12 show that rabbit sera fi'om all four rabbits produced an excellent response to 
the peptides. The rabbits were bled and antibodies were purified fi-om the sera using the 
antibody purification columns provided with the kit fi'om Pierce. Five 2 ml elutions were 
recovered fi'om the column and the amount of protein in each measured. The second 
elution contained the highest level of protein and this was tested by western blot and 
immunofluorescence.
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Peptide 1 (LD2)
MADGFSLNDALSGSGKPNPQGWPGA 
First 25 amino acids
Peptide 2 (LD3)
VIVCNSKLDNNWGREERQMVFPFEC 
Amino Acids 180-205
10 20 30 40 50 60 70 80 90 100
Pig c lo n e . MW im a y p
110 120 130 140 150 160 170 180 190 200
Pig clone. WKRmjTII. TVK!:mNR[AIDmXK REEBEMVF
210 220 230 240 250 260 270 280 290
. . . . | . . . . 1. . . . | . . . . | . . . . | . . . . | . . . . 1. . . . | . . . . | . . . . | . . . . 1. . . . 1. . . . | . . . . | . . . . | . . . . | . . . . | . . . . | . . . . | .
Pig clone. FFEC K£îKIQVLVE'4DHEKVA3M3fÆUjQiOT^^ IS  DIlI,TSASXTMI*EHÏR»ISSTlAAVrS SEL 'rKUClA*lEÏSIVS&K
3. 11 Galectin-3 peptide sequences - The 2 peptide sequences used to raise antisera are 
highlighted in yellow on the pig galectin-3 sequence. The first peptide, LD2, is in the N- 
terminal amino acids 1 to 25. The second peptide, LD3, is in the carbohydrate 
recognition domain amino acids 180 to 205.
Galectin-3 peptide antibody
3.000
2.500
I  2.000
9  1.500 
8  1.000 
0.500 
0.000
\  N
Dilution factor
- LD2 Rl
— wt—-LD2 R2
LD3 Rl
LD3 R2
3. 12 Graph showing ELISA results of galectin-3 present in rabbit sera - the
graph shows results of an ELISA testing the amount of galectin-3 antibody produced 
in the sera of each rabbit injected with the four different peptide preparations. The 
OD is on the y axis and the dilution factor of the sera along the x axis. The different 
coloured lines represent the 4 different antibodies produced and their names are 
shown in the graph legend.
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3.5 Antibody characterisation
Purified antibodies were tested by western blot and immunofluorescence for their ability 
to recognise porcine galectin-3. In these experiments the plasmid expressing porcine 
galectin-3 (TriExW5/G3) was transfected into cells and used as a positive control.
3.5.1 Detection of porcine galectin-3 by western blot
Antibodies were tested to see if they could detect porcine galectin-3 expressed fi'om the 
cloned gene as well as endogenous galectin-3 in Vero cells and alveolar macrophages. 
Vero cells were transfected with TriEx/G3 using Lipofectamine (Invitrogen). In parallel, 
cells were also infected with ASFV. As controls mock-infected and non-transfected 
Vero cells were harvested and Vero cells which had been infected but not transfected 
were used as controls. Cell extracts were prepared by lysis in SDS/PAGE sample buffer. 
Extracts fi'om porcine alveolar macrophages harvested from a previous experiment were 
also run on the same gel. Four gels were prepared so each antibody could be tested at the 
same time. Figures 3.11 and 3.12 show western blots of cell extracts probed with all four 
antibodies. The results confirmed that all four antibodies detected endogenous galectin-3 
in Vero cells and porcine macrophage cells as well as porcine galectin-3 expressed in 
transfected Vero cells. The TriEx/V5/G3 plasmid was used in case the rabbit anti- 
porcine galectin-3 antibody did not work and I had to use an anti-V5 antibody.
In figure 3.13 Lanes 3 and 4 show endogenous galectin-3 in non-transfected Vero cells 
before (lane 3) and after (lane 4) infection with ASFV. Lane 1 shows Vero cells which 
have been tranfected with the plasmid TriEx/G3. There are two bands around 30 kDa. 
The highest band shows the galectin-3 protein expressed by the transfected plasmid and 
the lower band is the endogenous monkey galectin-3 present in the Vero cells. Lane 2 
shows the same pattern as lane 1 but these cells have also been infected with ASFV. 
Lane 5 shows the endogenous galectin-3 expressed in alveolar macrophage cells. It is 
clear that porcine galectin-3 is slightly bigger than monkey galectin-3 in the Vero cells. 
In this gel the endogenous galectin-3 in the macrophages is clearly larger than the
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endogenous galectin-3 in the Vero cells but it is not clear if it is different in size from the 
transfected gaectin-3 in lanes 1 and 2. In figure 3.14 the transfected galectin-3 is slightly 
larger than the endogenous galectin-3 detected in porcine macrophages. This is due to 
the inclusion of the sequence encoding the PK V5 tag at the 3’ end of the gene. In figure 
3.14, lane 1 shows transfected galectin-3 and endogenous galectin-3 are detected by the 
three antibodies. Lane 2 shows non-transfected Vero cells with only the endogenous 
galectin-3 detected by all three antibodies. Lane 3 shows the galectin-3 expressed in 
alveolar macrophages is also detected by these three antibodies. No other protein bands 
were detected demonstrating the high specificity of the antibodies for galectin-3.
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1 2 3 4 5
Galectin-3 m m #  — y ,
LD2 Rl
•
1. Vero cells + TriEx/G3
2. Vero cells + TriEx/G3 + ASFV
3. Vero cells + ASFV
4. Vero cells
5. Macrophage cells
3. 13 Detection of galectin-3 by the anti-porcine galectin-3 antibody LD2 Rl -  Cells 
were transfected with TriEx/G3, left untransfected or infected with ASFV. Cell lysates 
were harvested and run on SDS-PAGE gels. Transferred proteins were then stained for 
galectin 3 with the anti-porcine galectin-3 antibody, LD2 Rl. In lane 1 and 2 Vero cells 
were transfected with TriEx/G3. In lanes 3 and 4 Vero cells were not transfected. Lane 5, 
alveolar macrophage cells were uninfected and untransfected. Vero cells in lane 2 and 4 
were also infected with ASFV Ba71V.
1. Vero cells + TriEx A/ 5/G3
2. Vero cell
3. Macrophage cells
LD2R2
LD3 Rl
LD3 R2
3. 14 Detection of galectin-3 by the anti-porcine galectin-3 antibodies -  Cells were 
transfected with TriEx/V5/G3, left untransfected or infected with ASFV. Cell lysates 
were harvested and run on SDS-PAGE gels. Transfered proteins were then stained for 
galectin 3 with the anti-porcine galectin-3 antobidies, LD2 R2, LD3 Rl and R2. In lane 
1 Vero cells were transfected with TriExA/^5/G3. In lanes 2 Vero cells were not 
transfected and Lane 3 shows porcine alveolar macrophage cells which were not 
transfected.
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3.5.2 Detection of porcine galectin-3 by immunofluorescence
All four porcine galectin-3 antibodies were also tested by immunofluorescence. Vero 
cells were transfected with TriEx/G3. The transfected cells were fixed the following day 
in 4% PFA for 20 minutes. Cells were then permeabelised and stained with each of the 
four antibodies. Figure 3.15 shows that all four antibodies can detect galectin-3 
expressed in transfected cells by immunofluorescence. Although endogenous galectin-3 
was detected in Vero cells by western blotting in non-transfected cells the signal 
obtained was much weaker and it is not clear whether the antibodies can detect 
endogenous galectin-3 in these cells by immunofluorescence. Figure 3.15 shows 
galectin-3 is present predominantly in the cytoplasm and often in a speckled pattern. 
There are a small number of cells, approximately 5 %, where the galectin-3 is 
predominantly located in the nucleus. Many of the cells, approximately 25 %, have 
galectin-3 distributed throughout the nucleus and the cytoplasm. These results are 
consistent with published data for human galectin-3 in various different cell types.
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3. 15 Immunofluorescence to test the rabbit anti-porcine galectin-3 antibodies -
Vero cells transfected with TriEx/G3 were permeabelised and stained with the anti 
porcine galectin-3 antibodies. Nuclei are stained with DAPI and galectin-3 is in green. 
Panels A to C are stained with LD2 Rl, panels D to F are stained with LD2 R2, panels G 
to 1 are stained with LD3 Rl and panels J to L are stained with LD3 R2.
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3.6 Discussion
Galectin-3 from a number of different mammals has been characterised previously. In 
this chapter the complete cDNA encoding the porcine galectin-3 has been sequenced and 
compared to pubhshed data on galectin-3 from other mammalian species. Key features 
identified in other species are also present in the porcine sequence as shown in figures
3.2 and 3.4. The galectin-3 protein ranges in size from 29 to 35 kDa in size depending 
on the species it is isolated from. The protein has two main domains, the N-terminal and 
the COOH- terminal carbohydrate recognition domain (CRD). There is also an N- 
terminal leader sequence of 12 amino acids which is thought to be significant in 
controlling cellular targeting (Yoshii, 2002). Although nuclear import and retention has 
been shown to be controlled by the CRD it requires a short additional random peptide 
sequence (Gaudin et al., 2000). The N-terminal domain encodes a variable number of 
repeats nine amino acids in length and consisting of Pro-Gly-Ala-Tyr-Pro-Gly + 3 
random amino acids. As expected (Dumic et al., 2006; Hughes, 1999) the number of 
repeats varies between species and this is clear in figure 3.3 of the nucleotide sequences 
from different mammalian species. The function of the repeated units is not known but 
evolutionary conservation suggests it has an important role (Cherayil et al., 1990). The 
N-terminal domain is also collagen-Hke in sequence as it is rich in Gly, Tyr and Pro 
residues which can serve as a substrate for matrix metalloproteins (Ochieng et al., 1998). 
Figure 3.3 shows the porcine sequence aligned with human, rabbit, rat, mouse, hamster, 
dog and bull sequences. The human sequence has been annotated previously (Jia, 1988) 
(Raz et al., 1991). Significant regions identified in sequences from other mammals have 
been labelled on the nucleotide (figure 3.3) and amino acid alignments (figure 3.5). In 
order for galectin-3 to act as an inhibitor of apoptosis it needs to be phosphorylated. This 
phosphorylation occurs at serine 6 which is marked in figure 3.5. Phosphorylation at this 
site also acts as an on/off switch for sugar binding activity (Yu et al., 2002a). Rabbit 
galectin-3 has also been sequenced and cloned (Gaudin et al., 1995) and this showed 
between 65% and 87% sequence identity compared with rat, mouse, human and hamster 
depending on the regions compared. The N-terminal leader sequence and the CRD have 
greater than 80% sequence identity between sequences analysed here. Previous
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comparison of dog galectin-3 sequence shows it has 14 repeated subunits (Herrmann et 
al., 1993). In figure 3.3 the dog and bull sequence clearly have more repeat units at 
region III. In the phylogenetic tree (figure 3.4) the bull and dog are more closely related 
to each other than the other sequences. Analysis of rat galectin-3 shows a 31 kDa protein 
the same size as the mouse protein. In figure 3.4 these two sequences are also very close 
to each other and in figure 3.3 the sequences are very similar.
The COOH-terminal contains the carbohydrate binding region. This is marked in both 
figure 3.2 and 3.4. The /3-galactoside binding site is at the start of the CRD and is also 
marked in these figures. This region is similar to other animal lectins and highly 
conserved between other galectins. Binding of galectin-3 in this region to various 
ligands is similar to that of galectin-1 and 2 but unlike galectin-1 and 2, galectin-3 can 
form a dimer. This ability to dimerize gives it more flexibility and makes it more like 
galectin-7 (Ahmad et al., 2002; Brewer, 2004). Multivalency seems to be an important 
characteristic of lectin mediated interactions (Vrasidas et al., 2003). Galectin-3 has the 
ability to form dimers and ohgomers enabling it to bind multivalent ligands with high 
affinity and in part, this explains the multi-fimctional nature of galectin-3 in lattice 
formation and cross finking with other cells by stabilising interactions and enabling 
efficient signalling (Morris et al., 2004; Rini and Lobsanov, 1999). Despite the N- 
terminal and CRD being very different they are both able to bind LPS (Mey et al., 1996) 
although clearly via different methods. The flexibility of galectin-3 to use both regions 
to bind various ligands and oligomerize make it more diverse in function than other 
galectins.
The localization of galectin-3 in various cell types was investigated using the anti­
human galectin-3 antibody by immunofluorescence. Figure 3.10 shows that in Vero cells 
galectin-3 is predominantly in the nucleus but with a speckled and quite random looking 
distribution of galectin-3 in the cytoplasm of some cells. In the NIH 3T3 cells galectin-3 
is cytoplasmic and in the Hela cells galectin-3 is localised to the nucleus of all but one of 
the cells. Published work looking at localization of endogenous and transfected galectin- 
3 in BHK fibroblasts show that it is usually found in the cytoplasm. However, in some
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cells like COS-7 cells it was shown to be in the nucleus (Gaudin et al., 2000). Galectin-3 
nuclear import is via two distinct methods using both active and passive method 
(Nakahara et al., 2006). The Hela cells used here are a cancer cell line and galectin-3 has 
been shown to be up-regulated in some types of cancer and may be a useful marker for 
diagnosis (Park et al., 2008; Saussez et al., 2008). This may explain why it is localised to 
the nucleus in these cells.
The rest of this chapter has focused on producing an anti-porcine galectin-3 antibody 
and testing its ability to recognise both transfected and endogenous galectin-3. The 
results of western blot analysis (fig: 3.13 and 3.14) and immuno fluorescence (Fig: 3.15) 
show that all 4 antibodies can clearly detect porcine galectin-3. In order to investigate 
the effect ASFV infection has on galectin-3, an antibody that recognises the porcine 
protein is required. The western blot in figure 3.8 shows the anti-human galectin-3 
antibody can detect the protein in Vero cells. However, in the porcine alveolar 
macrophages the antibody cannot recognise the pig protein. The anti-human galectin-3 
antibody was designed against the first 38 amino acids of the protein sequence. Looking 
at the alignment (fig: 3.5) of the predicted human and porcine protein sequence they 
look very similar and one might predict the anti-human antibody would also be able to 
detect the porcine protein. The porcine antibodies produced here were designed against 
the first 25 amino acids of the N-terminal and against the first 26 amino acids of the 
CRD which contain the jS-galactoside binding region. These antibodes were able to 
detect the endogenous galectin-3 in the Vero cells which may indicate that these 
antibodies could recognise galectin-3 fi*om other species as well as the human and 
porcine protein. Figure 3.13 and 3.14 shows the porcine galectin-3 is slightly larger than 
the monkey galectin-3 in the Vero cells. This is explained by the additional tandem 
repeat unit in region IV of the N-terminal of the porcine sequence shown in figure 3.4.
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These antibodies have been used in further experiments to investigate changes in 
expression and localization of galectin-3 during ASFV infection and the potential role 
the protein may play during infection is discussed in chapter 4.
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4. Galectin-3 expression and localization during ASFV infection
This chapter focuses on studying the effect of ASFV infection on galectin-3 expression, 
localization and secretion. Two approaches were taken. In one a plasmid containing the 
complete porcine cDNA encoding galectin-3 was transfected into cells and the 
expression of the encoded galectin-3 followed during infection. In the second approach 
antibodies raised against galectin-3 as described in chapter 3 were used to study 
endogenous galectin-3. -----
4.1 Intracellular localization of galectin-3 following ASFV infection
Transfection of TriEx/G3 plasmid was used to look at the effect of ASFV infection on 
galectin-3 locahzation over time. The TriEx/G3 plasmid was transfected into a number 
of different cell types using hpofectamine or nucleofectin according to the 
manufacturer’s instructions. Transfections were left overnight and then half of the cells 
were infected with ASFV BA71V or Malawi isolate for 18 hours. Cells were fixed in 
4% parafomaldehyde. Cell nuclei were stained blue with DAPI and galectin-3 stained 
green with the rabbit anti-porcine galectin-3 antibody, LD2 Rl, followed by a goat anti­
rabbit FITC 488 secondary antibody. Infected cells were also stained with an antibody 
against the viral p30 protein with a goat anti-mouse FITC 568 secondary antibody. Virus 
p30 staining is shown in red. Figure 4.1 shows Vero cells transfected with porcine 
galectin-3 (lanes A to L) and infected with BA71V virus (lanes E to L). In both infected 
and uninfected cells galectin-3 is present in the cytoplasm and the nucleus and there 
does not appear to be any obvious change in localization of galectin-3 during infection 
with ASFV BA71V isolate in Vero cells.
Localization of galectin-3 during ASFV infection by immunofluorescence was also 
investigated using Maxx cells, a pig cell line which has high transfection efficiency and 
can be infected at low levels with ASFV Malawi isolate. The results of these
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immunofluorescence experiments are shown in figure 4.2. In panels A to H cells have 
been transfected with TriEx/G3 and galectin-3 was stained using the rabbit antibody 
against porcine galectin-3, LD2 Rl followed by an anti-rabbit secondary antibody. 
Galectin-3 is shown in green. The cells in panels E to L were also infected with ASFV 
Malawi isolate. Infected cells are stained with an anti VP30 antibody and are shown in 
red. In the uninfected cells the localization of galectin-3 is similar to the Vero cells with 
the protein being located in the cytoplasm and nucleus in about 80% of cells. There were 
a number of cells, 10%, where galectin-3 was located predominantly in the cytoplasm 
and a similar percentage of cells, 10%, where galectin-3 was locahsed more to the 
nucleus. In cells that were also infected with ASFV it was not clear whether there was a 
difference in localization. There were very few cells infected and transfected at the same 
time. There did appear to be a more speckled distribution of galectin-3 in some of the 
infected cells.
Macrophage cells were also transfected with TriEx/G3 using nucleofectin, but these 
cells did not survive the transfection process very well and only a couple of transfected 
cells were observed (figure 4.3 panels A to F). It was not possible to transfect and infect 
these cells in sufficient numbers for staining by immuno fluorescnce. As an alternative, 
staining of endogenous galectin-3 in non-transfected alveolar macrophages was carried 
out as shown in figure 4.3, in panels G to I. The staining was very faint, but there was a 
clear speckled pattern at the periphery of the cells. Infecting these cells and staining for 
galectin-3 and viral proteins was difficult because staining for viral protein p30 was 
much brighter than the galectin-3.
4.1.1 Staining for galectin-3 in pig tissues
The aim of this part of the chapter was to see if galectin-3 could be detected by 
immunofluorescence in the tissue of infected pigs. Various tissues were harvested from 
pigs infected with the Benin 97/1 isolate of ASFV and from uninfected pigs. Small 
cubes of spleen, lungs, sub-mandibular lymph nodes, gastro-enteric lymph nodes and the 
mesenteric lymph nodes were fixed in PFA. The cubes were then sectioned into smaller
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pieces using the microtome so that they could be stained for ASFV VP30 and galectin-3. 
Figure 4.4 shows a section from the spleen stained for VP30 in red, nuclei are stained 
blue with DAPI. There are clearly quite a few cells infected with ASFV in the spleen. 
The galectin-3 staining did not work. Even using the antibody at very high 
concentrations no staining was observed.
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Figure 4.1 Immunofluorescence of Vero cells transfected with porcine galectin-3 
and infected with ASFV BA71V -  Panels A to P show Vero cells transfected with 
TriEx/G3. Galectin-3 was stained using an anti-porcine galectin-3 antibody (LD2 Rl) 
and a goat anti-rabbit Alexa Fluor 488 secondary antibody and is shown in green. In 
panels 1 to P cells were also infected with ASFV BA71V overnight. These cells were 
also stained with the anti VP30 antibody and a goat anti-mouse Alexa Fluor 568 
secondary antibody as shown in red. Nuclei were stained with DAPI and are shown in 
blue.
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Figure 4.2 Maxx cells transfected with galectin-3 and infected with ASFV -  Max
cells transfected with TriEx/G3 plasmid are shown in panels A to L. Galectin-3 was 
stained by immunofluorescence using a rabbit anti-porcine galectin-3 antibody (LD2 Rl) 
and a goat anti-rabbit Alexa Fluor 488 secondary antibody, shown in green. Cells in 
pannles B to L were also infected with ASFV Malawi isolate overnight and stained for 
VP30 using an anti- VP30 antibody followed by a goat anti-mouse Alexa Fluor 568 
secondary antibody, shown in red. The nuclei have been stained with DAPI and are 
shown in blue.
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Figure 4.3 Alveolar macrophage cells stained for galectin-3 -  Porcine alveolar 
macrophage cells were transfected with plasmid TriEx/G3 expressing porcine galectin-3 
(panels A to F) and stained with the anti-porcine galectin-3 antibody (LD2 Rl) followed 
by an anti- rabbit Alexa Fluor 488 secondary antibody shown in green. Cells in panels G 
to I were stained for endogenous galectin-3 using the same antibodies.
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Figure 4.4 Spleen stained for ASFV and galectin-3 -  Spleen was harvested from pig 
infected with ASFV Benin isolate and sections of tissue were cut for 
immunofluorescence staining. Sections were stained for galectin-3 using the rabbit anti- 
porcine galectin-3 antibody, LD2 Rl and a goat anti-rabbit Alexa Fluor 488 secondary 
antibody. Sections were also stained for VP30 using an anti-VP30 antibody followed by 
a goat anti-mouse Alexa Fluor 568 secondary antibody. Infected cells are shown in red. 
The nuclei have been stained with DAPI and are shown in blue.
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4.2 Galectin-3 protein expression and secretion from cells
In order to examine the levels of galectin-3 protein expression following ASFV infection, 
a number of experiments were set up in which cells were infected for a range of times 
and the total galectin-3 in cells examined by western blotting. Time course experiments 
were set up in Vero cells and porcine macrophages. Cells were plated into 6 well plates 
and infected or mock-infected for a range of time points from 0 to 20 hours. Mock 
infections were carried out using media without virus in the same volumes as the virus 
infections. Virus was incubated with cells for 1 hour then cells were washed and left 
with 1 ml of media for the remainder of the time course. Supernatants were harvested 
and cells lysed in 500pl sample preparation buffer. Extracts from cells and supernatants 
were separated by SDS/PAGE and transferred to nitocellulose membranes.
As shown in chapter 3 infection of Vero cells showed no change in the levels of 
galectin-3 over time and during infection with ASFV (see figure 2.7). The supernatants 
recovered from Vero cells contained no detectable galectin-3. Figure 4.5 shows the 
western blot from alveolar macrophages infected with ASFV Malawi isolate for a range 
of time periods and mock-infected cells. The cell lysates and supernatants were 
harvested. Total proteins were separated by SDS/PAGE, transferred to nitrocellulose 
membranes and stained for galectin-3 using the porcine antibody (LD2 Rl). Western 
blots of cell lysates were also stained for alpha-tubulin to ensure equal protein loading 
and stained for VP30 to show cells were infected. There appears to be sHghtly more 
galectin-3 in the cell lysates from the infected macrophages compared to mock infected 
controls. There is also more galectin-3 present in the supernatants from infected cells at 
each time point than in the supernatants from mock-infected cells. In figure 4.6 the same 
experiment has been carried out using blood macrophages matured in GMCSF. In these 
cells no galectin-3 was detected in supernatants from uninfected cells and there is a 
dramatic increase in the amount of galectin-3 in the supernatants from infected cells. In 
the cell lysates there is also possibly an increase in galectin-3 in infected compared to 
mock-infected cells.
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A similar time course experiment was also carried out to compare levels of galectin-3 in 
cell lysates and supernatants from alveolar macrophages infected with the non- 
pathogenic ASFV OUR T88/3 isolate and the pathogenic Malawi isolate. Since CURT 
88/3 is a less virulent isolate it may have a different effect on levels of galectin-3 protein 
expression. The levels of galectin-3 in cell lysates and supernatants were assayed by 
western blot and the results shown in figure 4.6. Cell lysates and supernatants were 
stained for galectin-3. Cell lystaes were also stained for alpha-tubulin to demonstrate 
even protein loading and for VP30 to show cells were infected with ASFV. It appears 
there is no difference in the amount of galectin-3 in cell lysates or supernatants from the 
two infections. However, it is clear from the alpha-tubulin staining that there is not even 
loading of proteins and so it is hard to draw any concluions from these results.
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Figure 4. 5 Expression of galectin-3 in cell lysates and supernatants from alveolar 
macrophages infected for a range of different times - Cell lysates and supernatants 
were harvested from ASFV Malawi infected and mock infected alveolar macrophage 
cells over a range of time points and western blots were stained for galectm-3 using the 
porcine galectin-3 antibody LD2 Rl described previously. Cell lysates were also stained 
for alpha-tubulin to ensure even protein loading and VP30 to show virus infection.
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Figure 4. 6 Expression of galectin-3 in cell lysates and supernatants from blood 
macrophages infected for a range of different times - Cell lysates and supernatants 
were harvested from ASFV Malawi infected and mock-infected blood macrophage 
cells over a range of time points and western blots were stained for galectin-3 using 
the porcine galectin-3 antibody LD2 Rl described previously. Cell lysates were also 
stained for alpha-tubulin to ensure even protein loading.
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Figure 4. 7 Expression of galectin-3 in cell lysates and supernatants from alveolar 
macrophages infected for a range of different times with ASFV OURT88/3 or 
Malawi isolates - Alveolar macrophage cells were infected for varying time periods 
with either ASFV Malawi or OURT 88/3 isolates. Cells and supernatants were harvested 
and western blots stained for galectin-3, alpha-tubulin and viral protein p30.
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4.3 Reverse transcriptase real time PCR to compare levels of galectin-3 
transcripts in RNA from ASFV infected cells
Micro array analysis suggested that the transcription of galectin-3 was upregulated 
following ASFV infection (Zhang et al., 2006). To verify the results obtained by 
micro array analysis real time PCR was used.
4.3.1 Opitmization of real time PCR and 18s rRNA as the control house­
keeping gene
There are many different housekeeping genes that can be used to as controls for real­
time PCR and jS-actin had been used previously to look at gene expression in alveolar 
macrophages during ASFV infection (Zhang et al., 2006). Trial experiments were 
carried out here to test the suitability of jS-actin, glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and IBS ribosomal RNA (rRNA) as controls to analyse 
expression levels of galectin-3 in alveolar macrophages following infection. In these 
experiments both jS-actin and GAPDH were found to vary over time following infection 
with ASFV whereas IBS rRNA remained constant over time and during infection with 
ASFV (data not shown). Other groups have compared the use of different house keeping 
genes including IBS rRNA (Zhu and Altmann, 2005). They used a specific primer for 
IBS-ribosomal RNA and oligio dTs in the same reverse transcription reaction and found 
that the efficiency of the real time PCR was comparable to that obtained when carrying 
out separate reactions with both the 1 Bs rRNA and oligo dT primers. Performing the real 
time PCR on the same cDNA samples should also be more accurate than having to use 
different cDNA preparations. An IBS rRNA reverse transcription primer was designed 
as well as two internal primers for the real time PCR. The sequence of these primers is 
included in Chapter 2, materials and methods (table 2.2). A number of PCR reactions 
were carried out on cDNA produced using the IBS reverse transcriptase primer (rt 
primer) and the IBS internal reverse primer to check that all the primers worked as
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expected. The results showed that using the rt primer was not as efficient as using the 
internal reverse primer for both the reverse transcription step and the PCR reaction.
4.3.2 Reverse transcriptase real time PCR to compare levels of galectin-3 
transcripts in RNA from ASFV infected cells
Primers were designed to amplify galectin-3 from reverse transcribed RNA by real time 
PCR. The sequence of these primers is included in table 2 in the materials and methods, 
chapter 2. These primers were also tested by normal PCR before being used in a real 
time reaction to check they produced a single product of expected size of around 900bp. 
Standard curves for both 18S rRNA and galectin-3 showed almost identical primer 
efficiencies and the dissociation curves showed only 1 product for each set of primers. 
Real time PCR was carried out using SYBR green reaction mix fi-om Stratagene and 
performed on the MX3500 machine. The software used to analyse data from this 
machine is able to calculate relative quantities using 188 rRNA as the normalizer and 
mock-infected samples as calibrators. Previous analysis of real time data has shown that 
using relative quantification rather than raw ct values is more accurate (Livak and 
Schmittgen, 2001).
Reverse transcription real time PCR was carried out using total RNA samples harvested 
from alveolar macrophages at 4 hours post infection with ASFV, after treatment with 
UV-inactivated virus or from mock-infected cells. These were obtained from 
macrophages from 4 different pigs. These samples were prepared for the micro array 
experiments described in chapter 5. Fig 4.8 shows that galectin-3 is expressed in mock- 
infected and ASFV infected cells. Pig numbers 1, 3 and 4 show there is no real 
difference between expresion of galectin-3 in mock-infected cells compared with ASFV 
infected cells. Pig 2 however, shows a massive increase in expression of galectin-3 
following ASFV infection. Further reverse transcription real time PCR was also carried 
out on a number of other RNA samples harvested from other time course experiments in 
alveolar macrophages. These results also showed there was a lot of variation in the 
amount of galectin-3 transcripts in different pigs. Figure 4.9 shows the average relative 
quantity of galectin-3 transcripts from the 4 pigs. This shows more galectin-3 was
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detected in the Malawi infected cells than the mock-infected cells and cells infected with 
UV-inactivated virus.
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Figure 4. 8 Bar chart showing relative expression of galectin-3 -  RNA was
harvested from alveolar macrophage from 4 different pigs, 4 hours after being mock- 
infected, infected with ASFV Malawi or infected with UV-inactivated ASFV Malawi. 
Real time PCR was carried out to compare expression of galectin-3 in each sample 
relative to 18S rRNA expression (where dRn is the raw fluorescence which has been 
baseline coiTected and normalized). The error bars are derived from the standard error 
to the mean (SEM) of the cycle immediately before the plot crosses the threshold and 
the cycle immediately after the plot crosses the threshold for both the gene of interest 
and normalizer replicates.
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Figure 4. 9 Bar chart showing average relative expression of galectin-3 - RNA was
harvested from alveolar macrophage from 4 different pigs 4 hours after being mock 
infected, infected with ASFV Malawi or infected with UV-inactivated ASFV Malawi. 
Real time PCR was carried out to compare expression of galectin-3 in each sample 
and an average taken from the different pigs for each condition (where dRn is the raw 
fluorescence which has been baseline corrected and normalized). The error bars are 
derived from the standard error to the mean (SEM) of the cycle immediately before 
the plot crosses the threshold and the cycle immediately after the plot crosses the 
threshold for both the gene of interest and normalizer replicates.
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4.4 Apoptosis Assay
Secretion of galectin-3 from ASFV infected cells may be contributing to lymphocyte 
apoptosis which is observed during infection. Supernatants were harvested from mock- 
infected alveolar macrophages, ASFV infected macrophages and cells treated with 
TNFoj as a positive control. In order to assess whether galectin-3 secreted from infected 
cells can induce lymphocyte apoptosis, supernatants were harvested from ASFV- 
infected macrophage cells and uninfected cells. There are a number of methods 
available to investigate apoptosis in cells. Two methods have been tried here. The first 
was an ELISA based technique using a kit from Pierce to look at nucleosome 
degradation. The second method investigated levels of propidium iodide and annexin V 
staining by FACS analysis.
4.4.1 Nucleosome ELISA
Cell supernatants from infected and unifected macrophage cells were incubated over 
night with peripheral blood luecocytes (PBLs) extracted from whole pig blood. PBLs 
were also incubated with TNFoj at 6 ng/ml. This was used as a positive control for 
induction of apoptosis. The following day cells were harvested and a nucleosome ELISA 
(Pierce) performed to observe levels of apotosis. Unfortunately the ELISA did not give a 
clear result and there was an issue with availability of pig blood.
4.4.2 FACS analysis
Before investigating the effect of galectin-3 on PBLs by FACS analysis optimization of 
the staining procedure and a reliable positive control was needed. As there was limited 
pig blood available for extraction of PBLs a lymphocyte cell line (S-59) was used. These 
cells were obtained from Dr Takamatsu (Takamatsu et al., 1997). Staurosporine and 
TNFa were used as positive controls to induce apoptosis. Cells were incubated for 16 
hours with normal culture media, media containing 0.1 /tg/ml of staurosporine
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(Takamatsu et al., 1997), 1 /xg/ml staurosporine or TNFof at 6  /tg/ml. Cells were then 
stained with annexin V and PI before reading on a Bee ton Dickinson FACSCalibur with 
CellQuest software. Results were analysed using FCS Express version 3 (De Novo 
Software). Figure 4.10 shows graphs of the PI staining (y axis) against annexin V 
staining (x axis). In graph A, most of the cells are in the bottom left quadrant showing 
that the cells have not been stained with PI or annexin V. In the other graphs there are 
many cells in the bottom right quadrant indicating they have undergone apoptosis. There 
are also a large number of cells stained with PI and annexin V but these are probably 
cells which have undergone apoptosis and are dead.
Supernatants from ASFV infected cells would contain live virus and for this reason the 
cells used in the FACS machine need to be fixed in 4% paraformaldehyde for 20 
minutes. Repeating this experiment and fixing the cells after staining did not yield the 
same results. There were a lot of cells stained with both PI and annexin V even in the 
un-treated cells. Further experiments need to be done to optimise before being able to 
investigate the effects galectin-3 in supernatants would have on PBLs.
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Figure 4. 10 FACS data showing lymphocytes treated with staurosporin, TNF 
alpha or untreated and stained for PI and Annevin V - Lymphocytes were either 
treated with TNF-o: ( 6  jUg/ml) graph D, starosporine (1 and 0.1 jUg/ml) graph B and C, or 
untreated for 16 hours, graph A. Cells were then stained for PI and annexin V and 
Fluorescence data were collected using a Bee ton Dickinson FACSCalibur with 
CellQuest software.
122
4.5 Discussion
ASFV causes an acute haemorrhagic fever in domestic swine. The disease is 
characterised by massive lymphocyte apoptosis in cells surrounding infected 
macrophages in tissue (Ramiro-Ibanez et al., 1996). Research over the past decade 
shows galectin-3 could be a key player in immune modulation and it has been shown to 
be up-regulated in other viral infections such as HIV-1 (Fogel et al., 1999). In particular 
secreted galectin-3 has many functions; during kidney development, angiogenesis, 
neural functions, tumour metastasis, autoimmune disorders and can act as a mediator or 
modulator of cell to extra cellular matrix adhesion (Ochieng et al., 2004). The aim of 
this chapter was to investigate what affect ASFV infection has on level of galectin-3 
expression, localization and secretion from infected cells. As mentioned previously 
massive lymphocyte apoptosis occurs during ASFV infection and this could be due to an 
increase in secretion of proinflammatory cytokines such as IL-lo; IL-1/3, IL- 6  and TNFce 
from ASFV infected macrophages (Gomez del Moral et al., 1999; Salguero et al., 2005). 
Galectin-3 clearly has the ability to play a crucial role in immune modulation. 
Oligomerization of the N-terminal region may assist in cell-cell adhesion and signal 
transduction to neighbouring cells or may stabilize interactions through lattice formation 
(Sato, 2004). Galectin-3 has been shown to induce apoptosis in type II T-cells activating 
the caspase pathway through interaction with CD7 and CD29 (Fukumori et al., 2003). It 
is also apparent that galectin-1 and 3 have a closely linked antagonistic relationship both 
being expressed in many of the same types of cells such as T-cells, B-cells, NK cells, 
macrophages, dendritic cells, endothelial cells and fibroblasts with high levels in thymus 
and lymph nodes. Both can trigger T-cell death but probably rely on different 
glycoproteins receptors in order to do so (Stillman et al., 2006). Galectin-3 can stimulate 
extracellular Ca^  ^uptake in T-cells (Dong and Hughes, 1996) and can induce apoptosis 
in polymorphonuclear leukocytes (PMNs) possibly via the p38 MAPK pathway as 
inhibition of this pathway completely blocked galectin-3 mediated stimulation of 
phagocytosis, apoptosis and CD6 6  exocytosis (Fernandez et al., 2005).
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The lymphocyte apoptosis that occurs during ASFV infection can in part be explained 
by the action of TNF a  produced by cells (Gomez del Moral et al, 1999). However, there 
is clearly some other factor or factors that contribute and it is possible that galectin-3 
may be involved.
The first part of this chapter investigated localization of galectin-3 in various cells 
during ASFV infection by immunofluorescenece. In figure 4.1 Vero cells have been 
transfected with TriEx/G3 and some of the cells were also infected with ASFV Ba71 V. 
In panel K and O there are two cells with bright red spots indieating the site of a viral 
factory. In the cells I to L galectin-3 is located in the cytoplasm and a little in the nucleus 
of the unifected cells (bottom left). In the cell (right) with the intensely stained viral 
factory, galectin-3 is in the cytoplasm. However, in panels M to O galectin-3 is located 
predominantely in the nucleus of the cells with the intensely stained viral factory. In the 
uninfected cells A to H galectin-3 is in the nucleus and the cytoplasm. This suggests 
ASFV infection in these cells does not affect localization of galectin-3. The pictures 
probably represent the transient nature of galectin-3 and the natural shuttling between 
the nucleus and cytoplasm observed in some cell types. In the Maxx cells shown in 
figure 4.2 panels E to H there is possibly a change in galectin-3 distribution. Galectin-3 
appears to be in the cytoplasm but in blobs rather than evenly distribute around the cell. 
The Maxx cells are very difficult to infect with ASFV so very few cells were infected 
and transfected. These cells can be transfected with very high efficiency and ASFV can 
be adapted slightly to Maxx cells by passaging the virus through them many times. It 
would be interesting to repeat these localization experiments in Maxx cells with virus 
that is more efficient at infecting them. A similar experiment was also carried out in 
alveolar macrophage cells but these were very hard to transfect and infect. Staining for 
endogenous galectin-3 was possible and the results are shown in figure 4.3 panels G to I. 
It was not possible to detect the endogenous galectin-3 in infected cells as the galectin-3 
staining was very faint. The galectin-3 endogenously expressed in macrophage cells 
does show a different pattern of localization. In these cells it appears to be located at the 
surface. Considering these cells naturally secret galectin-3 at low levels this is not
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suprising. Several attempts to stain for galectin-3 in tissue from infected animals were 
unsuccessfiil.
The levels of galectin-3 protein during ASFV infection were also investigated. In Vero 
cells (fig: 3.8) in the previous chapter there was no change in the levels of galectin-3 in 
cell lysates over time in infected or uninfected cells. There was also no galectin-3 found 
in the supernatants from these cells. In alveolar and blood macrophage cells (fig: 4.5 and 
4.6) there was a definite increase in the amount of galectin-3 in supernatants from 
infected cells. This increased during infection. There is possibly a slight increase in the 
amount of galectin-3 in cell lysates from infected cells. In a similar time course 
experiment where cells were infected with the less virulent OUR T883 isolate of ASF 
there does not appear to be a change in the levels of galectin-3 in cell lysates or 
supernatants.
Analysis of galectin-3 transcription by real time PCR was less conclusive. The levels 
varied between samples from different pigs as shown in figure 4.8. In figure 4.9 where 
an average has been taken from the 4 pigs the levels of galectin-3 are higher in the 
ASFV infected cells than the uninfected cells and cells infected with UV inactivated 
virus. The error bars are large though and from figure 4.8 it is clear that the transcript 
levels in pig 2 are significantly higher and this will affect the overll average. Work 
carried out by other groups looking at levels of galectin-3 by real time PCR also showed 
significant variability between samples even in more stable systems.
The idea that gaelctin-3 might be contributing to the amount of lymphocyte apotosis 
during ASFV infection needs to be investigated. Experiments carried out here show that 
both TNFa and staurosporine can induce apotosis and this can be measured by staing for 
PI and annexin V and analysing by FACS. However, fixing the cells did not work. It 
may be because they were fixed with 4% which is twice as strong as paraformaldehyde 
usually used to fix for FACS analysis. It would be really interesting to be able to carry 
out the experiment without having to fix the cells. Galectin-3 can be blocked by 
incubating cells with lactose prior to the addition of galectin-3 or supernatants from
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infected cells which contain galcctin-3. This would be uscfiil to show that any apoptosis 
which occurred during incubation with supernatants from infected cells could be blocked 
by the addition of lactose to these cells prior to incubation. The porcine galectin-3 
antibody could also be used to block activity in similar experiments carried out by 
(Gomez del Moral et al, 1999) investigating the effect of TNFaon lymphocyte 
apoptosis.
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5. Microarray analysis of differentially regulated genes during infection with ASF
5.1 Microarray design, optimization and execution
The aim of the experiments described in this chapter was to use microarrays to 
investigate host gene expression in porcine alveolar macrophage cells during the early 
stages of infection with ASFV. In this experiment host gene expression was compared in 
cells infected with UV inactivated virus, which can bind and enter cells but does not 
replicate, and cells infected with untreated Malawi virus. The aim was to dissect the 
effects on host gene transcription of virus binding and entry from other early steps in the 
replication cycle including early virus gene expression. In this way it should be possible 
to identify cellular pathways which may be targeted by viral proteins transcribed early in 
ASFV infection. Host gene expression in mock-infected macrophages was investigated 
as a control and also to identify any effects that the binding and entry of the UV- 
inactivated virus may have on host cell signalling. Virus infection is known to activate a 
number of host cell signalling pathways, as described in chapter 1 .
The repHcation cycle of ASFV is described in chapter 1 and shown in figure 1.3. There 
are a number of inhibitors that can be used to block different stages in the replication 
cycle. Cycloheximide (CHX) can block early gene translation by interfering with the 
translocation step in protein synthesis, blocking translational elongation. However, this 
also blocks translation of host mRNAs. Cytosine arabinoside (CAR) blocks viral DNA 
synthesis and therefore inhibits late virus gene transcription, which is dependent on the 
onset of viral DNA synthesis. Although these drugs both worked well in blocking ASFV 
replication they have side effects on cells which could complicate the interpretation of 
data. Therefore, UV-inactivated virus treatment was used to compare against wild type 
virus infected and mock-infected cells in these micro array experiments. UV-inactivated 
ASFV has been used previously to examine the steps in virus replication which induce 
apoptosis (Carrascosa et al., 2002). The inhibitors CHX, CAR and chloroquine were 
used in conjunction with UV-inactivated virus to investigate caspase activation in 
infected cells. There was no caspase activation in cells treated with chloroquine or cells
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infected with UV-inactivated virus suggesting that apoptosis is induced during the 
process of viral uncoating.
5.2 Growth and purification of ASFV Malawi isolate and UV-inactivation of 
virus
In order to carry out the infections required for the microarray experiment, large virus 
stocks needed to be grown and purified. To obtain as consistent results as possible, the 
same virus preparation was used in all the microarray experiemts. The ASFV Malawi 
isolate was grown in pig bone marrow cells. Once a large amount was grown it was 
purified using an Optiprep gradient and concentrated using vivispin columns (Sartorius 
Stedim Biotech). The purified, concentrated virus stocks were pooled and then titrated in 
pig bone marrow cells, using a haemadsorption assay, and in lung macrophages by 
immunofluorescence as described in Chapter 2. In order to prepare material for mock- 
infections the supernatants fi-om uninfected pig bone marrow cells were treated in the 
same way as for virus purification.
In order to UV-inactivate the Malawi virus some prehminary test experiments were 
carried out using the ASFV BA71V isolate, since this can be grown in Vero cells and 
there were already large stocks available. The virus was UV-inactivated for varying 
times between 5 and 45 minutes at a range of distances fi-om the UV lamp. The UV- 
treated virus was then used to infect Vero cells and cultured overnight. Cells were fixed 
and then stained for the early viral protein VP30 by immuno fluorescence to check for 
early gene expression. After UV-inactivation for 15 minutes no VP30 could be detected 
when this virus was used to infect Vero cells. A portion of the Malawi virus stocks was 
then UV-inactivated. In order to make sure all virus particles were UV-inactivated the 
virus was treated in small volumes for 30 minutes. The Malawi virus was tested by 
infecting pig lung macrophages overnight and then staining for VP30. No VP30 staining 
could be detected on any of the slides. Figure 5.1 shows macrophage cells infected with 
untreated Malawi virus (panels A to C) and with UV-inactivated virus, (panels D to F). 
Nuclei are stained with DAPI and virus proteins have been stained with anti-VP30 
antibody in red.
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Figure 5.1 Infection of alveolar macrophage cells with Malawi virus and UV- 
inactvated virus. Alveolar macrophage cells were infected with ASFV Malawi virus 
(panels A to C) or UV inactivated virus (panels D to F) for 24 hours. Cells were then 
fixed and stained for virus protein P30 (VP30) in red. Cell nuclei are stained with DAPI 
and are shown in blue.
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5.3 Experimental design
Micro array experiments are lengthy and complicated in design, execution and analysis.
A major factor often influencing the experimental design is cost and this can impact on 
the number of replicates, conditions or time points that can potentially be investigated.
In addition RNAs are compared pairwise and this limits the number of comparisons that 
can be carried out. In this micro array experiment alveolar macrophage cells were 
harvested jfrom 4 pigs so there were 4 biological replicates. Macrophage cells can vary 
considerably fi-om pig to pig so ideally more biological replicates would be usefiil but 4 
was considered a reasonable compromise based on cost and ethics. Figure 5.2 shows a 
schematic of the comparisons used in the experiment. Technical replicates were also 
included in which the RNAs to be compared were labelled with each combination of the 
two fluorescent dyes. These “dye swaps” are indicated by double arrows on figure 5.2. 
The experimental “loop” design ensures that all conditions are compared with each other; 
for example, mock-infected cells are compared to cells infected with untreated Malawi 
virus and UV-inactivated virus and the two infections are compared to each other. This 
gives added confidence in the results when any two conditions are compared. The 
alternative would be to include a common reference RNA to which all samples were 
compared.
The first stage of the micro array experiment is to harvest RNA from cells that have been 
infected with virus or mock-infected. In preliminary experiments RNA was harvested 
fi-om 4 different time points; 1, 2, 4 and 6  hours post-infection. In order to decide which 
time point would be most interesting to use in the micro any experiments, a number of 
PCR reactions were carried out comparing levels of TNFa and IL-lj8  transcripts at each 
of the 4 time points with the control housekeeping gene. In these experiments 18S rRNA 
was used as the control as its expression was shown not to alter following infection. 
Figure 5.3 shows levels of TNFa expression detected by reverse transcriptase 
quantitative PCR (RTQPCR) using SYBR green, in cells infected with untreated Malawi 
virus and cells infected with UV-inactivated virus at 2, 4 and 6  hours post infection. The 
results of the RTQPCR show a significant drop in expression of TNFa between 2 and 4
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hours post infection and this continued to drop at 6  hpi in the RNA from cells infected 
with the UV-inactivated virus. In cells infected with the untreated Malawi virus the 
levels of TNFa RNA did not change much between 2 and 4 hours post-infection but 
decreased at 6  hours post-infection. In a non-quantitative PCR analysis of IL- 1(3 
expression in the same samples, there was also a greater difference between cells 
infected with the UV-inactivated virus and untreated virus at 4 hours post-infection than 
at 2 and 6  hours post-infection (data not shown). The 4 hour post-infection time point 
was, therefore, chosen for investigation in the micro array experiment. It is known that 
transcription of ASFV early genes begins immediately following release of virus cores 
in the cytoplasm and that early virus proteins can be detected as early as 2  hours post­
infection.
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UV-inactivated
Mock infected Malawi isolate
Figure 5.2 Design of microarray experiment - This diagram is a plan of the 
comparisons made in the micro array experiment. RNA from mock-infected 
macrophages was compared to RNA from cells infected with untreated and UV- 
inactivated Malawi virus. RNAs from these infections were also compared.
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Figure 5.3 Reverse transcriptase quantitative PCR (RTQPCR) showing expression 
of TNFof during infection with ASFV over time -  RTQPCR was carried out on RNA
samples harvested from 4 pigs at 4 time points to investigate expression of TNFa 
Levels ofTNFotmRNA at 2, 4 and 6  hours post infection are shown post-infection with 
Malawi virus and UV inactivated virus.
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5.4 Microarray optimization
There are many steps involved from start to completion of micro array experiments with 
large amounts of data to analyse at the end. In order to obtain as accurate results as 
possible every step must be optimized to minimize experimental variations as mueh as 
reasonably possible. Since microarrays were first developed there has been a huge 
increase in the number of companies supplying materials and components to carry out 
the experiments. Previous micro array experiments carried out in the group (Zhang et al, 
2006) were carried out using a porcine, 2, 880 gene cDNA array known as the Pig 3K 
Immune cDNA array. This was developed to specifically target genes associated with 
the immune response. In the micro array experiment carried out here this Pig 3K Immune 
cDNA list of genes was combined with a porcine oligonucleotide array containing the 
Operon Sus scrofa vl.O and Sus scrofa extension Array-ready Oligo sets™ (Operon 
Biotechnologies). This array contains 13, 297, 70-mer ohgonucleotides. The whole 
Operon array contains all known porcine gene sequences with a hit to human, mouse or 
pig gene transcripts and also a number of sequences containing a 3’ expressed sequence 
Tag (EST) without hits to other organisms (https://www.operon-biotech.com/index.nhr)T 
The Operon Sus scrofa array was chosen for these micro array experients because of the 
diverse and large number of probes which were targeted to a wide range of cellular 
responses.
5.4.1 Slide spotting and preparation
There are many companies that provide equipment and reagents for micro array 
experiments and a number were tested within the group before deciding on slides from 
SCHOTT Nexterion®. Shdes were spotted with an oligo array purchased from Operon, 
using a Biorobotics Microgrid TASII Microarray spotter (Genomic Solutions, 
Cambridge, England). Once the slides had been spotted they were stored in a special
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humidified chamber until use. Shdes were prepared for each hybridization as described 
in chapter 2  using reagents recommended for use with this type of slide and oligos.
5.4.2 RNA extraction and amplification
Alveolar macrophage cells were harvested by lung lavage as described in chapter 2.
These cells were plated onto three 6  well plates and each plate was either mock-infected 
or infected at a high multiplicity of infection with untreated Malawi virus or UV- 
inactivated virus for 1, 2, 4 and 6  hours. After the specified time of infection cells were 
scraped off the well and RNA was extracted using the QIAGEN RNA extraction kit. 
Total RNA was tested for its purity and concentration using the Agilent biolanalyser 
2100 (Agilent technologies). This is a highly accurate method of gel electrophoresis 
carried out on a chip which can analyse 1 2  samples at once using only nanomolar 
quantities of RNA in 1 pi volume. The software produces graphs for each sample 
measuring the height and ratio of the 18S and 28S ribosomal RNA peaks to give an 
indication of how pure the RNA sample is. The software also calculates the 
concentration of RNA in each sample. Two peaks representing the 18S and 28S rRNA 
were observed for all samples and the ratios were within acceptable limits according to 
manufacturer’s guidelines. All samples were also measured on the NanoDrop™ 1000 
(Thermo scientific) spectrophotometer which is another highly accurate way of 
measuring RNA concentration. The 260/280 nm ratio gives an indication of 
contaminating DNA and protein levels in the samples. All samples had ratios between 
1 .8  and 2 .1 , showing they were free from contamination.
In order to ensure there was enough RNA to carry out the micro array experiment and 
subsequent validation experiments RNA was amplified using the Amino Allyl 
MessageAmpTM aRNA Kit (Ambion, catalogue number 1752). This kit contains all 
components needed to perform aRNA amplification, including first- and second-strand 
cDNA synthesis using an oligo(dT) primer containing a T7 promoter, cDNA 
purification, large scale in vitro transcription and aRNA purification. The kit has been 
designed to produce high yields of amplified RNA producing as much as 150 fig fi-om an
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input of just 2 fig. The kit also includes purified amino allyl UTP and reagents for dye 
coupling and cleaning of samples. The amplification of RNA was carried out for the 
maximum time of 14 hours to ensure high levels of RNA amphfication. The aRNA was 
then tested on the Agilent biolanalyser 2100 to check RNA had been amplified over a 
range of product sizes. All RNA samples gave a typical profile o f250 to 5500 
nucleotides with the majority of products between 1 0 0 0  and 1500 nucleotides (data not 
shown).
5.4.3 aRNA Labelling
The next step was chemically labelling the amino allyl modified RNA (aRNA) using 
CyDye NHS-esters. CyB and Cy5 dye was obtained from Amersham (GE Healthcare). 
The Cy3 and Cy5 dye comes in individual aliquots for easy labelling which can be 
carried out and then cleaned on a column in a few hours. The clean up columns are 
designed to remove any free dye to help reduce any background in the hybridizations. 
Cye dyes were added in a coupling reaction after aRNA synthesis to add the label to an 
amino allyl-modified rNTP incorporated during the in vitro transcription (IVT) step. 
Indirect labelling was chosen as it can be more efficient than direct labelling in which 
dyes have different incorporation efficiencies. An amino allyl NTP is incorporated into 
aRNA and the reactive amino group is subsequently coupled with an NHS (N- 
hydroxysuccinimide) ester label. The indirect method allows allyl modified NTPs to be 
incorporated with almost identical efficiencies to unmodified NTPs.
Initially the incorporation of dye into the aRNA was well below the recommended 
range of 30 to 60 dye molecules per 1000 nucleotides. Altering the volumes of sodium 
bicarbonate and making sure it was the right pH made a massive difference to levels of 
dye incorporation. Dye incorporation was measured using the Nano Drop™ 1000 which 
enables the researcher to check for Cy3 and Cy5 labelling efficiencies by using only lfi\ 
of the purified, labelled RNA. The table 5.1 shows the levels of dye incorporation before 
and after the labelling was optimized. Samples labelled in bold are the results after
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optimization. The level of incorporation increased from a range between 11 and 23 dye 
molecules to a range of 39 to 62 dye molecules per 1000 nucleotides.
5.4.4 Hybridization
Initially hybridizations were carried out manually for 16 hours, using 2 pg RNA, in mini 
hybridization chambers designed to keep the atmosphere around the slide humid and 
constant while in a 65°C incubator. This method requires mounting the coverslips evenly, 
loading the slides in the chamber and maintaining the same conditions within the 
chamber for each slide. The coverslpis then had to be removed and slides washed 
manually after the hybridization period. This was difficult to regulate. A ftilly automated 
hybridization chamber Tecan HS 400™ Pro was purchased from Tecan. This machine 
enables 4 slides to be pre-washed, hybridized to the labelled RNA, washed and then 
dried ready for reading on a scanner. This cuts out time consuming and hard to regulate 
wash steps and also means the actual hybridization is carried out in a very controlled 
environment. Figure 5.4 shows data from two slides after being scanned and analysed 
using Spotfinder from the TM4 suite (formerly the Institute for genomice research, TIGR 
and now part of the J. Craig Venter institute). The first sHde (A) was from a manual 
hybridization before optimization and the second slide (B) from hybridization on the 
Tecan HS 400™ Pro after optimization. Slide A has a lot of streaking and there is a clear 
bias in the hybridization of Cy3 labelled RNA. Slide B shows neat spots with varied 
hybridization of RNA samples and low background.
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Table 5.1 Levels of dye incorporation in labelled RNA from samples from one pig -
The table shows the amount of Cy3 and Cy5 dye incorporated into labelled RNA 
samples for 1 of the hybridization experiments before and after optimization of labelhng. 
The numbers highlighted in bold are fi-om samples after optimization.
Sample RNA cone, 
(ng/pl)
260/280 Dye (pmol) Dye
incorporation
Cy5 Mock 264.8 2 .0 1 11.3 13.8
Cy5 Malawi 2 2 0 .1 2 . 0 0 1 0 .6 15.6
Cy5UV 235.6 2 . 0 2 1 1 .1 15.3
Cy3 Mock 274.3 1.95 9.6 11.46
Cy3 Malawi 213.0 1.98 11.9 18.3
Cy3UV 225.6 1.93 15.7 2 2 . 6
Cy5 Mock 236.4 1.98 32.9 45.2
Cy5 Malawi 194.6 2.03 23.2 38.7
Cy5UV 2 1 2 . 6 1.98 28.4 43.3
Cy3 Mock 229.3 1.78 45.4 64.2
Cy3 Malawi 203.0 1.81 37.0 59.1
Cy3UV 201.7 1.82 38.3 61.6
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Figure 5.4 A comparision of microarray slides before and after optimization of 
hybridization -  Picture A shows a segment of a micro array slide before optimization of 
the procedure and using the manual hybridization method. Picture B shows a section of a 
slide after optimization of the procedure and using the Tecan HS Pro 400 hybridization 
chamber.
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5.5 Analysis
A wide range of software packages have been developed in order to capture and analyse 
micro array data. In these micro array experiments spot fluorescence intensities were 
captured using the GenPix 4000B scanner fi-om Agilent. The scanner is supplied with 
GenePix Pro software which measures raw spot data producing the standard 16-bit TIFF 
image which can be used by many other programmes for initial analysis and further 
statistical investigations. Other software packages which can be used to process spot 
intensity data include bluefuse (BlueGnome Ltd) and Spotfinder which is part of the 
TM4 suite (formerly the Institute for genomice research, TIGR and now part of the J. 
Craig Venter institute). It is important to have control and understanding of each stage of 
the analysis in order to get the most information out of the data, but it is important to 
remember the analysis is only ever as good as the data put in. The output of every 
analysis algorithm apphed to microarray data will also require further biological analysis 
and validation.
The advantage of the GenePix Pro software is that it can automatically balance the PMT 
(photomultier) gain. There is also a choice of local and global methods for background 
correction or negative controls within the slide that can be used. The software is also 
integrated with the web so data can be linked to a specific URL for database queries 
using gene names or identities (ids). The software calculates 108 measurements for each 
spot. Measurements for each slide include; the number of features and background 
pixels for each feature at scanned wavelength, mean, median and sum of pixel intensities, 
the ratio of mean and median pixel intensities, the signal to noise ratio (including the 
ratio of means and medians, pixel-by-pixel), regression ratios, standard deviations of 
feature and background pixel intensities, spot quality measurements like feature and 
background coefficients of variation and feature circularity. These measurements are all 
usefiil in assessing how good your data is.
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5.5.1 Software and analysis methods
There are many software packages available for analyzing micro array data and the 
choice of package used may be more of a personal preference depending on what the 
user finds easiest or most flexible for them. The other major contributing factor may be 
cost. Many packages which are very popular and easy to use such as Genespring are 
expensive.
The TM4 suite is a set of tools consisting of 4 major apphcations; micro array data 
manager (MADAM), spotfinder, micro array data analysis system (MIDAS) and multi­
experiment viewer (MeV) developed for two-colour array analysis. Spotfinder reads 
paired 16-bit TIFF image files. Semi-automated grid construction defines the areas of 
the slide where spots are expected. Grids can be adjusted manually to make sure spots 
are in the centre of each square in the grid. Spot intensities are calculated as an integral 
of non-saturated pixels with local background subtracted fi-om each intensity value. 
TIGR array viewer files named ‘tav.’ are created which contain calculated spot 
intensities, the position on the array, the spot area and quality control flags amongst 
other things. Bad spots or areas of high background can be manually discounted fi-om 
the analysis.
Data from spot intensities, for each hybridization, is usually given as a log2 ratio of the 
relative intensities of the two test conditions (colours) for each feature, this ensures that 
up-regulated and down-regulated genes are treated in the same way. The first step in 
normalization is to adjust individual hybridization intensities to enable meaningful 
comparison of biological samples. Common defects that show up on the slide can be 
smearing of spots and specs of dust or hairs. Some spots may also be saturated or not 
uniform in size and shape or there may be a large amount of background. There might 
also be slightly uneven RNA quantities and uneven detection efficiencies of the two 
dyes. Although optimization and care while carrying out the microarray experiment 
should make all of these problems minimal, there will always be an element of variation 
across a slide. GenePix is not good at identifying spots fi-om smearing and the manual
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circulatory feature was difficult to use and did not appear very good at defining the spots 
in areas of high background. Bluefuse on the other hand is very good at detecting spots 
from high or smeary back ground using algorithms based on Baysian probability. In 
analysis of early slides, which contained a lot of smearing, the Bluefiise software was 
excellent at pulling out features. However, there were many incidents where the 
software appears to make out a feature from an area of noisy background. The 
Spotfinder software is also very good at searching for features but it is less likely to 
conjure them up from a patch of messy background. The Spotfinder software can also be 
set to look for spots within a certain area and of a certain size. These can be viewed and 
corrected on each slide by eye for each spot. Although the placement of grids for spot 
detection in bluefuse can be adjusted by eye, it is not as flexible as Spotfinder. The 
Bluefuse and Spotfinder software were both used for the primary analysis. However, the 
Spotfinder output was taken forward for further normalization and analysis.
There are a number of methods for data normalization such as linear regression analysis, 
log centring, rank invariant methods and Cheris ratio statistics. These don’t take into 
account systematic bias unlike locally weighted linear regression (LOWES S) which can 
remove intensity dependent effects on Logi (ratio) values (Quackenbush 2002). Data 
from Spotfinder was normalized using both ‘R’ and MIDAS (TM4 suite, J. Venter 
Institute). ‘R’ is a freely available environment which is designed for statistical 
computing and graphics (http://www.r-project.org/). It can be used for a range of 
statistical and graphics techniques such as linear and non-linear modelling, classic 
statistical tests and clustering and therefore can be used to analyse micro array data. Data 
was normalized by print tip Loess followed by scale normalization between arrays. The 
box plot in figure 5.5 shows how data of Log ratios from one slide looks before (plot A) 
and after (plot B) normalization. In plot B there is a much more even distribution about 
zero.
Data was also normalized in MIDAS (TM$ suite). MIDAS is an intuitive interface which 
can be used to design and carry out normalization and filtering protocols. This means 
many hybridizations can be treated in exactly the same way. Normalization using
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MIDAS was by Lowess and then dye swaps were carried out to eorrect for across slide 
variation. The aim of the normalization at this stage is to get as accurate data as possible 
for a single experiment which can be compared to other slides or conditions. This 
normalization step should correct for any differences in the dyes. In general the most 
common form of normalization is ratio-based but for many micro array experiments this 
may not be suitable and a Hnear method is required such as Lowess/Loess. This 
separately normalizes sub-intervals of intensity giving data which is symmetrical about 
zero and with an overall dynamic range which is smaller.
In this experiment there were four biological replicates which were kept separate 
throughout analysis with both ‘R’ and the TM4 package. Analysis of variance (ANOVA) 
was performed on both data sets. The number of differentially-regulated genes identified 
by the two packages is shown in table 5.2. The number of genes for which annotation 
was available is also included. The MeV (TM4) results showed 764 genes were 
differentially-regulated with annotation available for 559 of these genes. The results 
from the analysis in ‘R’ showed the total number of differentially-regulated genes as 
1571 with annotation available for 1024 of these genes. The number of genes 
differentially-regulated by at least two fold and with a p value less than 0.05 is also 
shown. There were 237 genes differentially-regulated with annotation available for 189. 
Clearly there are many fewer genes if only the two fold differentially-regulated genes 
with p < 0.05 are counted. The number of differentially-regulated genes obtained using 
the MeV programme (TM4 suite, J. Venter Institute) is somewhere between these two 
numbers. In this analysis data was filtered to remove low intensity spots before the 
ANOVA analysis was carried out and this explains why the number is so different. In 
this MeV analysis the ANOVA results show the differentially-regulated genes for each 
condition. In the ‘R’ analysis the list is of differentially-regulated genes compared 
between samples from cells infected with Malawi untreated virus and UV-inactivated 
virus, using the samples from mock-infected cells as a reference.
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Figure 5.6 shows a selection of genes from the heat map of samples and genes clustered 
after ANOVA analysis using the MeV programme (TM4). Each lane or column (1 to 12) 
represents a different comparison. A comparison of samples from all 4 pigs is shown. 
Samples from all 4 pigs were kept separate in order to identify any that were behaving 
differently to the other samples. The hybridizations have naturally clustered together 
into the test conditions, for example, the comparisons between samples obtained from 
cells that were; mock-infected and infected with untreated Malawi virus; mock-infected 
and UV-inactivated virus; infected with untreated Malawi virus and UV-inactivated 
virus. Genes have also clustered together into groups with similar expression patterns. 
There are two samples (4 and 5) which look as if they have been clustered incorrectly 
and that they could just be swapped round. This may be the result of experimental error. 
Lane 4 shows a comparison between a mock-infected verses UV-inactivated virus 
infected sample and lane 5 shows a comparison between samples from untreated Malawi 
virus infection verses a mock-infected sample. The first block of differentially-regulated 
genes (block A) contains about 45% of the total differentially-regulated genes and these 
are down-regulated during infection with untreated Malawi virus and UV-inactivated 
virus compared with mock-infection of cells. A schematic diagram of the changes in 
expression across the 3 conditions is also shown on figure 5.6 with examples of 
differentially-regulated genes falling in each cluster given. It can be seen that in block A 
the effects of the UV-inactivated virus are less than the untreated virus. The 
differentially regulated-genes in block A include ATP dependent DNA helicase, cyclin c, 
synexix, AP-3 complex sub-unit, MAPK8  and c-Src. Block B shows approximately 20% 
of the differentially-regulated genes are up-regulated in samples from Malawi and UV- 
inactivated virus infected cells compared with mock-infected cells, but many of these are 
up-regulated to a greater degree in the untreated Malawi virus infection compared to 
UV-inactivated virus infected cells. The difference between the two virus conditions and 
the mock-infected cells is high. This is clearly shown by the very bright red colour 
observed. The difference between the UV-inactivated virus and normal Malawi virus is 
less obvious. In some blocks there is not much difference if any, illustrated by the pale 
green or grey colour. Results from the samples from different pigs are also much more 
variable in this block of genes. Genes in this block include NF-kB2 (pi 05 sphce form).
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Heat shock protein 90 (HSP90), RAB6  interacting kinase, cytochrome c oxidase subunit 
and a Bcl-2 like protein.
In block C there are many fewer genes and the colours are also not as bright indicating 
smaller differences in regulation. This block contains about 5% of the total genes. Here 
the genes are down-regulated during the Malawi virus infection but up-regulated by the 
UV-inactivated virus compared to mock-infected cells. Using this data and the data from 
R analysis, examples of genes in this group include sphcing factor argentine/serine rich 
6  (SFRS6 ), IL-15, c-Fos, CREBLl, TNF receptor associated factor 4 (TRAF4) and 
STAT4. Block D shows a cluster of genes up-regulated in Malawi virus infection but 
down-regulated by UV-inactivated virus compared to mock-infected cells. This group 
only contains about 2% of the differentially-regulated genes and again using the R 
analysis data to investigate in more detail this group includes genes such as CXCL14, 
NADH dehydrogenase sub-unit 2, a RIKEN cDNA clone, IL-17 and IL-18.
B144
G
4
2
a>O)
c
TO 0 
u
T3
O 2 
U.
0 -
-4
■6
S R NS § R
Experiment number (pig and slide number) Experiment number (pig and slide number)
Figure 5.5 A box plot of microarray data -  Box plot A shows the fold change in gene expression for 
each hybridized slide before normalization (A) and after normalization (B) by Loess.
Table 5.2 Table showing the number of differentially regulated gene by 
ANOVA -  The number of differentially regulated genes found using the TM4 suite and 
R are shown including the number of genes for which annotation is available.
Differentially regulated genes
Total Annotated
ANOVA TM4 764 559
‘R ’ ANOVA 1571 1024
‘R ’ ANOVA (p>= 0.05 and 2 fold 
change in expression)
237 189
145
Malawi / UV
Mock /Mock /Malawi
1 2 3 4 5 6 7 8 9 10 11 12
Mock
45%
Malawi
e.g ATP dependent DNA helicase, cyclin c, 
synexin, AP-3 complex B1 sub-unit, MAPK8, 
C-src
Malawi 20%
Mock'
e.g. NF-KB2 (pi 00 splice form), HSP90, RAB6 
interacting kinase, cytochrome c oxidase 
subunit, Bcl-2 like protein.
Mock
5%
Malawi
splicing factor argentine/serine rich 6 (SFRS6), IL- 
15, c-Fos, CREBLl, TNF receptor associated 
factor 4 (TRAF4) and ST AT4
Malawi 2%
Mock
UV
CXCL14, NADH dehydrogenase sub-unit 2, a 
RIKEN cDNA clone, lL-17 and lL-18
Figure 5.6 Heat map and expression profiles from icroarray experiment - A heat 
map showing clusters of differentially regulated genes with schematic of pattern of 
regulation with examples of genes changed for each cluster.
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5.6 Validation of microarray data by quantitative reverse transcriptase PCR
Reverse transcriptase quantitative PCR (QRTPCR) was used to validate some of the 
gene expression data obtained from the micro array experiments. The QRTPCR method 
using SYBR green has already been discussed in chapter 3, where levels of galectin-3 
expression were investigated using 18S rRNA as a normalizer. Other commonly used 
housekeeping genes such as actin and GAPDH varied in expression levels during ASFV 
infection so were deemed unsuitable. Various sets of primers were already available 
within the group to investigate expression levels of various immunoregulatory genes. 
Zhang et al (Zhang et al., 2006) various cytokines and transcription factors were up- 
regulated 4 hours after infection with Malawi virus. These included CREE, the NF-kB 
pl00/p49 subunit, the p50 precursor and IkB-ce as well as a number of CCL and CXCL 
cytokines. Dr C. Abrams more recently has carried out a number of micrarray 
experiments looking at host gene expression after infection with a range of ASFV 
isolates varying in pathogenicity. These experiments were carried out using the same 
oligo set from Operon in the same system. The ASFV Malawi isolate was also used. As 
various primers sets and data were already available from these experiments, the initial 
QRTPCR for the micro array samples in this project were carried out using these primers. 
A number of other primers were also designed specifically to investigate expression of 
genes identified by these micro array experiments. These include a number of genes 
involved in regulation of the MAPK pathway. The real time primers were designed 
against the 3’ end of the gene using Primer 3 (http://frodo.wi. mit.edu/T The full list of 
primer sequences is included in chapter 2  (table 2 .2 ).
The results of the real time PCR are shown in table 5.3. This data is combined from the 
analysis of samples from 4 pigs. The arrows represent genes that were up-regulated, 
down-regulated or unchanged in untreated Malawi and UV-inactivated virus infections 
compared with mock-infected cells. Data for both the micro array and QRTPCR analysis 
are shown. The ATF2, cJUN, CREB, IRFl QRTPCR results all confirm the micro array
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data although differences in relative fold change varied between the two methods. 
However, for most of the other genes analysed the QRTPCR results varied from the 
micro array data. If the QPCR results from individual pigs are compared with each other 
and with the results for individual pigs from the micro array data the results from the two 
methods are very similar. When an average is taken from the QRTPCR data the levels of 
IRF3 and IRF7 are up-regulated in Malawi infected cells but down-regulated in cells 
infected with UV-inactivated virus. In contrast the microarray data from all 4 pigs show 
IRF3 and IRF7 are down-regulated by Malawi infection but not changed in expression 
compared to mock-infected cells by the UV-inactivated virus. In the QRTPCR analysis, 
data from pigs 2 and 3 show increased expression ofIRF3 and IRF7 in Malawi infected 
cells and down-regulated in UV-inactivated virus treated cells. Data from pigs 1 and 4 
are the same as for the average microarray data for all pigs. In the QRTPCR results 
OASl is greatly increased in samples from pig 3 from both Malawi and the UV- 
inactivated virus infected cells. This skews the overall results. The data for the other 3 
pigs for this gene is very similar as analysed by both methods. The data for transcript 
levels for TGF-jS for pig 2 shows a large up-regulation following infection but in the 
other pigs expression is down-regulated. Akt was shown to be down-regulated by both 
QRTPCR and microarray in samples from the Malawi infected cells. However, in 
samples from cells infected with the UV-inactivated virus it was up-regulated in the 
QRTPCR analysis and unchanged in the micro array data. This may be due to micro array 
data being less sensitive than real time PCR. Zhang et al (Zhang et al., 2006) found the 
QRTPCR was more sensitive for some genes when validating microarray data. Data for 
c-Fos varies considerably from pig to pig by QRTPCR. In pig 2 it is massively up- 
regulated in Malawi virus infection but not with UV-inactivated virus. The micro array 
data and real time data from pigs 1 and 4 suggest it is down-regulated in Malawi virus 
infection. Figure 5.7 shows graphs of QRTPCR and micro array data for cJun for all four 
pigs. Graph a shows log fold change for each pig and the average between the 4 pigs.
The average bars show that cJun is up-regulated compared to mock-infected cells and 
cells infected with UV-inactivated virus. The data for individual pigs varies quite 
significantly as for other genes. However, for pigs 2 and 3 there is a 2 and 2.5 fold 
increase respectively in levels of cJun. In pigs 1 and 4 cJun is down-regulated compared
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to mock. Graph b shows the log fold change observed in Malawi infected cells compared 
to mock and in cells infected with UV-inactivated virus compared to mock for the 4 pigs. 
The data here shows cJun is up-regulated during infection with untreated Malawi virus 
in all 4 pigs. In the cells infected with UV-inactivated virus cJun is down-regulated in 
pigs 1, 2 and 4 but slightly up-regulated in pig 3 compared to mock-infected cells. This 
corresponds with the QPCR data for pig 3 where it was also up-regulated in this pig.
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Table 5.3 Table showing real time PCR results and micrarray results for selected 
genes. The arrows indicate whether genes are up or down-regulated or unchanged. The 
stumpy arrows indicate only a small change in expression, less than a two-fold change.
QPCR Microarray
Malawi/mock UV/Mock Malawi/mock UV/Mock
ATF2 t  t t &
cJUN tr tr &
CREB 1 tr t 1 = 5
IRF1 Ü tr tr
IRF3 t r 1 = 5
IRF7 t r  tJ . tr = 5
0AS1 t r t r 1 = ^
TGFB t r &  &
AKT 1 tr J3. 1 = 5
cFOS t r IL &
aI
s 2
1 1
0
1 -1
■o
2 -2
-3
1 n n
\ k  \ k  \ k
"bT -%> 1b, lb/  V ü» 7
9L %  SL % 4
150
F old  c h a n g e  in cJ u n  e x p r e s s io n  by QRTPCR
Mock Malawi UV
H
k- ‘k-
%  \  %
C on d ition
b Fold change in cJun expression by micorarray analysis
o' 2 1
i
1.5 -cs
O 1 -
0)o>c 0.5
1
o 0 -
"O
ou_ -0.5 J
Malawi Malawi Malawi Malawi UV pig UV pig UV pig UV pig
pig 1 pig 2 pig 3 pig 4 1 2 3 4
Condition
Figure 5.7 Graphs showing the change in cJun expression in all 4 pig samples 
analysed by QRTPCR (a) and microarray (b). Graph a, shows the QRTPCR data with 
the purple bars indicating the fold change in expression of cJun for each pig in mock- 
infected, untreated ASFV infected and UV-inactivated virus infection. The Blue 
diamonds show the average fold change for the 4 pigs for each condition. Graph b shows 
the fold change in eJun expression for each pig in cells infected with untreated Malawi 
virus or UV-inactivated virus compared to mock-infected cells by micro array analysis.
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5.7 Discussion
The aim of this chapter was to investigate porcine macrophage gene expression in 
response to ASFV infection. ASFV encodes a large repertoire of proteins, the functions 
of some of these are discussed in the introduction, but many have unknown functions. It 
is known that early ASFV mRNAs are transcribed when virus cores are released into the 
cytoplasm and that early proteins can be detected from as early as two hours post­
infection. The physical effects of binding and entry to a cell are likely to have a 
considerable impact on cells. It was hypothesised that comparing global gene expression 
profiles in response to ASFV infection with expression levels in cells infected with UV- 
inactivated virus could help define the fiinction of some of these early ASFV proteins. A 
comparison of gene expression levels in these infected cells to mock-infected cells 
should enable the effects that binding and entry of ASFV has on host cell signalling 
pathways to be investigated.
The planning, optimization and execution of micro array experiments is time consuming 
and is the main foeus of the first part of this chapter. Malawi ASFV isolate was chosen 
as it is a highly virulent isolate. The decision to use UV-inactivated virus was taken to 
minimise any adverse or unnatural effects any drug treatment may have on the cells and 
hence make interpretation of data easier. Alveolar macrophage cells were ehosen also in 
a bid to keep the system as close to a natural scenario as possible. The ASFV BA71V 
isolate is a tissue culture-adapted strain of the virus which replicates and grows well in 
Vero cells, although this isolate does not replicate well in primary macrophages. Using a 
cell line may have produced less varied biological replicates compared with using 
primary cells. It is also much quicker and easier to grow up large stocks of BA71V in 
culture than a wild type virus like the Malawi isolate in primary macrophage cells. There 
are significant differences between the genomes of tissue culture-adapted isolates, and 
pathogenic and non-pathogenic isolates. (Chapman et al., 2008). These genome 
differences will include changes which account for the different tropisms although as yet 
the molecular basis for this is not yet known. Since the aim of this project was to get an
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accurate idea of host genes affected by a natural ASFV infection, using a tissue culture 
cell line and adapted virus may not have been representative of a natural infection.
UV inactivation of ASFV has been carried out before at a distance of 10 cm for 30 
minutes exposure using a UV lamp (Carraseosa, 2002) and titration of the virus before 
and after UV inactivation confirmed there was no viral replication. ASFV UV- 
inactivation was carried out in the same way in this project. Carasocsasa et al 
(Carraseosa, 2002) showed UV-inactivated virus did not induce activation of a caspase 
cascade whereas caspase 3 was activated two hours post-infection after treatment with 
chloroquine. These results suggest that ASFV induces apoptosis by an intracellular 
pathway triggered by infection, after binding, but during or after uncoating.
In the experiments described here the aim was to use a similar approach to dissect the 
effect of the early stages of infection on host gene transcription by comparing the effect 
of UV-inactivated virus with that of untreated virus and mock infection. Figure 5.2 
shows a summary of the experimental design. The three conditions (infections) were 
compared to each other and dye swaps were included in each comparison as technical 
replicates. Using technical replicates in this way should make the micro array data more 
robust and enable the researcher to be more confident in the accuracy of the results. Four 
biological replicates were included. In an ideal world, when dealing with biologieal 
organisms one would use many more than four. However, due to the expense of both 
animals and micro array experiments and the ethics of using many animals, four 
replicates was deemed sufficient. All samples fi*om the biological replicates were kept 
separate throughout analysis to identify any obvious and large differences in expression 
levels in a single pig. Macrophage cells are likely to vary considerably fi*om different 
animals depending on their activation state at any particular time. The general trend 
observed across a number of samples should be evident.
There are lots of different methods for data analysis (Tamames et al., 2002) which may 
give slightly different results although the data should be generally complementary.
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Analysis of data in the experiment described here was carried out using the TM4 suite 
and ‘R’. The Acuity (Molecular devices) paekage was also available and is easy to use 
sharing many features with other packages such as the MeV program from the TM4 suite. 
Some preliminary analysis was carried out using Acuity but it was not elected for 
analysis of the fiill data set. A comparison of different methods of analysis has been 
carried out where a number of scientists from various different institutions were given a 
set of data to analyse by their preferred method. Most used a form of LOWESS 
normalization and the student statistic corrected for multiple testing at a level of 5% as a 
method of identifying differentially-regulated genes. A number also used ANOVA to 
find differentially-regulated genes. Most of the analysis methods seored 95% in 
identifying the differentially-regulated genes. It was clear that intensity dependent 
normalization such as LOWESS/LOESS is preferred and that between slide 
normalization such as dye swaps can be useful (Watson et al., 2007). Dye swaps may 
exclude some outliers which may be useful and there is clearly a trade off between the 
number of false positives and false negatives
There are many computer packages available to help with analysis and data mining. 
Normalization refers to computational data transformations intended to remove 
systematic biases for example dye effects, intensity dependence and spatial or print-tip 
effects. Scale normalization adjusts the range of data rather than the centre of 
distribution, making data more comparible across arrays. Local background variation 
can have an effect on the results and it is often better to go through and manually check 
data as was carried out in these experiments. In this experiment a number of negative 
control genes were included, which were not differentially-regulated. A number of viral 
genes were included and as expected came out as massively up-regulated in cells 
infected with Malawi virus compared to the UV-inactivated virus or mock-infected cells. 
This confirmed infection had occurred with untreated virus and that negligible levels of 
transcription of viral genes occurred when cells were infected with UV-inactivated virus. 
The virus genes included ASFV MGF 110 and MGF 360 which were up-regulated 6  
fold and Malawi virus transcripts 46315-46374 (SSX0006242, SSX0006240 AND 
SSX0006244) which were up-regulated between five and two fold.
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There are many ways to analyse microarray data from basic clustering of samples or 
genes to more sophisticated statistical tests. The choice of analysis is usually dictated by 
the type of experiment in terms of samples being compared and condition variables. The 
type of experiment where three conditions are being compared at one time point lends 
itself to ANOVA analysis and this was carried out here using two different packages. 
The analysis in R compared samples from infections with untreated Malawi virus and 
UV-inactivated virus directly using the samples from mock-infections as a reference. In 
contrast the TM4 analysis produced a list of genes differentially-regulated between the 
three conditions so that genes differentially-regulated between the samples from; mock- 
infected and Malawi virus infected cells, mock-infected and the UV-inactivated virus 
infections and Malawi virus infected compared to UV-inactivated virus infected are 
flagged. This is shown in the heat map in figure 5.6 where all the conditions from the 4 
different biological replicates can be seen. If the IDs that are used in the Gal file for 
analysis were included in a different format, for example if the Genbank accession 
numbers were included, this could be linked to annotation files directly and it would be 
easier to identify the more interesting genes. ANOVA is a popular way to analyse data 
and can be more useful than just clustering (Kerr et al., 2000). ANOVA results can be 
summarized and displayed in a PGA plot. This summarizes the data and shows how 
samples or genes of significance group together. Analysis of the data presented here by 
ANOVA followed by a PGA plot in the TM4 analysis demonstrated the clustering very 
well. However, it is more interesting to show related frmctions and networks than lots of 
different cluster arrangements.
Previously it was common to identify only genes that were differentially-regulated by at 
least two fold but this may eliminate important or interesting genes. Again the quality of 
the data and appropriate checks must be used (Zhang et al., 2006). For some genes, such 
as for transcription factors, small changes in the amount of a particular transcription 
factor can have significant effects on the overall cell response. Many transcription 
factors activate a number of molecules with many causing a cascade effect which can 
amplify the response. Macrophages are an integral part of the innate immune system and
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their secretory products central to pathology of inflammatory diseases and hence their 
expression is controlled tightly. Many people have been investigating these host 
pathways which are exploited by pathogens. Macrophage signalling pathways change 
dynamically during infection or exposure to foreign material and a system approach to 
micro array analysis is recommended (Nilsson et al., 2006).
The heat map in figure 5.6 shows clusters of genes with similar regulation patterns. The 
largest cluster, shown in block A, contains 45% of the differentially-regulated genes and 
these genes are down-regulated following infection with Malawi virus and also with 
UV-inactivated virus compared to mock-infected cells. The effect on expression of most 
of these genes by UV-inactivated virus is less than that caused by the untreated Malawi 
virus infection and some are not changed or even slightly up-regulated following 
treatment with UV-inactivated virus. This difference between the effeets of untreated 
Malawi virus and UV-inactivated virus infection implies that a step downstream of virus 
entry is involved in inhibiting transcription of these host genes. This group of genes 
included the adaptor protein 3 (AP-3) complex B1 subunit. This protein forms part of the 
AP-3 complex which is involved with maintenance of early endosomes for sorting and 
targeting to late endosomes and lysosomes for degradation (Baust et al., 2008). ASFV 
enters cells by receptor-mediated endocytosis and virus cores are released into the 
cytoplasm following a pH dependent fiision of the virus membrane with that of 
endosomes. The AP3 complex has been shown to be targeted by other viruses for 
example, during infection with HIV-1, AP3 is involved in maintenance of endosomes to 
facilitate replication and early dissemination of virus in dendritic cells (Garcia et al., 
2008). Other parts of cellular machinery identified which are involved in the AP3- 
dependent lysosome targeting include a number of GTPases. In the data presented here 
transcription of the Rac GTPase activating protein was down-regulated by Malawi virus 
compared to UV-inactivated virus infection. This protein is normally activated during 
endosome formation and, once activated, is targeted to plasma membranes where it is 
involved in regulating migration (Palamidessi et al., 2008).
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Transcripts for MAPK8 , a protein kinase involved in regulation of the INK signaling 
pathway, were shown to be massively down-regulated in samples from Malawi virus 
infection compared to UV-inactivated virus infection in the analysis carried out in ‘R’.
In block A from the analysis using Mev (TM# suite) MAPK8  is also down-regulated.
P38 and JIP3 were also more down-regulated by Malawi virus infection and are also part 
of the MAPK eascade. These may be involved in down-regulation of CREB and ATF2 
transcription. Transcription of these genes can all be activated by signalling through the 
TGF-/3 receptor. Since expression of TGF-jS is also down-regulated by Malawi virus 
infection, this may account for part of the effect on targets of this pathway. C-Src is a 
tyrosine kinase, proto-oncogene, which is also part of the MAPK pathway, but interacts 
with PI3K and not the p38 MAPK or INK pathways. Instead c-src is involved in 
activating Akt. Akt has been shown to phosphorylate IKKof in the IKK complex to 
activate NF-kB (Ozes et al., 1999). C-src associates with TNFRl making it 
constitutively active by dephosphorylation of tyrosin 527. TNFRl/c-src can also activate 
NF-kB independently of Akt by IKKjS phosphorylation (Pincheira et al., 2008). The 
down-regulation of various components of the MAPK kinase pathway by ASFV is very 
interesting and the effect of the whole virus on this pathway has not been published 
before. Recent work on the effect of ASFV A238L protein on host gene transcription has 
shown it causes down-regulation of genes in the MAPK pathway (Silk, R. thesis 
submitted). Other genes in block A, which are down-regulated by virus infection, 
include cyclin c and ATP dependent DNA helicase. It is possible these may both be 
down-regulated during infection as part of the process of shutting down cellular 
processes to enable ASFV to replicate more effectively.
Block B in figure 5.6 contains genes which are up-regulated following Malawi virus and 
UV-inactivated virus infection. This group consisted of about 20% of the differentially- 
regulated genes. Again there are a number of genes which are affected differently by the 
UV-inactivated virus and untreated virus infection. This is shown by the varied pattern 
of red and green, in columns 9 to 12, representing the genes which were identified as 
being differentially-regulated between UV-inactivated virus and Malawi virus infection. 
This group of genes included the NF-kB2 (pi GO slpice form), cytochrome c oxidase sub­
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unit and Bcl-2 like protein. The Bcl-2 family of proteins act as pro-apoptotic and anti- 
apoptotic regulators with Bcl-2 itself being anti-apoptotic. Activation of anti-apoptotic 
proteins is important for many viruses in order for them to replicate before the cell is 
destroyed by apoptosis. Many viruses encode Bcl-2 homologues or proteins which 
interact specifically with cell death machinery (Galluzzi et al., 2008). Cytochrome c 
oxidase is a multimetallic enzyme which can reduce O2 to H2O providing energy to
power cells through respiration (Co liman et al., 2008). Up-regulation of these genes is 
therefore likely to be advantageous for virus replication..
Perhaps the more interesting genes to look at are the ones in blocks C and D from figure 
5.6. These show differences in up or down-regulation of transcription between samples 
from infection with Malawi virus compared to the UV-inactivated virus. The differences 
indicate a difference in modulation of host cell transcriptional responses between the 
steps of binding and entry and early gene expression. The differences between the 
pathways and genes which are differentially-regulated between the UV-inactivated virus 
and untreated virus infection are analysed in greater detail in the next chapter. Genes 
which were down regulated in Malawi but not UV-inactivated virus infection included 
IL-15, c-Fos, Splicing factor 6 , TRAF4 and STAT4. IL-15 is a potent pro inflammatory 
cytokine secreted by activated macrophage cells. Recently it has been shown to increase 
MHC class II expression and it is also able to induce TNFa and IL-1/3 (René Rüekert, 
2008). It has also been proposed by several groups that it could enhance vaecine 
responses due to its effects on memory T cells (Perera et al., 2007). Down-regulation of 
IL-15, could inhibit expression of viral proteins with MHC II and potentially contribute 
to a reduction in memory T cell responses. This would be a distinct advantage to the 
virus. The fact that c-Fos is down-regulated ties in with micro array data for other genes 
where c-myc and MKP were also down-regulated. Details of the expression of these 
genes and the MAPK pathway are discussed in chapter six.
Genes up-regulated in samples from cells infected with untreated Malawi virus, but not 
by UV-inactivated virus infection included; IL-17, IL-18, CXCL14 and a RIKEN cDNA.
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IL-17 is also a pro-inflammatory cytokine and 6  types have been identified in humans.
So far only one of these has been characterized in pigs. IL-17 is known to be up- 
regulated in various airway inflammatory diseases. It can be activated by TNFa and 
ILl/5 but also increases levels of such cytokines itself (Katoh et al., 2004). The 
regulation and control of many cytokines clearly overlaps in many cases and is tightly 
regulated. IL-18 is a pro-inflammatory cytokine closely related to IL-1/3 in that it is part 
of the IL-1 family of ligands. Although closely related, it is likely to have a different 
effect on cells. It has been shown to be up-regulated in diseases such as Japanese 
encephalitis (Das et al., 2008) but also has antiviral effects during some viral infections 
(Tanaka-Kataoka et al., 1999).
Quantitative real time PCR is the most common method used to validate micro array data 
(Chuaqui et al., 2002). QRTPCR measurements are much more sensitive than 
micro array analysis sometimes producing much higher differences in fold change in 
transcripts. Despite this, the trend should be for changes to be in the same direction 
(Sharif et al., 2007). The correlation between microarray data and QPCR data may be 
increased if the list of differentially-regulated genes selected have at least a 1.4 fold 
change in expression and a p value less than 0.0001. There is often a greater correlation 
between the two techniques with genes that are up-regulated (Morey et al., 2006). The 
validadtion data obtained in these experiments using QRTPCR broadly agree with the 
data fi'om microarray experiments when analysed at the level of samples fi*om individual 
pigs. Discrepancies were observed for some genes when average values across all 4 pigs 
were used for QRTPCR. Given that primary cells from separate animals were used in 
these experiments it is not unexpected that some variation in response was observed.
One of the problems with using the Operon porcine array is the annotation file does not 
contain gene ids or names that can be linked to other databases. The Gal (GenePix Array 
List) file used here contains TIGR cluster numbers (TCXXXX) or Operon identification 
numbers (SSXXXXXX). It does not contain Ensemble, Genbank or Affymetrix 
accession umbers. This means that any analysis output can not be liked directly to 
pathway analysis software and does not have any direct gene annotation details linked to
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the output. After various analysis and gene lists were produced fi'om the micro array data 
Genbank and ENSEMBLE ids were added so the lists could be up-loaded easily to 
pathway analyis software. This process was very time consuming and tedious. 
Annotation of genes was taken fi'om the Pig Genome Oligo Set Extension VI.0 gene list 
last updated in 2004 (OMAD Release: 04/13/04). Increasingly more information about 
porcine genes is becoming available, with completion of the pig genome project and 
various web sites (www.piggenome.org: http://www.animalgenome.org/pigs/I people 
can share information and this will continue to improve (Chen et al., 2007; Ruan et al., 
2007). Unfortunately the information available at the moment is limited for a lot of the 
oligos investigated in this micro array. In the next chapter, various host cell signalling 
pathways affected by genes differentially-regulated during ASFV infection with 
untreated and UV-inactivated virus have been investigated.
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6. Pathway analysis of genes differentially regulated between normal Malawi 
virus infection and infection with UV inactivated virus
The focus of this chapter is to investigate in more detail the networks and pathways 
containing genes that are differentially-regulated by untreated virus infection and the 
UV-inactivated virus. In the previous chapter the experimental details, optimization of 
the micro array experiment and methods for analysis of differentially-regulated genes 
were discussed. The data has been analysed using two different software packages, the 
TM4 suite (formally the Institute for genomic research, TIGR and now part of the J. 
Craig Venter Institute) and ‘R’ (R is an official GNU project and distributed under the 
FSF General Public License). In this analysis it is expected that the virus infection will 
have a primary effect on a particular pathway which may result in either its activation or 
inhibition. This primary effect would result in a secondary effect on downstream targets 
of the pathway, which could be detected by changes in transcription level of these 
targets. For example, activation of the IFN induction pathway would have a primary 
effect of activating transcription of the IFN gene. The resulting increase in IFN would 
have the secondary effect of activating transcription of genes in the interferon response 
pathway and potentially also additional targets of these genes.
6.1 Functional classification of differentially regulated genes
Table 5.2 in the previous chapter shows the number of differentially-regulated genes 
identified using the two analysis methods. A total of 764 genes were identified by the 
TM4 paekage and of these annotation was available for 559. The analysis in R gave a 
total of 1571 differentially-regulated genes with annotation available for 1024 genes. 
Annotation was obtained fi'om the Pig Genome Oligo Set Extension VI.0 gene list last 
up-dated in 2004 (OMAD Release: 04/13/04). Gene-GO term enrichment analysis was 
used to highlight the most relevant biologieal classifications associated with the gene 
lists (Gene Ontology, 2004). The Database for Annotation, Visualisation and Intergrated 
Discovery (DAVID) (Dennis et al., 2003) is a large integrated knowledge-base linking
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information from a number of bio informatics resources including; NCBI, SWISS-PROT, 
GO and KEGG. GENBANK accession numbers were applied to all the genes for which 
annotation was available and the gene lists up-loaded into DAVID where they can be 
compared against a background of 30,000 genes. EASE, a modified Fischer’s exact P- 
value, was used to determine the probability that gene-enrichment for specific 
annotation was not due to chance alone (Hosack et al., 2003). The gene lists from the 
MeV (TM4) and ‘R’ software were both put into DAVID. Gene-GO term enrichment 
analysis and Kyoto Encyclopedia of genes and genomes (KEGG) pathway analysis was 
used to identify and cluster common, significant, biological themes, molecular fiinctions, 
processes and signalling pathways included in the differentially-regulated gene list. GO 
annotations are designated by the ontology consortium and provide a common 
vocabulary to link databases http://www.geneontologv.0 rg/T KEGG is a knowledge­
base linking genomic information with higher order functional information and thus 
providing graphical maps of networks relating to cellular processes such as signalling, 
metabolism and the cell cycle (Kanehisa et al., 2008). Another software package used 
for pathway analysis was Ingenuity (Ingenuity systems^). This program enables gene 
lists to be uploaded and analysed to identify relationships, functions, and pathways of 
relevance. It is very user fiiendly and can even be used to build new pathway maps with 
genes specifically relating to the users research.
A list of general functional themes was produced in Ingenuity using the gene lists from 
the ANOVA analysis in the MeV program (TM4 suite) and ‘R’. Short lists of general 
functional networks were produced. The MeV analysis lists the differentially regulated 
genes identified between the three infection conditions (mock-infected compared to 
Malawi-infected, mock-infected compared to UV-inaetivated virus infection and 
Malawi-infected compared to UV-inactivated virus infection), whereas ‘R’ lists genes 
which were differentially-regulated by infection with Malawi virus compared to the UV- 
inactivated virus. The functional list shown in table 6 .1 is for the analysis carried out 
using the MeV program and ‘R’. The MeV analysis showed genes in the functional 
catagories of development, DNA replication and repair were most represented with 
amino acid and protein synthesis having a similar score. In the ‘R’ analysis genes in the
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category carbohydrate metabolism were the most represented with gene expression and 
cell compromise next, followed by cell cycle and cell growth, proliferation and disease. 
Cell assembly and organization only had a low score of two genes, whereas organization 
and assembly category contained more genes in the MeV gene list. Table 6.2 shows a 
list of the major functional groups of genes produced using DAVID when all the gene 
lists were added. Only the most represented groups were included in the table and those 
in the category transcription regulator activity scored highest. The list also includes 
intracellular signalling cascades, cell cycle regulation, protein phosphorylation and 
protein kinase activity.
The scores obtained using Ingenuity and DAVID, were calculated based on the number 
of network eligible molecules they contain. It takes into account the number of 
molecules, its size and number available in the experimental list along with the number 
available in the system. Network eligible molecules are uploaded genes that have 
interactions with other molecules in the knowledgebase. The higher the score, the lower 
the probability of finding the observed number of molecules in a given network by 
random chance.
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Table 6.1 - Table showing the functional networks represented by the differentially-regulated genes 
after analysis in the MeV (TM4) program and in ‘R’. The list was produced using Ingenuity software 
(Ingenuity systems^). The score represents how likely the genes are to be represented in each group with 
the highest score meaning the group is most likely to be a real finding and not by chance.
A ssociated  n etw ork  functions Score
MeV ANNOVA
Development, DNA replication and repair 51
Amino acid metabolism and protein synthesis 49
Cell function, compromise and assembly 44
Cell signaling and organization 38
Cell death and disease 37
‘R’ ANNOVA
Carbohydrate metabolism 37
Gene expression and cellular compromise 26
Cell cycle and gene expression 23
Cell growth, proliferation and disease 12
Cell assembly and organization 2
Table 6.2 -  Table showing the main functional groups represented by all the differentially-regulated 
genes. The list was produced in DAVID using EASE and contains the most represented groups or 
functional groups with the highest scores.
EASE Score
Protein kinase activity 21
Energy metabolism 9
RNA association 11
Protein degredation 11
Organelle oraganization 18
Carboxylic acid metabolism 19
Protein biosynthesis 31
Protein and amino acid phosphorylation 19
Transcription regulator activity 32
Cell cycle regulation 18
Intracellular signaling cascade 31
Defense responses 22
Transferase activity 29
Proteolysis and peptidolysis 21
Cell adhesion 21
Vesicle mediated transport 21
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6.2 Pathway analysis of differentially-regulated genes
The DAVID and Ingenuity programs were used to identify pathways which were 
activated during Malawi virus infection or with UV-inactivated virus. The Ingenuity 
software was only available for a trial period so only limited investigation was carried 
out using this package. The diagram in figure 6.1 shows a network diagram linking some 
of the differentially-regulated genes. It illustrates the complexity and overlap between 
signalling pathways. The three main branches of the MAPK pathway, ERK, Jnk and p38 
are shown with many arrows linking these kinases to various transcription factors (Jun D, 
NFat and NF-kB) and other molecules. The pathway analysis results fi'om DAVID 
showed a number of pathways which were modulated by infection with untreated 
Malawi virus and by infection with UV-inactivated. The pathways affected include the 
mitogen-activated protein kinase (MAPK) pathway fi'om which various genes were up 
or down-regulated. This is discussed in detail later on in this chapter. Table 6.3 lists the 
main pathways containing genes which were either up or down-regulated by Malawi 
virus infection compared with UV-inactivated virus. These pathways included the JAK 
STAT, cytokine signalling, ubiquitin-regulation and antigen presentation pathways. The 
main pathways containing genes that were up-regulated by untreated Malawi virus 
infection compared to UV-inactivated virus infection included regulation of the actin 
cytoskeleton, calcium signalling, regulation of autophagy, cell-cell communitcation. Toll 
like receptor (TLR) signalling and various molecules involved in leukocyte trans- 
endothelial migration. ASFV is known to cause rearrangement of the actin cytoskeleton. 
Pathways which were predominantly down-regulated by untreated Malwai virus 
infection included TGFjS signalling, cell cycle regulation, the complement cascade, p53 
signalling and regulation of inflammation. Although ASFV does not shut off global host 
cell functions during infection, there are probably a large number of host processes that 
are altered to allow the virus to replicate efficiently. The down-regulation of a number of 
genes encoding cyclins involved in cell cycle regulation is perhaps not surprising. 
Controlling the host ceU cycle may enable the virus to utilize cellular machinery to 
replicate more efficiently. Figure 6.2 shows a schematic diagram of the JAK-STAT
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pathway with genes up-regulated by Malawi virus infection highlighted with red boxes 
and genes down-regulated shown by green boxes. The cytokine R receptor is in purple. 
This was identified in both the list of up-regulated genes and the list of down-regulated 
genes using the DAVID analysis. This may be because the ENSEMBLE identification 
numbers assigned to the genes used in the micro array are not always exact matches to 
the porcine genes, but are similar in sequence and possible function. There may also be 
more than one type of cytokine R receptor. IL-6 and IFN/ILIO were up-regulated in this 
pathway and IL2/3, c-myc, cyclin D, PIAS and Akt were all down-regulated. Figure 6.3 
shows the regulation of MHC I and II pathways analysed using DAVID. The heat shock 
proteins (HSP) 70 and 90 were both down-regulated by Malawi virus infection and these 
are involved in MHC I regulation. The lower half of the diagram shows MHC II is up- 
regulated by Malawi virus infection.
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Figure 6.1 A network diagram of differentially regulated genes -  Differentailly regulated genes from the 
analysis in R were put into the Ingenuity pathway analysis software. The diagram shows some of the differentially 
regulated genes and the many ways the pathways intersect and link with each other.
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6.3 The MAPK pathway
The MAP kinase pathway is a complex signalling network with numerous receptors 
which can be activated by many extra-cellular or intracellular signals. Activation of the 
MAP kinase pathway is involved in activation of the inflammatory response amongst 
other responses. There are three well defined arms to the pathway which follow either 
the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK) or p38 
route. These arms, although distinct, are closely related and many factors cross-react and 
overlap to regulate activation. Following activation, via extralcellular signals delivered 
through a receptor, a cascade of phosphorylation events occurs. These begin with 
activation from MAP kinase kinase kinases which then phosphorylate the MAP kinase 
kinases which in turn phosphorylate the MAP kinases. These MAP kinases then target 
various transcription factors. Figure 6.4 shows genes which were up-regulated and down 
regulated during Malawi virus infection compared to infection with UV-inactivated 
virus in the MAPK pathway. Up-regulated genes are highlighted with red boxes and 
green boxes show down-regulated genes. The purple boxes show genes which were 
altered between Malawi and UV but only showed up in the MeV (TM4 suite) analysis. 
The network map in figure 6.4 was produced using the DAVID software and is rather 
complicated with lots of genes which are not altered during infection. Figure 6.4 shows a 
more simplified version highlighthng the main genes differentially regulated during 
ASFV Malawi infection.
In the ERK arm of the MAP kinase pathway the tyrosine kinase receptor A/B (TyrkA/B), 
protein kinase A (PKA) and ribosomal S6 kinase (RSK2) genes were up-regulated in 
Malawi infection compared to UV-inactivated virus infection. RSK2 is normally 
abundant in the cytoplasm but on activation a portion moves to the nucleus where it can 
activate Fos, activating transcription factor 4 (ATF4), serum response factor (SRF) and 
microphthalmia associated transcription factor (MITF) genes (Hauge and Frodin, 2006). 
Two factors which were down-regulated in this ERK/MAPK pathway in Malawi
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infection compared to UV-inactivated virus infection were c-myc and c-Fos. C-myc is 
an oncogene which functions mainly in stimulation of cell proUferation. However, it has 
been shown to promote TRAIL induced apoptosis (Nieminen et al., 2007). C-fos can be 
activated or inhibited by many alternative proteins.
Genes in the JNK branch of the MAP kinase pathway were mainly up-regulated in 
Malawi infection compared to UV-inactivaed virus infection with an increase in c-Jun 
and JunD transcripts. This is likely to be due to several factors acting in this pathway. 
Firstly the MAPK phosphatase gene is down-regulated. This protein can down-regulate 
JNK activation by dephosphorylating it. The JNK interacting proteins 1 and 2 (JIPl/2) is 
up-regulated and these proteins act as scaffolds to stabalise JNK. The JIP3 and heat 
shock protein 72 (HSP72) are both down-regulated and these both act to block JNK 
activation. Taking these into account it is not surprising to find JunD and c-Jun were up- 
regulated.
The p38 branch of the MAPK pathway has a number of genes which are down-regulated 
following infection with Malawi compared to UV-inactivated virus. These include p38 
itselfi the TGF/3 receptor, GASP, Myocyte Enhancer Factor 2 (MEF2C), Akt and CREB. 
The down-regulation of many of these genes follows on from the observation that the 
TGFjS receptor gene is down-regulated. However, the Akt protein blocks p38 activation 
and this gene was also down-regulated during infection with untreated Malawi virus.
Akt can also be induced by TNFR binding to c-src and activation of PI3K (see figure 
6.5).
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Table 6.3 Table showing some of the pathways containing up and down-regulated 
genes differentially regulated between Malawi virus and UV-inactivated virus 
infection - The list of pathways was produced using DAVID. Up-regulated pathways 
include those containing genes up-regulated by Malawi virus infection compared to UV- 
inactivated virus infection. Down-regulated pathways include genes that are down- 
regulated by Malawi virus infection compared to UV-inactivated virus infection.
Up-regulated pathways Down-regulated pathways
MAPK MAPK
Actin regulation JAK STAT signalling
Calcium signalling Cytokine regulation
Cell communication P53 signalling
Ubiquitin regulation Inflammatory response
Regulation of autophagy Cell cycle regulation
JAK STAT signalling TGF/3 signalling
Toll like signalling Antigen presentation and processing
Cytokine regulation Complement cascade
Antigen processing Ubiqitin regulation
Leukocyte trans-endothelial migration
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6.4 Discussion
Activation of the innate immune system is a critical immediate response to 
pathogens and this is involved in initiating the inflammatory response to; produce 
cytokines and chemokines and thus mobilise leukocytes to the site of infection; 
release reactive nitrogen and oxygen species crucial for the killing of invading 
pathogens. Recognition of pathogens by macrophages and dendritic cells (DCs) at 
the site of infection activates signalling pathways such as NF-kB (discussed in detail 
in the introduction) and mitogen activated protein kinase (MAPK) pathways. NF-kB 
binds to promoter regions of many genes including those which encode pro- 
inflammatory cytokine and chemokines. MAPKs can induce cytokine production by 
enhancing gene transcription via factors such as AP-1 and by increasing the 
translation and stability of cytokine and chemokine mRNAs. There are three well 
defined branches of the MAPK pathway; ERK, JNK and p38. Each branch is 
activated through a series of phosphorylation events starting with the activation of 
MAP kinase kinase kinases. These in turn activate the MAP kinase kinase by 
phosphorylation of two serine residues. These in turn phosphorylate MAP kinases at 
the adjacent threonine and tyrosine residues. The activated MAP kinases can 
phosphorylate a large number of downstream targets including protein kinases and 
other enzymes. They can also translocate to the nucleus and phosphorylate numerous 
transcription factors such as AP-1, NFAT, ATF2 and ATF4. MAP kinases can also 
modulate protein expression by altering stability and translation of mRNAs 
containing AU-rich elements (AREs). These are cis-acting elements known to confer 
instability on mRNAs by promoting removal of poly(A) tails leading to accelerated 
mRNA degradation. Many pro-inflammatory cytokine transcripts such as TNFce and 
IL-lj8 contain AREs in their 3’ -untranslated regions (UTRs) and have been shown to 
be targets of tristetrapolin (TTP) mediated mRNA degradation (Lai et al., 2006).
MAP kinases are primarily inactivated by a group of dual specificity protein 
phosphatases through dephosphorylation of the critical tyrosine residues of acitvated 
kinases (Keyse, 2000). These phosphatases act as pivotal feedback regulators. MKP- 
1 functions as a feedback control mechanism that governs the production of pro- 
inflammatory cytokines by limiting the activation of MAP kinases. There are 10
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MKPs known in humans and MKP-1 is the archetype. The transcript for MKP-1 was 
found to be down-regulated by ASFV Malawi virus infection and not by UV- 
inactivated virus infection. MKP-1 has been shown to dampen down the 
inflammatory responses of alveolar macrophages and was identified first by its 
ability to inhibit ERK 1 and ERK 2 (Zhao et al., 2005). More recent work suggests 
ERKs can actually stabilize MKP-1 and that MKP-1 is actually a much more potent 
inhibitor of JNK and p38 (Wang and Liu, 2007) at least in macrophage cells. There is 
a low level of basal expression of MKPs in quiescent immune cells and this can 
rapidly be induced following cytokine production to counteract the inflammatory 
response. It is likely that different MKPs preferentially regulate different kinases. 
MKP-3 has been shown to be specific for ERK 1/2 and ERK 5. MKP-4 blocks 
ERKl/2 and p38 and also has a highly specific tissue distribution. MKP-5 seems to 
block JNK and p38 but in macrophage cells a decrease in the amount of MKP-5 
caused an increase in JNK activity but not p38 activity (Kondoh and Nishida, 2007). 
Knockout of the MKP-1 gene in macrophages caused increased production of p38 
and JNK after microbial infection whereas levels of ERK were not changed. The 
MKP-1 knockout cells also produced more pro inflammatory cytokines, TNFo; IL-6 
and IL-1/3 and chemokines including macrophage inflammatory proteins (MIP) -la; 
MlP-ljS and MIP-2. Both MIP-la;and MIP-1/5 genes were shown to be up-regulated 
by ASFV Malawi virus infection at early times in previous micro array experiments 
(Zhang et al., 2006). Possibly down-regulation of MKP-1 expression is one 
mechanism that may contribute to increased expression of these chemokines 
following virus infection. MAPK transcription is regulated by continuous re­
adjustment in response to extra-cellular activation and intracellular signalling events. 
P38 also enhances cytokine production through post-transcriptional mechanisms 
leading to enhanced cytokine mRNA stability and accelerated cytokine mRNA 
translation. MKP-2 can be stabilized by p38 phosphorylation which in turn leads to 
phosphorylation and inhibition of tristetrapolin (TTP) mediated degradation of ARE 
containing mRNAs (Mahtani et al., 2001).
Many viruses have been shown to regulate various parts of the MAPK pathway. 
Karposis sarcoma-associated Herpes virus (KSHV) has been shown to induce ERK 1 
and ERK 2 very early, within 30 minutes post-infection. This is probably to stop
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restrictions on viral replication and to help establish infection. These experiments 
showed that UV-inactivated KSHV virus also activates ERKl/2, suggesting this is 
caused by binding and entry and does not require de novo viral protein synthesis 
(Sharma-Walia et al., 2005). Following Vaccinia virus infection ERK was shown to 
be activated following viral entry and this required a change in actin dynamics and 
micro tubule polymerization. In this study ERKl/2 and ribosomal 86 kinase (RSK2) 
were activated and this was sustained possibly to allow virus replication as disruption 
of this pathway led to a decrease in virus production and DNA replication. In these 
experiments UV-inactivated virus was also used to investigate ERKl/2 activation 
and the UV-inactivated virus did not cause activation of ERKl/2. Therefore, the 
activation probably requires production of early viral proteins as well as actin 
polymerization (Andrade et al., 2004). As shown in figure 6.4 and 6.5 RSK2 
transcripts were shown to be up-regulated by Malawi virus infection compared to 
UV-inactivated virus infection. It is possible that ERKl/2 is activated very early 
during infection producing an increase in RSK2 which is maintained for a while after 
ERK activation returns to normal levels. In HIV-1 ERK has been shown to actually 
associate with virions before viral protein synthesis commences, possibly to aid viral 
infection. It then dissociates to allow replication and assembly (Jacque et al., 1998).
MAPKs are highly selective in their choice of substrate. Among the proteins 
regulated by MAPKs is the activating protein-1 (AP-1) family of transcription factors 
composed of Eos (c-Fos, Fos B, Fra-1, Fra-2) and Jun (c-Jun, JunB, JunD) proteins. 
Fos proteins require Jun proteins in order to bind DNA, but the Jun proteins can bind 
DNA directly. In order to act as transcriptional activators they need to undergo 
phosphorylation and the JNK protein kinases are the only proteins know to 
efficiently do this. ERK 1 and ERK 2 phosphorylate Jun at sites which inhibit its 
transactivation potential. More recently p38 MAPK has been shown to efficiently 
phosphorylate c-Jun at positive regulatory sites and modulate AP-1 (Humar et al., 
2007). Regulation of activation of transcription factors such as c-Jun is tight and 
involves many molecules. Even the presence of varying amounts of JNK iso forms 
can effect the activation of c-Jun and thus the activation state of cells (Jaeschke et al.,
2006). Transient activation of JNK leads to cell survival whereas a prolonged 
activaion of JNK can lead to apoptosis (Weston and Davis, 2007). An increase in
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JunD activation leads to its binding on the AP-1 consensus binding sequence which 
is involved in transcriptional activation of many genes and can therefore be a major 
determinant of macrophage activation (Behmoaras et al., 2008). The three Jun 
proteins c-Jun, JunB and JunD share almost identical C terminal regions which are 
involved in dimerization and DNA binding. The more variable N-terminal domian is 
involved in transcriptional transactivation. These jun proteins have different effects 
on cell growth, c-Jun is important in transformation and normal cell growth 
(Castellazzi et al., 1991) (Vandel et al., 1996) whereas high Jun-D levels lead to slow 
growth and low levels of Jun-D lead to faster growth. In addition Jun-D partially 
suppresses transformation but c-Jun aids in transformation in some sytems. The two 
closely related transcription factors seem to have antagonistic functions in regulating 
cell growth and proliferation (Pfarr et al., 1994). Jun-D plays a role in lymphocyte 
proliferation and cytokine expression. In hepatitis B virus (HBV) infection the X 
protein has been shown to increase JNK phosphorylation and levels of cJun leading 
to sustained AP-1 activation (Tanaka et al., 2006). It has been proposed that binding 
of activator proteins (AP-1) can aid human T-cell leukemia virus (HTLV) gene 
expression and macrophage differentiation. Increased levels of c-Jun and c-Jun 
combined with c-Fos caused up-regulation of basal transcriptional activation of 
HTLV long terminal repeats (LTRs) (Grant et al., 2006). It is possible that up- 
regulation of these transcription factors during ASFV infection also aids virus 
transcriptional activation.
c-Jun N-terminal kinsae (JNK)/stress-activated protein kinase associated protein 1 
(JIP3) and other JIPl and JIP2 family members were originally identified as JNK- 
binding proteins and are thought to serve as scaffold factors for MAPK signaling 
cascades. JIP3 has also been shown to act on the extracellular signal-regulated kinase 
(ERK) MAPK cascade to act as a suppressor. The JIP3 might be involved in 
determining to what extent the JNK and ERK cascades can be activated, since with 
high levels of JIP3 lowering activation of ERK and increasing the JNK cascade 
(Kuboki et al., 2000). The binding of JIP3 to JNKs is very specific but the binding of 
JIP3 to ERK2 and p38 is either low or non-existent (Ito et al., 1999; Koyano et al., 
1999). Cross talk between the scaffolds JIPl and JIP3 mediated in part by Aktl can
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regulate JNK signaling (Song and Lee, 2005) and regulation of cell migration 
(Takino et al., 2005). TGFjS treatment of cells can inhibit binding of c-FOS to the 
AP-1 complex possibly by altering c-Fos protein synthesis or its stability (Ge Jin, 
1999). Genes in the JNK branch of the MAP kinase pathway were mainly up- 
regulated in Malawi infection compared to UV-inactivated virus infection with an 
increase in c-Jun and Jun-D transcripts. This may be due to several factors including 
down-regulation of MAPK phosphatase, JIP3 and HSP72 which block JNK and up- 
regulation of JIPl and JIP2 which stabilize JNK Up-regulation of c-Jun and Jun-D 
by untreated Malawi virus infection at this early stage in infection may help maintain 
cell viability in order for the virus to replicate.
Signal transducer and activator of transcription 2 (STAT2) -DNA binding activates 
transcription of a number of interferon stimulated genes (ISGs) involved in growth 
inhibition and antiviral responses. Jun-D and Claudin 4 (CLDN4) are activated by 
STAT2 and may be critical mediators of the antiviral effects of type 1 IFNs (Jia et al.,
2007). Various Claudius including Claudin 4 were found to be up-regulated by 
Malawi virus compared to UV-inactivated virus infection. These molecules are 
involved in leukocyte trans-endothelial migration. In the case of ASFV infection this 
could potentially aid virus dissemination through tissue. An increase in expression of 
Claudin 4 has been shown to increase cell-cell interactions and is negatively 
regulated by TGF/3. It is also down-regulated by the inhibition of the Ras/Raf 
signalling pathway (Michl et al., 2003).
Another protein which has received much attention in recent years is Akt. This was 
found to be down-regulated by Malawi virus and up-regulated by UV inactivated 
virus in some pigs. The results from the QRTPCR in chapter 5 confirm this 
observation. The QRTPCR was carried out using primers specific to Akt 1.
Expression levels of Akt 2 still need to be investigated. Akt is a serine/threonine 
kinase also known as protein kinase B and is a downstream effector of PI3K (Franke 
et al., 1995). There are three known iso forms of Akt, although Akt 1 is the 
predominant form. Akt is activated by extracellular signals which activate PI3K to 
generate phophatidylinisitol 3’ phosphate (PIP3) and is negatively regulated by
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phospholipid phosphatases that dephosphorylate PIP3. Following activation, Akt can 
phosphorylate a number of target proteins including a number of forkhead box O 
proteins (FoxOl, Fox03a, Fox04), Bad, IKKo; (phosphorylation at threonine 23)
(Ozes et al., 1999) and caspase 9. All of these are involved in regulating apoptosis 
and the effect of Akt helps promote cell survival (Manning and Cantley, 2007).
There are clearly many proteins involved in Akt regulation. Recently Akt has been 
shown to interact with two distinct targets of rapamycin (TOR) proteins (Bhaskar 
and Hay, 2007), which function in cell cycle progression and polarization of actin. 
The c-src oncogene was also found to be down-regulated in these micro array 
experiments following Malawi virus infection. C-src interacts with TNFR and 
activates PI3K which in turn can activate Akt but not the MAPK p38 and JNK 
pathways (Pincheira et al., 2008). PI3K/Akt has been shown to be important for early 
cell survival to SARS virus infection induced apoptosis whereas JNK, Bcl-2 and Bcl- 
XL are important for establishing persistence (Mizutani et al., 2006). The M protein 
of SARS has been shown to down-regulate Akt protein phosphorylation and thus 
promote mitochondrial-mediated caspase dependent apoptosis (Chan et al., 2007).
Clearly the MAPK pathway is very complicated and there is still much to be 
investigated to determine exactly how each step is controlled. Using the micro array 
data to investigate whole pathways has been incredibly useful in highlighting the 
involvement of the MAPK pathway during ASFV infection. Other work carried out 
in the group looking at 1 and 4 hours post-infection with a baculovirus recombinant 
expressing A238L showed many genes were down-regulated at these time points. 
This indicates that this protein has the ability to rapidly alter the activation state of a 
cell. The whole virus is therefore even more likely to induce rapidly changing 
responses including effecting regulation of many genes with opposing functions. 
GADD45, Promyeloytic Leukemia (PML-1), and caspase 3 were all downregulated 
by A238L. A238L activation of genes with directly opposing functions, possibly 
results from targeting the activity of one or several common features involved in 
regulating the transcription of theses genes.
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7. Final discussion
7.1 Aims of the project
The aims of this project were; to investigate the expression and localization of 
galectin-3 during ASFV infection, to investigate which early stages in ASFV 
infection are involved in activating host transcriptional responses and to highlight 
signalling pathways activated by these early events in ASFV infection. The project 
has been divided into two parts. In the first section, chapter 3 and 4, porcine galectin- 
3 was characterized and four antibodies produced against the pig protein. These 
antibodies were subsequently used to investigate the localization of endogenous and 
transfected galectin-3 in cells by immuno fluorescence. Levels of galectin-3 protein 
expression during ASFV infection were also analysed. The second part of the project, 
chapters 5 and 6 , investigated the effect ASFV infection has on host macrophage 
gene expression. This work focused on early events during infection by comparing 
gene expression in macrophage cells infected with UV-inactivated virus and 
untreated ASFV. As a reference, cells were also mock infected. Host cell signaling 
pathways activated by the treated and untreated virus were investigated.
7.2 GaIectin-3 expression, localization and function during ASFV infection
The work on galectin-3 has two main parts. In chapter 3, the cDNA for porcine 
galectin-3 was cloned and sequenced. The sequence was compared to data available 
for galectin-3 from other animals and four antibodies were produced which recognize 
the porcine protein. The second part of the galectin-3 work focused on the effect 
ASFV infection has on the protein.
Galectin-3 is a multifunctional protein which may play an important role in immune 
regulation or development. It is naturally expressed and secreted from macrophage 
cells but in previous microarray experiments has been shown to be up-regulated by 
ASFV infection. Galectin-3 is predominantly expressed in cells involved in innate 
immune responses and inflammatory responses like macrophages. Galectin-3 is 
unique to other galectins in that it possesses an N-terminal region and CRD giving it
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multiple functions. Galectin-3 sequence has been described for dog, rabbit, and rat 
(Gaudin et al., 1995; Hughes, 1999) but recently it has been found in bovine 
reproductive, respiratory and digestive tract (Kim et al., 2008) and in various mouse 
tissues (Kim et al., 2007). As well as being expressed by immune cells it can also be 
found in endothelial cells often at slightly different sizes depending on its 
phosphorylation state (Thijssen et al., 2008).In chapter 3 the porcine galectin-3 
nucleotide sequence was compared to galectin-3 from other mammalian species 
including bull, dog, hamster, mouse rat and rabbit. The alignment is shown in figure 
3.3. The pig sequence was most closely related to the rabbit sequence as shown by 
the phylogenetic tree in figure 3.4. Region III in the pig sequence contains an extra 3 
nucleotides which is not present in the rabbit sequence and there is a stretch of 54 
nucleotides missing just before and in region IV. The two human sequences also 
have 30 nucleotides missing in this region compared with the porcine sequence. This 
explains the slight difference in size of the endogenous monkey galectin-3 protein 
expressed in Vero cells compared with the endogenous porcine galectin-3 expressed 
in alveolar macrophages (figures 3.13. and 3.14). All the regions described in 
galectin-3 sequences for other mammals (Gaudin et al., 1995; Herrmann et al., 1993; 
Hughes, 1999) are present in the porcine sequence. An anti-human galectin-3 
antibody is commercially available but this antibody was unable to detect the porcine 
protein. Four antibodies were produced and tested (chapter 3) in order to investigate 
galectin-3 expression during ASFV infection.
In chapter 4 levels of galectin-3 protein over time were analysed in ASFV-infected 
and mock-infected cells. The western blot data in figures 4.5 and 4.6 show that there 
was more galectin-3 secreted from ASFV-infected cells and the levels of galectin-3 
increased with time after infection. QRTPCR results (figure 4.8 and 4.9), although 
variable, suggest that galectin-3 expression may be up-regulated during infection 
with ASFV Malawi isolate. This up-regulation in galectin-3 experiments was 
observed in micro array experiments carried out previously in the group (Zhang et al.,
2006) although QRTPCR data on galectin-3 is not actually included in this paper.
Galectin-3 interacts with numerous ligands including Bcl-2 (it contains sequence 
similarity with the NWGR motif conserved in Bcl-2 family) which suppresses
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apoptosis (Yang et al., 1996) and it also interacts with Akt (Oka et al., 2005) and 
synnexin (Yu et al., 2002a). It recognizes various receptors for example CD95 
(Fukumori et al., 2003) and CD98 (Hughes, 2001) on T cells. Galectin-3 has also 
been shown to be involved in regulation of apoptosis (Dumic et al., 2006) and 
mRNA splicing (Liu et al., 2002). Recent work also suggests an importance in 
regulation of T cells by galectin-3 and galectin-1. T-cell activation requires 
clustering of a threshold number of T-cell receptors (TCRs) at the site of antigen 
presentation, galectin-3 has been shown to be associated with the TCR complex at 
the cell surface and data indicates that a galectin-glycoprotein lattice restricts TCR 
recruitment to the site of antigen presentation (Demetriou et al., 2001). One of the 
characteristics of acute ASFV infection is massive lymphocyte apoptosis. The cause 
of this apoptosis has not been completely defined. It is likely that cytokines released 
fi-om infected macrophages such as IL-ljS, and TNFceplay a role (Oura, 1998a; 
Ramiro-Ibanez et al., 1996; Salguero et al., 2008; Salguero et al., 2002; Salguero et 
al., 2005; Vallee, 2001). In particular, TNFo; present in supernatants fi*om infected 
cells has been shown to induce lymphocyte apoptosis although not to the extent 
observed in vivo (Gomez del Moral et al., 1999). The last part of chapter 4 
investigated the effect galectin-3 has on lymphocyte apoptosis by using supernatants 
harvested from infected cells. It is possible that galectin-3 may be acting in 
conjunction with other factors such as TNFato induce apoptosis in bystander cells. 
Galectin-3 can easily be blocked by the addition of lactose to culture medium. The 
four antibodies produced in chapter 3 could also be used to inhibit its action and 
asses whether it does induce lymphocyte apoptosis during ASFV infection.
ASFV is not the only virus which causes a haemorrhagic fever and which is 
characterized by lymphoid destruction by apoptosis. There are a number of virus 
families which contain viruses capable of causing haemorrhagic fever (HF). These 
include the Arenaviridae family member Lassa virus, the Bunyaviridae family 
member Rift Valley fever virus, the Filoviridae family member Ebola virus and the 
Flaviviridae family member Dengue virus and classical swine fever virus. These are 
all characterized by fever, malaise, lymphopenia and increased vascular permeability 
which also occurs during ASFV infection. These viruses can infect a range of cell 
types but typically infect macrophage where they are then rapidly spread throughout
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the body targeting lymphoid tissue. Pathogenesis of HF caused by different viruses 
involves some specific viral interactions and some more general ones (Bray, 2005; 
Geisbert and Jahrling, 2004). Some have been shown to block type IIFN responses 
such as Ebola viral protein 35 (VP35) which can block IRF3 (Easier et al., 2003) and 
the Rift Valley fever virus NSs protein which inhibits IFN gene transcription rather 
than inhibiting specific transcription factors (Billecocq et al., 2004). A common 
feature to these virus infections is vascular leakage and coagulation (Schnittler and 
Feldmann, 2003). This often occurs with no viral replication observed in endothelia 
cells suggesting this may be a response to inflammatory mediators (Esmon, 2004). 
During infection with Ebola virus and possibly other HF viruses there is lymphocyte 
apoptosis but lymphocytes themselves are not infected as with ASFV. This 
lymphocyte destruction is likely to be indirect and caused by the release o f pro- 
inflammatory cytokines such as TNFo; IL-ljS, IL- 6  and others (Hensley et al., 2002; 
Mahanty et al., 2003). However, there may also be a direct cytopathic effect caused 
by virus binding to common glycoprotein motifs which leads to specific destruction 
of cellular architecture or hijack of host cell machinery (Geisbert and Jahrling, 2004). 
Depletion of T cells during Ebola virus infection has been shown (Reed et al., 2004) 
and the lack of any adaptive immune response in the second week of infection 
correlates with an increased mortality (Ksiazek et al., 1999; Sanchez et al., 2004).
It might be interesting to investigate levels of galectin-3 in other HF virus infections. 
Galectin-3 may be a common glycoprotein which binds to cell surfaces and causes T- 
cell apoptosis. Recent work at the Institute for Animal Health suggests galectin-3 
may be involved in pathogenesis of classical swine fever virus (data unpublished). 
The precise mechanism of lymphocyte apoptosis during ASFV infection and 
infection with other haemorrhagic viruses still remains to be defined. If galectin-3 
plays a role in lymphocyte apoptosis during ASFV infection it is possible it may be a 
contributing factor in other viral HFs.
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7.3 Modulation of host cell signaling by ASFV
The second half of this project has focused on host signaling pathways activated 
during ASFV infection and in particular during early events in infection. ASFV is a 
large virus which expresses a large number of proteins many of which can regulate 
the state of a cell in order to enhance virus infection, replication and dissemination. 
The A224L gene encodes an lAP homologue which can inhibit apoptosis by 
interaction with the proteolytic fragment of caspase-3 and inhibiting the activity of 
this protease during ASFV infection. These observations could indicate a conserved 
mechanism of action for ASFV lAP and other lAP family members to suppress 
apoptosis (Nogal et al., 2001). The A179L gene encodes a Bcl-2 homologue which 
inhibits cell death. This finding suggests that the A179L gene has a function similar 
to that of Bcl-2 in preventing apoptosis and may play an important role during 
productive ASFV infection (Brun et al., 1996). It was found that the Gly-to-Ala 
mutation in the BHl domain of the viral protein abolished its capacity to protect the 
K562 cells from apoptosis, indicating that this Glycine is essential for A179L action. 
This finding stresses the functional similarity of the BHl domains of the viral protein 
and cellular Bcl-2 (Revilla et al., 1997). These results suggest a fine regulation for 
A179L action in the suppression of apoptosis in infected cells, which is essential for 
efficient virus replication (Galindo et al., 2008b). The A238L protein has probably 
been studied the most. It has various fiinctions during ASFV infection. It is a dual 
inhibitor of NFAT and NF-kB transcription factors. A238L inhibition of transcription, 
dependent on NF-kB and NFAT has been shown (Miskin, 1998; Powell, 1996;
Revilla et al., 1998). A238L may also target CBP/p300 to inhibit gene transcription 
(Granja et al., 2006a; Granja et al., 2008; Granja et al., 2006b). A238L can interact 
with the amino terminal ofp300 inhibiting acétylation and transcriptional activities 
of NFAT, NF-kB and c-jun in human T cells. Recent micro array experiments carried 
out in the group suggest A238L may act as a potent immunosuppressor protein by 
inhibiting transcriptional activation of genes dependent on the MAPK and 
JAK/STAT signaling pathways. This is supported by work showing A238L inhibits 
immune response genes such as COX-2, iNOS and TNFckf (Granja, 2004a; Granja et 
al., 2006a; Granja et al., 2006b).
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In the introduction Chapter 1, the regulation of signaling pathways including MAPK 
and transcription factors such as NFAT, NF-kB and c-jun were discussed.
Micro array experiments have been carried out to establish the effect ASFV has on 
these and other host signaling pathways. The micro array experiments used a porcine 
oligo array which contained all known porcine gene sequences with a hit to human, 
mouse or pig transcripts and a number of 3’ expressed sequences tags (ESTs) 
without hits to other organisms (https://www.operon-biotech.com/index.php). 
Infection with untreated Malawi virus was compared to mock-infected cells and cells 
infected with UV inactivated Malawi virus. UV inactivation of ASFV has been 
carried out before (Carrascosa et al., 2002) to investigate ASFV induced apoptosis. 
Other people have used UV inactivated virus in order to gain a better understanding 
of how the physical process during viral binding and infection affect host cells. In 
bovine herpes virus I infection the induction of apoptosis was shown to be caused by 
the infection process and not by active promotion of cell death (Devireddy and Jones, 
1999). Other investigations using UV-inactivated Vaccinia virus, indicate that a post­
binding step associated with cell entry is sufficient and required for induction of 
apoptosis in CHO cells. Recent progress on apoptotic signaling pathways raises the 
possibility that a cellular receptor for W  may be involved in inducing apoptosis 
(Ramsey-Ewing and Moss, 1998). The rationale behind using UV-inactivated virus 
was to identify differences in host cell activation caused by binding and entry of 
ASFV compared to normal ASFV infection after 4 hours when early viral proteins 
are being produced. Understanding what the differences are between entry and early 
virus replication allows us to understand how viral proteins can manipulate the host 
cell. By gaining a better understanding of pathways affected by the virus new 
targeted mechanisms which can block infection or limit disease could be developed. 
The use of various recombinant ASFVs as vaccines is currently being investigated. 
Understanding which genes or proteins are involved in stimulating the host immune 
system or involved in pathogensis means that these recombinants can be developed 
specifically to invoke a good immune response leading to antibody production with 
minimum affect on the vaccinated animal.
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The micorarray data produced in this project was analysed using two different types 
of software. The details are discussed in chapter 5. The first method highlighted 
differentially-regulated genes between all three conditions; infection with untreated 
Malawi virus, infection with UV-inactivated virus and mock-infected cells. The heat 
map produced in chapter 5 (figure 5.6) shows the results of this analysis with 
expression patterns for the different pigs and conditions all separate. Block A 
contained approximately 45% of the differentially regulated genes were down- 
regulated by Malawi virus infection compared to mock-infected cells. Many of these 
genes were also down-regulated by UV-inactivated virus but many were also , 
unchanged or even up-regulated by the UV-inactivated virus. Expression of early 
virus proteins, such as A238L, which inhibit host transcriptional responses may 
explain this result. Block B in figure 5.6 contained about 20% of the differentially- 
regulated genes which were up-regulated by Malawi virus infection. This group 
included the NF-kB pi 00 subunit which was up-regulated by both untreated and UV- 
inactivated virus. Block C and D show genes differentially-regulated by untreated 
Malawi virus and UV-inactivated virus infection. Genes down-regulated by untreated 
Malawi virus but not UV-inactivated virus included IL-17, IL-18, CXCL14 and 
RIKEN. Expression of specific virus proteins which target these pathways may 
explain this result. The second method of analysis compared the differentially- 
regulated genes between the UV-inactivated virus and the untreated virus using the 
mock infected cells as a reference. The pathways affected by these differentially- 
regulated genes were discussed in detail in chapter 7. As with the analysis in the TM4 
suite many of the genes in the MAPK pathway were affected.
MAKP8  was down-regulated by Malawi virus compared to mock infected cells and 
UV-inactivated virus along with various other components of the MAPK pathway 
such as JIP3 and p38 (shown in figure 6.5). One of the genes of particular interest 
which was down-regulated by Malawi virus was Akt. This was also shown to be 
down-regulated by Malawi virus by QRTPCR in 3 out of 4 pigs. The UV-inactivated 
virus up-regulated Akt in 3 out of 4 pigs by QRTPCR. This was looking at Aktl 
expression. Further work needs to be carried out to investigate Akt2 and also to look 
at protein expression during ASFV infection. Akt facilitates growth-mediated signal 
transduction pathways involved in cell cycle. There is also extensive cross talk with
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many different pathways. Akt has been shown to be increased during hepatitis B 
virus (HBV) infection and it is possible that this increase may be involved in 
development of hepatocellular carcinoma. Other proteins shown to be increased 
during HBV infection were ERK, c-Myc, cyclin Dl, A and B1 (Chin et al., 2007).
Regulation of the MAPK pathway is controlled by dual specificity protein 
phosphatases which act as pivotal feedback regulators. MKPl was down-regulated 
by untreated Malawi virus and potentially warrants further investigation and 
validation by QRTPCR. In general regulation of the MAPK pathway is tightly 
controlled by a series of feedback loops. Regulation of proteins such as MKPl and 
Akt by ASFV enable the virus to control different branches of the MAPK pathway 
and possibly regulate other signaling pathways at the same time. Up-regulation of the 
MAPK pathway by the papillomavirus E6 protein may be involved in tumorigenesis 
(Chakrabarti et al., 2004) and activation of the MAPK pathway may be important for 
productive influenza virus A replication (Marjuki et al., 2006). The presence of the 
E2 protein from hepatitis C virus (HCV) has been shown to increase ERK and p38 
phosphorylation which corresponded with enhanced cell proliferation (Zhao et al.,
2007). As mentioned earlier in this chapter Ebola virus (EBOV) causes a deadly 
haemorrhagic fever in humans. In mouse and bat cell cultures persistently infected 
with EBOV, activation of the Ras/MAPK pathway is required to suppress the type 1 
IFN response and enable productive viral infection (Strong et al., 2008). Micro array 
experiments with influenza virus (IV) infection showed 165 genes were up-regulated 
and of these 49 were interferon stimulated genes (ISGs). In addition, expression of 
29 of these genes was regulated by either p38 of JNK activation (Hayashi et al.,
2008). ERKl/2, p38 and NF-kB are also important mediators of innate immune 
responses during adenovirus infection (Appledom et al., 2008).
7.4 Summary
The work carried out here has highlighted a number of genes and proteins which 
warrant further investigation. The modulation of the MAPK pathway by ASFV and 
the numerous proteins it produces has not been investigated as yet. The fact that the
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ERK, JNK and p38 branches were all affected by ASFV infection suggest there may 
be a number of ASFV proteins working in conjunction with each other in order to 
manipulate the host to its advantage. The number of differentially-regulated genes 
activated by UV-inactivated virus and the untreated Malawi virus show that binding 
and entry of ASFV activates a cascade of signaling events. The findings that Akt is 
up-regulated by the UV-inactivated virus but down-regulated by untreated Malawi 
virus is of particular interest.
The increased secretion of galectin-3 during ASFV infection may also be important 
to the pathogenesis of ASFV infection and for this reason needs to be investigated 
further. This may also have potential significance for understanding the mechanisms 
of pathogenesis during other hemorrhagic diseases.
189
Appendix 
Script for ‘R’
setwd("N://MicroArray//public//Mick//Becky Herbert//Spotfinder") 
library(limma)
targets <- readTargetsCTargets.txt")
RG <- read.maimages(targets$File, source="generic",
columns=list(R="MNB", G="MNA", Rb="MedBkgB",
Gb="MedBkgA"),
annotation=c("MR","MC","SR","SC","NAME","ID")
lo <- list(ngrid.r=12, ngrid.c=4, nspot.r=18, nspot.c=18) 
RG$printer <- lo
# R background
jpegCRbgplots.jpg", width=1600, height=2400, quality=100) 
split.screen(c(6,4)) 
for (i in 1 :nrow(targets)) { 
screen(i)
imageplot(RG$Rb[,i], layout=lo, low="white", high="red", 
zlim=c(0,500))
}
close.screen(all=TRUE) 
dev.off()
# G background
jpegCGbgplots.jpg", width=1600, height=2400, quality=100) 
split.screen(c(6,4)) 
for (i in 1 :nrow(targets)) { 
screen(i)
imageplot(RG$Gb[,i], layout=lo, low="white", high="green")
}
close.screen(all=TRUE) 
dev.off()
# some have high BG, others do not
# recommend we subtract background
# also evidence of spatial effects
# loess
MA <- MA.RG(RG)
jpeg("MAprenorm.jpg", width=1600, height=2400, quality=100) 
split.screen(c(6,4)) 
for (i in 1 :nrow(targets)) {
screen(i) 
plotMA(MA[,i])
}
close.screen(all=TRUE) 
dev.off()
# not too bad, but there is some curvature
# overall boxplot
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jpegCboxplot_all.jpg", width=800, height=600, quality=100) 
par(mar=c(7,4,4,2), ps=10)
boxplot(MA$M ~ col(MA$M), las=2, names=colnames(MA$M)) 
dev.off()
# each array, within print tip boxplot
jpeg("boxplot_eacharray.jpg", width=2400, height=2400, quality=100) 
split.screen(c(6,4)) 
for (i in 1 :nrow(targets)) { 
screen(i)
boxplot(MA$M[,i] ~ paste(RG$genes$MR, RG$genes$MC, sep="."), las=2)
}
close.screen(all=TRUE) 
dev.off()
# definite evidence of spatial effects
# so, loess normalize within print tip
MA.norm <- normalizeWithinArrays(RG, method="printtiploess")
# overall boxplot
jpegCboxplot_all_norm.jpg", width=800, height=600, quality=100) 
par(mar=c(7,4,4,2), ps=10)
boxplot(MA.norm$M ~ col(MA.norm$M), las=2, names=colnames(MA.norm$M)) 
dev.off()
# good stuff
# now fit the model
design <- modelMatrix(targets=targets, ref=="Mock") 
contrasts.matrix <- makeContrasts(MalawiVsUV=Malawi-UV, 
levels=design)
fit <- ImFit(MA.norm, design)
fit2 <- contrasts.fit(fit, contrasts.matrix)
fit2 <- eBayes(fit2)
tt <- topTable(fit2, coef=l, adjust="BH", number=15552)
write.table(tt, "MalawiVsUV.csv", sep=",", col.names=TRUE, 
row.names=FALSE)
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